Document:

Exhibit 10.04

 

CONFIDENTIAL
TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND,
WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

PRIVILEGED AND CONFIDENTIAL

 

 

 

 

 

 

COLLABORATION AGREEMENT

BY AND BETWEEN

 

GINKGO BIOWORKS, INC.

 

AND

 

AMYRIS, INC.

 

 

 

 

 

 

 

 

 

 

    	 

     

    

COLLABORATION AGREEMENT

 

THIS COLLABORATION AGREEMENT (the “Agreement”)
is entered into as of September 30, 2016 (the “Effective Date”) by and between Ginkgo Bioworks, Inc., a Delaware
corporation having its principal office at 27 Drydock Avenue, 8th Floor, Boston, MA 02210 (“Ginkgo”),
and Amyris, Inc., a Delaware corporation having its principal office at 5885 Hollis Street, Ste. 100, Emeryville, CA 94608 (“Amyris”).
Ginkgo and Amyris may be referred to in this Agreement individually as a “Party” and, collectively, as the “Parties”.

 

RECITALS

 

WHEREAS, Ginkgo and Amyris each have certain
capabilities, technology and know-how useful in collaborating to develop a biotechnology platform that will benefit both Parties’
customers;

 

WHEREAS, Ginkgo and Amyris are interested in
forming an alliance in the Field (as hereinafter defined) whose goal is to discover, develop and commercialize a robust portfolio
of products to address the needs of each Party’s customers; and

 

WHEREAS, concurrent with the execution and delivery
of this Agreement, (a) Amyris has issued to Ginkgo the warrant attached hereto as Exhibit A, (b) Amyris and Stegodon
Corporation have entered into the Amendment to Loan and Security Agreement Relating to (i) Maturity Date, (ii) Payments and (iii)
Cash Covenants, and (c) Amyris and Ginkgo have entered into an Escrow Agreement (the “Escrow Agreement”) in
the form attached hereto as Exhibit B.

 

NOW, THEREFORE, in consideration of the respective
representations, warranties, covenants and agreements contained herein, and for other valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties agree as follows:

 

Article
I.    DEFINITIONS

 

When used in this Agreement, each of the following
terms shall have the meanings set forth in this Article I:

 

1.1             
“Action” means any claim, audit, examination, action, cause of action or suit (whether in contract or tort or
otherwise), litigation (whether at law or in equity, whether civil or criminal), assessment, arbitration, mediation, investigation,
hearing, charge, complaint, demand, notice or proceeding.

 

1.2             
“Accounting Principles” means GAAP, to the extent applicable. In the event of a conflict between GAAP and any
provision of this Agreement, this Agreement shall control.

 

1.3             
“Actual Cost of Goods Sold” means, with respect to a Product, the costs and expenses per unit, such as a kilogram,
of manufacturing said Product associated with the manufacturing, and commercialization of such Product under this Agreement, including:
(a) the direct labor costs (including salary and wages and fringe benefits) incurred by the applicable Party or its Affiliates
in conducting the applicable activity; (b) the cost of materials used by the applicable Party or its Affiliates (including feedstock
and raw materials, intermediates,

 

    	 

     

    

components and packaging materials, and including
shipping and handling costs, freight-in charges and any applicable sales taxes and/or customs duties therefor); (c) a reasonable
allocation of overhead (including without limitation indirect labor costs, supplies and materials, plant insurance and property
taxes) and facilities and equipment expense (including utilities, repairs and maintenance costs, and equipment rental), (d) costs
for administration and for management of material procurement and other manufacturing or other applicable activities, including
QA/QC, performed directly in support of the applicable activity, calculated in accordance with reasonable cost accounting methods
in effect from time to time, consistently applied; (e) if applicable, amounts paid (net of rebates or discounts, if any) to Third
Party manufacturers or service providers in connection with their supply of the product or subcontracting of the applicable activity
(including shipping costs and any applicable taxes and/or duties therefor), and (f) any royalties payable to a Third Party directly
attributable to the applicable activity; provided, however, that no cost may be counted more than once in such calculation.
Actual Cost of Goods Sold shall not include non-cash GAAP expenses such as depreciation expense and utilization charges except
that for Products manufactured at Amyris’ existing BROTAS facility, a reasonable allocation of either (1) depreciation expense
over the expected life of the buildings and equipment in existence as of the Effective Date or (2) rent, leaseback fees and similar
costs for the existing BROTAS facility shall be included in facilities and equipment expense, which amount of all such depreciation
expense, rent, leaseback fees, and similar costs for all products manufactured (whether or not for customers under this Agreement)
at the existing BROTAS facility for purposes of calculating Actual Cost of Goods Sold hereunder is capped at $[*] in the aggregate
per year. For clarity, under this Agreement, the payment of a share of the Net Profits to the other Party does not constitute a
royalty under this definition. Actual Cost of Goods Sold shall be calculated in accordance with the Accounting Principles. For
the avoidance of doubt, (A) any Losses hereunder, (B) any Capital Expenditures, (C) any costs or expenses associated with the Parties’
activities directed to the development or scale up of technologies necessary for the manufacture of any Product, (D) any losses
in excess of the amount that the JSC has agreed to be greater than generally expected (i.e., for theft, spillage, etc.)
for the applicable Product, (E) any losses related to manufacturing or batch failures, which failures shall be the sole responsibility
of Amyris, (F) any depreciation expense, rent, leaseback fees, and similar costs in excess of $[*] in the aggregate per year for
the existing BROTAS facility or any depreciation expense, rent, leaseback fees, and similar costs for any new facility (including
without limitation the proposed BROTAS2 facility), and (G) any amounts determined by the JSC that should not be included in ACOGS
for the applicable Product, and (H) fees and royalties under Section 2.3(g) herein shall be excluded from the calculation of Actual
Cost of Goods Sold, and the applicable Party will calculate the Actual Cost of Goods for Products under this Agreement in the manner
at least as favorable to Ginkgo as compared with other Amyris products not subject to this Agreement. In the event that a Party
uses a Third Party contract manufacturing organization (“CMO”) for the manufacturing of a Product in accordance
with the terms hereof, the Actual Cost of Goods Sold for such Product shall be equal to the pricing paid by the applicable Party
to such Third Party CMO attributable solely to the manufacture of such Product.

 

1.4             
“Affiliate” means, as to a Person, any entity which, directly or indirectly, controls, is controlled by, or
is under common control with such Person. For the purposes of this definition, “control” refers to any of the following:
(a) direct or indirect ownership of fifty percent (50%) or more of the voting securities entitled to vote for the election
of directors or managers in the case of a corporation or limited liability company, or of fifty percent (50%) or more of the equity
interest

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

     

     

    

with the power to direct management in the case
of any other type of legal entity; (b) status as a general partner in any partnership; or (c) any other arrangement where
an entity possesses, directly or indirectly, the power to direct the management or policies of another entity, whether through
ownership of voting securities, by contract or otherwise.

 

1.5             
“Amyris Customer Agreement” means any agreement between Amyris and a customer entered into during the
Term pertaining to the development, improvement and/or manufacturing of one or more chemical small molecule compounds in the Field
other than (a) the agreement between Amyris and [*]; (b) any agreement with a Governmental Entity; (c) agreements related
to the [*]; and (d) the agreements listed on Exhibit 1.5. [*].

 

1.6             
“Average Selling Price” means, with respect to a Product sold by a Party, the aggregate net sales price per
unit (such as a kilogram) of said Product for all items, instances, or increments of such Product by all customers of the Party,
excluding any Incentive Payments related to such Product. Average Selling Price shall be calculated in accordance with the Accounting
Principles.

 

1.7             
“Background Intellectual Property” means, with respect to a given Party (i) any and all information and inventions,
and all Intellectual Property rights therein or pertaining thereto, including all Intellectual Property in the Strains, that are
in existence and Controlled by such Party or its Affiliates at the beginning of the Term and that are necessary, required or actually
used in the development, manufacture and/or commercialization of any Product under this Agreement, and (ii) such Party’s
Included Non-Collaboration Intellectual Property. Background Intellectual Property excludes Foreground Intellectual Property, Foundry
Intellectual Property and Non-Collaboration Intellectual Property.

 

 

 

[*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

 

    	 

     

    

1.8             
“Business Day” means a day other than a Saturday or Sunday or other day on which banking institutions located
in New York, New York, USA are authorized or obligated by law or executive order to close.

 

1.9             
“Calendar Quarter” means a calendar quarter ending on the last day of March, June, September or December.

 

1.10         
“Calendar Year” means a period of time commencing on January 1 and ending on the following December 31.

 

1.11         
“Capital Expenditures” means the funds used by a Party to acquire or upgrade fixed or physical assets, including
property, industrial buildings, or equipment, including without limitation any costs associated with the Parties’ activities
directed to the development of technologies necessary for the manufacture of any Product. Capital Expenditures shall be calculated
in accordance with the Accounting Principles.

 

1.12         
“Change in Control” means, with respect to a Party, an event in which: (a) any Third Party not then beneficially
owning more than fifty percent (50%) of the voting power of the outstanding securities of such Party acquires or otherwise becomes
the beneficial owner of securities of such Party representing more than fifty percent (50%) of the voting power of the then-outstanding
securities of such Party with respect to the election of the board of directors, board of managers or similar governing body; or
(b) such Party consummates a merger, consolidation or similar transaction with a Third Party where the voting securities of
such Party outstanding immediately preceding such transaction represent less than fifty percent (50%) of the voting power of such
Party or surviving entity, as the case may be, immediately following such transaction; or (c) such Party sells all or substantially
all of its assets relating to this Agreement to a Third Party.

 

1.13         
“Control” of Intellectual Property means that the applicable party has the rights necessary to grant the rights
and licenses granted or to be granted in this Agreement, whether by ownership or otherwise, without breaching any Third Party obligation
included in an agreement set forth on Exhibit  1.13, which may be updated from time to time by agreement of
the Parties. For clarity, any new restriction on Control after the Effective Date (and therefore any addition to Exhibit
1.13), whether pursuant to a Customer Agreement or an agreement of a Party excluded from this Collaboration, requires approval
by the JSC, which approval, solely in regards to a Customer Agreement, may be provided by virtue of joint approval of a Customer
Agreement pursuant to Article IV.

 

1.14         
“Customer Agreement” means any agreement between one or more of the Parties and a Third Party for the development,
manufacture, and/or commercialization of a Strain or a Product.

 

1.15         
“Earned Incentive Payments” means any Incentive Payments under a Customer Agreement in effect prior to the Effective
Date, which Incentive Payments have been earned prior to the Effective Date or are reasonably expected to be earned during the
term of such Customer Agreement.

 

    	 

     

    

1.16         
“Executive Committee” means a committee comprised of the Chief Executive Officers of each of Ginkgo and Amyris
(or a senior executive officer of Ginkgo or Amyris designated by such Chief Executive Officers).

 

1.17         
“Field” means activities related to the development, scale-up, and manufacture of a chemical small molecule
compound(s) whose manufacture is enabled at least in part by the use of microbial strains and fermentation technologies.

 

1.18         
“Flavors and Fragrances Market” means the worldwide market for individual ingredient(s), including the ingredient(s),
flavor(s) and/or fragrance(s), whose intended or primary functionality (individually or as part of a blend with auxiliary materials)
is to: (a) impart, modify, boost or enhance a desirable scent or odor, in consumer and industrial grade products (including, without
limitation, fine fragrances, cosmetics, toiletries, home and body care, detergents, repellants, fertilizers, air fresheners and
soaps); and (b) impart, modify, boost or enhance a desirable taste, flavor or sensation, or to conceal, modify or minimize an undesirable
taste, flavor or sensation, in materials designed for consumption (including food, beverages, drugs, tobacco and any animal feed).

 

1.19         
“Force Majeure Event” means, with respect to a Party, an event, act, occurrence, condition or state of facts,
in each case outside the reasonable control of such Party (which may include acts of God, acts of any government, any rules, regulations
or orders issued by any governmental authority or by any officer, department, agency or instrumentality thereof, fire, storm, flood,
earthquake, accident, war, rebellion, insurrection, riot, terrorism and invasion) that interferes with the normal business operations
of such Party.

 

1.20         
“Foreground Intellectual Property” means, with respect to a given Party, any and all information and inventions,
and all Intellectual Property rights therein or pertaining thereto, including all Intellectual Property in the Strains and the
Products, that have been or are conceived, discovered, developed or otherwise made or obtained by or on behalf of either Party
or its Affiliates or jointly by or on behalf of the Parties or their Affiliates in the performance of any activities under this
Agreement and Controlled by either Party or its Affiliates, and, in each case, all Intellectual Property rights therein or pertaining
thereto, and excludes Foundry Intellectual Property (that is not Overlapping Process Intellectual Property), and Non-Collaboration
Intellectual Property.

 

1.21         
“Foundry Intellectual Property” means any and all information and inventions, which information or inventions
relate to the design and genetic engineering, measurement or analysis of microbial host cells, and all Intellectual
Property rights therein or pertaining thereto and excludes (i) [*] , (ii) analytical methods related to [*] and (iii) any Non-Collaboration
Intellectual Property.

 

 

 

[*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

 

    	 

     

    

1.22         
“GAAP” means U.S. generally accepted accounting principles, consistently applied between years in the normal
course of business.

 

1.23         
“Ginkgo Customer Agreement” means any agreement between Ginkgo and a customer entered into during the Term pertaining
to the manufacturing of one or more chemical small molecule compound(s) in the Field where such customer requires third party manufacturing
of such chemical small molecule compound(s) other than: (a) any agreement between Ginkgo and a Governmental Entity, (b) certain
aspects of existing Ginkgo agreements with both [*] (related to the scale-up and manufacture of [*]) and [*] (related to the scale-up
and manufacture of [*]), and (c) the agreements listed in Exhibit 1.23. For the avoidance of doubt, Ginkgo Customer
Agreements exclude agreements between Ginkgo and a Third Party under which such parties are engaged in the development of strains
or strain improvements only (i.e., the agreement does not contemplate the industrial scale manufacture of chemical small
molecule compounds).

 

1.24         
“Governmental Entity” means any instrumentality, subdivision, court, administrative agency, commission, official
or other authority of any country, state, province, prefect, municipality, locality or other government or political subdivision
thereof, or any quasi-governmental, private body or arbitral body exercising any executive, legislative, judicial, quasi-judicial,
regulatory, taxing, importing, administrative or other governmental or quasi-governmental authority.

 

1.25         
“Incentive Payments” means any fees and/or milestone payments under a Customer Agreement.

 

1.26         
“Included Non-Collaboration Intellectual Property” means Non-Collaboration Intellectual Property of a Party
that such Party has used or offers for the other Party to use for the development, manufacture and/or commercialization of any
Product under this Agreement.

 

1.27         
“Independent Accounting Firm” means an independent certified public accounting firm that is one of the six (6)
largest, by revenue, accounting firms in the United States and is approved by both Parties (such approval not to be unreasonably
withheld).

 

1.28         
“Initial Strategic Partnership Agreement” means the Initial Strategic Partnership Agreement, dated June 28,
2016, by and between Amyris and Ginkgo.

 

1.29         
“Intellectual Property” means any and all rights in data, discoveries, goodwill, information and inventions,
specifically including each of copyright, know-how, patent, and trade secret rights and any documents or materials that may embody,
incorporate, or utilize them.

 

1.30         
“Isoprenoid” means [*]

 

[*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

 

    	 

     

    

[*].

 

1.31         
“Isoprenoid Strain” means [*].

 

1.32         
“Law” means any law, statute, common law, rule, regulation, ordinance, code or other pronouncement having the
effect of law, of any federal, national, multinational, state, provincial, county, city or other political subdivision, including,
as applicable: (a) good manufacturing practices, good laboratory practices, good clinical practices and all other rules, regulations
and requirements of any applicable Governmental Entities; (b) the Foreign Corrupt Practices Act of 1977, as amended, or any
comparable laws in any country; (c) the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended;
and (d) all export control laws.

 

1.33         
“Net Profits” means, with respect to a Product, the number of units of Product sold multiplied by the difference
between the (a) the Average Selling Price for such Product and (b) the product of (i) 1.1 and (ii) the Actual Cost of Goods Sold
for such Product. Net Profits shall be calculated in accordance with the Accounting Principles. In the event such difference is
a negative number, then such Net Profits shall equal zero.

 

1.34         
“Non-Collaboration Intellectual Property” means, with respect to a Party, any Intellectual Property created
(whether as of or following the Effective Date) outside the scope of this Agreement, including (i) the Intellectual Property listed
on Exhibit 1.34, (ii) all Intellectual Property granted to Amyris pursuant to (a), (b) and (c) from the definition
of “Amyris Customer Agreement”, (iii) any Intellectual Property arising out of Excluded Products, and (iv) any Intellectual
Property related to pharmaceuticals, including without limitation Amyris’ “microPharm” platform; provided
that Non-Collaboration Intellectual Property shall not include any Intellectual Property of a Party that such Party has used or
voluntarily includes for the development, manufacture and/or commercialization of any Product under this Agreement. Any such use
or voluntary inclusion will render the relevant Intellectual Property a part of Included Non-Collaboration Intellectual Property.
For clarity, any of Amyris’ Intellectual Property related to pharmaceuticals and/or Amyris’ “micropharm”
work is excluded from this Agreement, unless such Intellectual Property related to pharmaceuticals and/or Amyris’ “micropharm”
work is voluntarily provided to Ginkgo by Amyris.

 

[*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

 

    	 

     

    

1.35         
“Non-Isoprenoid” means [*].

 

1.36         
“Non-Isoprenoid Strain” means [*].

 

1.37         
“Overlapping Process Intellectual Property” means the Intellectual Property rights pertaining to analytical
methods related to small molecule end product and side-product detection and purity determination for the purposes of product quality
and suitability in the intended application, as well as scale-down fermentation methods and compositions including microtiter
plates, flasks and fermenters of less than [*] in volume, as required for successful development of a commercial process for production.
Overlapping Process Intellectual Property excludes Non-Collaboration Intellectual Property.

 

1.38         
“Patent Filing” includes any application or patent, whether provisional or nonprovisional, filed and/or granted
anywhere in the world.

 

1.39         
“Patent Lead” is the Party that has ultimate decision making authority with respect to patent prosecution strategy
and is responsible for filing, prosecution, and maintenance of patents, including any related interference, re-issuance, re-examination,
opposition, inter partes review, or post grant review proceedings.

 

1.40         
“Permitted Subcontractor” means an Affiliate or a Third Party to which a Party may subcontract portions of the
activities allocated to it under a Technical Development Plan or any other Product development plan in accordance with the terms
of this Agreement.

 

1.41         
“Person” means any natural person, general or limited partnership, corporation, limited liability company, limited
liability partnership, firm, association or organization or other legal entity.

 

1.42         
“Prior Confidentiality Agreement” means the Mutual Confidential Disclosure Agreement, dated May 11, 2016, by
and between Amyris and Ginkgo, as amended.

 

1.43         
“Priority Access” means being provided with the right to first access when taking into account lead times and
reasonably balancing capacity with utilization, including any access required to meet requirements or other obligations under Customer
Agreements, unless otherwise approved by the JSC

 

 

 

[*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions..

 

    	 

     

    

1.44         
“Process Intellectual Property” means any and all information and inventions, which information or inventions
relate to fermentation methods for making compounds using genetically modified host cells, recovery of such chemical small molecule
compound(s) from fermentation broth (or other media), purification of such chemical small molecule compound(s) isolated from fermentation
broth (or other media), finishing of such chemical small molecule compound(s) isolated from fermentation broth (or other media)
and all Intellectual Property rights therein or pertaining thereto.

 

1.45         
“Product” means an ingredient created pursuant to a Ginkgo Customer Agreement or an Amyris Customer Agreement,
and any other ingredient listed on Tables 1 through 4 on Exhibit  6.2(a).

 

1.46         
“Program” means a program to develop, manufacture, commercialize and/or sell Products for a single customer
under this Agreement.

 

1.47         
“Strain” means [*]

 

1.48         
“Strain Intellectual Property” means [*].

 

1.49         
“Third Party” means any Person other than a Party or its Affiliates.

 

1.50         
Construction.  In construing this Agreement, unless expressly specified otherwise:

 

(a)               
references to Articles, Sections and Exhibits are to articles and sections of, and exhibits to, this Agreement;

 

(b)              
except where the context otherwise requires, use of either gender includes any other gender, and use of the singular includes the
plural and vice versa;

 

(c)               
headings and titles are for convenience only and do not affect the interpretation of this Agreement;

 

(d)              
any list or examples following the word “including”, “include” or “includes” shall be interpreted
without limitation to the generality of the preceding words;

 

(e)               
except where the context otherwise requires, the word “or” is used in the inclusive sense;

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

    	 

     

    

(f)               
the terms “hereof”, “hereto”, “hereby”, “herein” and “hereunder” and
words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this
Agreement;

 

(g)              
the term “extent” in the phrase “to the extent” means the degree to which a subject or other thing extends,
and such phrase does not mean simply “if”;

 

(h)              
except where the context otherwise requires, “will” means “shall”;

 

(i)                
references to an agreement or instrument mean such agreement or instrument as from time to time amended, modified or supplemented
(subject to any restrictions on such amendments, supplements or modifications set forth herein);

 

(j)                
references to a Person are also to its successors, heirs and permitted assigns;

 

(k)              
except if Business Days are specified, “day” or “days” refers to calendar days;

 

(l)                
if a period of time is specified and dates from a given day or Business Day, or the day or Business Day of an act or event, it
is to be calculated exclusive of that day or Business Day; 

 

(m)            
“monthly” means on a calendar month basis;

 

(n)              
“quarter” or “quarterly” means on a Calendar Quarter basis;

 

(o)              
“annual” or “annually” means on a Calendar Year basis;

 

(p)              
“year” means a three hundred sixty-five (365) day period unless Calendar Year is specified;

 

(q)              
references to a Law include any amendment or modification to such Law and any rules or regulations issued thereunder, whether such
amendment or modification is made, or issuance of such rules or regulations occurs, before or, only with respect to events or developments
occurring or actions taken or conditions existing after the date of such amendment, modification or issuance, after the Effective
Date, but only to the extent such amendment or modification, to the extent it occurs after the date hereof, does not have a retroactive
effect;

 

(r)                
all references to “Dollars” or “$” herein shall mean U.S. Dollars; 

 

(s)               
a capitalized term not defined herein but reflecting a different part of speech than a capitalized term which is defined herein
shall be interpreted in a correlative manner; 

 

(t)                
any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement,
instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such
amendments, supplements or modifications set forth herein); and

 

    	 

     

    

(u)              
each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it
has participated in the drafting hereof.  In interpreting and applying the terms and provisions of this Agreement, the Parties
agree that no presumption will apply against the Party which drafted such terms and provisions.

 

Article
II. LICENSES

 

2.1             
Technology Transfer.

 

(a)               
The Parties hereby confirm that, pursuant to the Initial Strategic Partnership Agreement, Amyris has provided Ginkgo with access
to certain Intellectual Property owned or Controlled by Amyris, including, without limitation, certain Foundry Intellectual Property
(the “ISPA Intellectual Property”). For clarity, the Initial Strategic Partnership Agreement itself did not
obligate Amyris to provide Ginkgo access to any updates and/or modifications to the ISPA Intellectual Property; any and all obligations
to update are solely as set forth in this Agreement.

 

(b)              
Amyris shall provide Ginkgo any Intellectual Property that is necessary or has a material benefit for Ginkgo to engineer and develop
robust strains that scale up to commercial production of Product(s) under this Agreement and that has not already been provided
to Ginkgo under the Initial Strategic Partnership Agreement; Amyris commits to continue providing such access throughout the Term,
including updates and modifications to such Intellectual Property (including the ISPA Intellectual Property) for the purposes of
Ginkgo performing its obligations under this Agreement (including without limitation to the full extent necessary or useful under
this Agreement, and specifically to facilitate strain design, engineering, production, and small scale fermentation by Ginkgo under
this Agreement). For clarity, Amyris shall not provide Foundry Intellectual Property or Overlapping Process Intellectual Property
to Ginkgo that (i) is not owned or Controlled by Amyris or (ii) is not necessary or does not have a material benefit for Ginkgo
to engineer and develop robust strains that scale to commercial production of Product(s) under this Agreement. For clarity and
notwithstanding anything to Section 1.5 to the contrary, Amyris shall not be obligated to provide ASE or Foundry Intellectual Property
developed under the Amyris DARPA Agreement to Ginkgo under this Section 2.1(b) unless otherwise determined by the JSC. 

 

(c)               
Ginkgo shall provide Amyris with access to the Intellectual Property licensed by Ginkgo to Amyris pursuant to this Article II,
including the current stable and best performing version of any Strain; Ginkgo commits to continue providing such access throughout
the Term, including updates and modifications to such Intellectual Property for the purposes of Amyris performing its obligations
under this Agreement (including without limitation to the full extent necessary or useful under this Agreement, and specifically
to facilitate scale up, manufacture and commercialization of Products by Amyris under this Agreement). For clarity, Ginkgo shall
not provide Foundry Intellectual Property to Amyris, unless mutually agreed to in writing by the Parties.

 

2.2             
Inventions. Subject to the value sharing provisions provided in Article VI, the Parties agree to the following:

 

(a)               
Inventorship. The determination of inventorship for any invention which arises in connection with performance of activities
conducted under this Agreement (i.e., 

 

    	 

     

    

Foreground Intellectual Property and Foundry Intellectual
Property) shall be made in accordance with the patent laws of the United States. Should any dispute arise with respect to determination
of inventorship, the JSC shall attempt in good faith to resolve the dispute. In the event that the JSC is unable to resolve such
dispute within thirty (30) days after receipt of notice of the dispute, such dispute will be resolved by independent patent counsel
not engaged or regularly employed in the past two (2) years by either Party and reasonably acceptable to both Parties. The decision
of such independent patent counsel will be binding on the Parties. Expenses of such patent counsel will be shared equally by the
Parties. For the avoidance of doubt, nothing in this Agreement shall change or modify a Party’s ownership of its Background
Intellectual Property or any of its Foundry Intellectual Property that exists as of the Effective Date.

 

(b)              
Ownership and Control.

 

(i)                
Foreground IP and Overlapping Process IP. (A) Foreground Intellectual Property that is Process Intellectual Property (and
that is not Strain Intellectual Property) and (B) Overlapping Process Intellectual Property, regardless of inventorship, in each
case, are and will be owned and Controlled by Amyris. Ginkgo agrees to assign, and hereby does assign, to Amyris any and all rights
in and to such Foreground Intellectual Property and such Overlapping Process Intellectual Property, including any and all rights
in any patent filings and/or rights of priority to such patent filings, that claim such Foreground Intellectual Property or such
Overlapping Process Intellectual Property. Foreground Intellectual Property, other than Process Intellectual Property and Overlapping
Process Intellectual Property but including Strain Intellectual Property, regardless of inventorship, is and will be owned and
Controlled jointly by the Parties.

 

(ii)              
Foundry IP. As between the Parties, ownership and Control of Foundry Intellectual Property (and that is not Overlapping
Process Intellectual Property) created in the performance of any activities under this Agreement will be determined according to
inventorship as set forth in Section 2.2(b)(iii). Any Foundry Intellectual Property owned by a Party prior to the Effective Date
shall continue to be owned by such Party.

 

(iii)            
Ownership according to Inventorship. For clarity, ownership “determined according to inventorship” means that,
as between the Parties, any invention (and any Patent Filing with claims to that invention) made by one or more inventors from
Ginkgo and no inventors from Amyris is and will be owned and Controlled by Ginkgo; any invention (and any Patent Filing with claims
to that invention) made by one or more inventors from Amyris and no inventors from Ginkgo is and will be owned and Controlled by
Amyris; any invention (and any Patent Filing with claims to that invention) made by one or more inventors from Ginkgo together
with one or more inventors from Amyris is and will be owned jointly by Ginkgo and Amyris. 

 

(c)               
Patent Lead. For any Patent Filing which arises in connection with performance of activities conducted under this Agreement
and, as between the Parties, is solely owned or Controlled by one Party, that Party is Patent Lead for that Patent Filing. For
any Patent Filing which arises in connection with the performance of activities conducted under this Agreement and that is jointly
owned and Controlled by the Parties, the JSC will designate a Patent 

 

    	 

     

    

Lead. In accordance with the previous sentence,
it is expected that the JSC will designate Amyris as Patent Lead for all Foreground Intellectual Property that is Process Intellectual
Property, for all Overlapping Process Intellectual Property, [*], and will designate Ginkgo as Patent Lead for all Foreground Intellectual
Property that is primarily related to a [*] and for all Foundry Intellectual Property that arises as a result of performance under
this Agreement. Any disputes as to which Party will be designated as the Patent Lead will be resolved by the JSC.

 

(i)                
Responsibilities. The Patent Lead shall be responsible for preparation, filing, prosecution and maintenance of patents,
including any related interference, re-issuance, re-examination, opposition, inter partes review, or post grant review proceedings,
and shall give the other Party at least five (5) days’ notice prior to filing an application for a patent hereunder for any
Foundry Intellectual Property, unless filing sooner is necessary to avert an impending loss of patent rights. The other Party shall
be permitted but not obliged to provide input to the Patent Lead on the determination of whether and where to seek patent protection
and shall assist the Patent Lead. The Patent Lead shall consider any suggestions timely provided by the other Party in good faith,
and, for any jointly-owned and Controlled Intellectual Property, the Patent Lead shall implement such suggestions or provide a
reasonable explanation for a decision not to implement them. Each Party shall provide the status of jointly-owned Patent Filings
to the other party on a quarterly basis.

 

(ii)              
Costs. The Patent Lead shall bear all costs associated with the preparation, filing, prosecution and maintenance of patents
which arise in connection with the performance of activities conducted under this Agreement, including any related interference,
re-issuance, re-examination, opposition, inter partes review, or post grant review proceedings unless the JSC determines
otherwise. 

 

(d)              
Enforcement. 

 

(i)                
Subject to Section (ii) below, each Party has an independent right to assert any Foreground Intellectual Property or Foundry Intellectual
Property that it solely owns or Controls. Should either Party become aware of any infringement of any jointly owned Intellectual
Property (A) during the Term, it will promptly notify the JSC which will determine whether the jointly owned Intellectual Property
should be asserted against the particular alleged infringer and develop an enforcement strategy or (B) after the Agreement has
been terminated, it will promptly notify the other Party and the Parties will work together to jointly determine whether the jointly-owned
Intellectual Property should be asserted against the particular alleged infringer and develop an enforcement strategy.

 

(ii)              
Each Party has a perpetual option to assert Intellectual Property of the other Party (the option-granting party) (A) that is owned
or Controlled by such other Party or (B) that is licensed under this Agreement, in each case, in a proceeding against any Third
Party who has brought or threatened to bring an action against the option-holding Party, or against any Intellectual Property owned
or Controlled by the option-holding Party. For clarity, this Section 2.2(d)(ii) does not constitute a license to practice such
Intellectual Property of such other Party.

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

    	 

     

    

(iii)            
Whenever one Party is exercising a right to assert Intellectual Property hereunder, the other Party hereby agrees to be named in,
or otherwise join, initiate or perform, any such assertion or Action if necessary for standing or otherwise to ensure that the
asserting Party can effect the assertion. If the other Party should be required to be so named or otherwise join, initiate or otherwise
facilitate an assertion, then the option-holding Party will pay all reasonable costs associated with such naming, joining or assertion.

 

(iv)            
Any royalties, damage awards, or other payments resulting from any assertion of Intellectual Property hereunder shall first be
applied to recover all reasonable costs incurred by the asserting Party in pursuing the assertion or such costs of both Parties
if the Intellectual Property is jointly asserted, and thereafter shall be shared between the Parties in such amounts as determined
by the JSC subject to the guiding principles that (i) to the extent that such royalties, damage awards or other payments relate
to a Product or jointly owned Intellectual Property, they shall be shared between the Parties in accordance with the terms herein
applicable to sharing of Net Profits related to such Product; (ii) to the extent that such royalties, damage awards or other payments
relate to products or operations outside the scope of this Agreement or Intellectual Property that is not licensed under this Agreement,
they shall be retained one hundred percent (100%) by the Party owning or Controlling the asserted Intellectual Property (or split
50%/50% if the Intellectual Property is jointly owned or Controlled); and (iii) to the extent that such royalties, damage awards
or other payments relate to punitive awards, they shall be retained one hundred percent (100%) by the asserting Party or split
50%/50% if the Intellectual Property is jointly asserted by both Parties. 

 

(v)              
Whenever a Party wishes to or does assert Intellectual Property of the other Party, the asserting Party will consult with and consider
in good faith all recommendations from the other Party regarding the assertion. 

 

(vi)            
Each Party will have the first right, but not the obligation, at its sole expense, to control the defense of any claim by a Third
Party, including any defenses or counterclaims, that any of such Party’s Controlled Intellectual Property is invalid, unpatentable
or unenforceable. Each Party will have the first right, but not the obligation, at its sole expense, to control the settlement
and licensing of such Party’s owned or Controlled Intellectual Property.

 

2.3             
Licenses

 

(a)               
License of IP.

 

(i)                
Amyris grants to Ginkgo, as of the effective date of the Initial Strategic Partnership Agreement, a royalty-free, fully paid-up,
sublicensable, non-exclusive, perpetual (i.e., surviving any termination and extending after the Term) license under any
of its (A) Foundry Intellectual Property that is provided pursuant to Section 2.1 of this Agreement and (B) Overlapping Process
Intellectual Property that is provided pursuant to Section 2.1 of this Agreement or that is invented in whole or in part by Ginkgo.
For clarity, such licenses shall survive termination (regardless of basis) under Section 7.2. 

 

    	 

     

    

For further clarity, the license provided
in this Section 2.3.(a)(i) with respect to Foundry Intellectual Property and Overlapping Process Intellectual Property includes,
but is not limited to, any and all Foundry Intellectual Property and Overlapping Process Intellectual Property that was included
in the ISPA Intellectual Property, and also any updates and/or modification thereto that Amyris provided pursuant to Section 2.1(b).

 

(ii)              
Subject to the value-sharing provisions in Article VI, each Party hereby grants to the other Party, as of the effective date of
the Initial Strategic Partnership Agreement, a royalty-free, fully paid-up, sublicensable (only as provided in Section 2.3(b)),
non-exclusive license to its Background Intellectual Property and its Foreground Intellectual Property within the Field for the
purpose of allowing such other Party to carry out relevant activities under this Agreement. For clarity, the license granted with
respect to Background Intellectual Property in this Section 2.3.(a)(ii) includes, but is not limited to, any and all Background
Intellectual Property that was included in the ISPA Intellectual Property

 

(iii)            
Amyris perpetually (i.e., surviving any termination and extending after the Term) covenants not to sue Ginkgo or its customers
with respect to Process Intellectual Property that is necessary or required for Ginkgo to exploit Foreground Intellectual Property
that relates to a Non-Isoprenoid Strain for products not subject to this Agreement, including such Intellectual Property that Amyris
provided Ginkgo access to pursuant to the Initial Strategic Partnership Agreement. 

 

(b)              
Sublicensing. If a Party enters into a sublicensing arrangement with a Third Party, such Party will ensure that such sublicense
will be consistent with the terms of this Agreement and such Party will be responsible for the actions of its sublicensees. Neither
Party may sublicense its rights related to the other Party’s Background Intellectual Property or Foreground Intellectual
Property, other than to a customer pursuant to a Customer Agreement (in accordance with Article IV), without the prior written
consent of the licensing Party except that each Party may sublicense its rights to the other Party’s Background Intellectual
Property or Foreground Intellectual Property to any Third Party manufacturer solely for the purpose of performing obligations under
this Agreement, including without limitation the manufacture of Refused Products, without the consent of the other Party. 

 

(c)               
Rights of First Refusal. Upon termination of this Agreement, the Parties agree as follows:

 

(i)                
From Amyris. Amyris grants to Ginkgo a royalty-free, sublicensable, fully paid-up, perpetual (i.e., surviving any
termination and extending after the Term) license to its Background Intellectual Property and Foreground Intellectual Property
for the purposes of strain engineering and process development, scale-up and production within the Field with respect to the small
molecule compound identified below in (A), subject to the following conditions: 

 

(A)            
Ginkgo grants Amyris a right of first refusal (“ROFR”) pursuant to the process described in Section 2.3(c)(iii)
for scale-up and production (including strain engineering and optimization but only if necessary for scale-up 

 

    	 

     

    

and production) for any new chemical small
molecule compound in the Field (other than an Excluded Product) developed by Ginkgo for a Third Party that requires third-party
manufacturing after the Term;

 

(B)             
in the event Amyris declines to exercise its ROFR, such license shall be subject to the Supplier Restrictions; 

 

(C)             
if Amyris exercises its ROFR, the Net Profits will be split between the parties in accordance with Section 6.2(a)(i) as though
such molecule or ingredient were a “Product” hereunder; if Amyris declines its ROFR, then the Net Profits will be split
as though such molecule or ingredient were a “Refused Product” hereunder where such molecule or ingredient uses the
other Party’s Intellectual Property that is licensed under this Agreement; and

 

(D)            
Ginkgo provides prompt written notice to Amyris for any such small molecule compounds for which Ginkgo will provide a ROFR pursuant
to Section 2.3(c)(i)(A).

 

(ii)              
From Ginkgo. Ginkgo grants to Amyris a royalty-free, sublicensable, fully paid-up, perpetual (i.e., surviving any
termination and extending after the Term) license to its Background Intellectual Property and Foreground Intellectual Property
for the purposes of strain engineering and process development, scale-up and production within the Field with respect to the small
molecule compound identified below in (A), subject to the following conditions: 

 

(A)            
Amyris grants Ginkgo a ROFR pursuant to the process described in Section 2.3(c)(iii) for strain engineering and small-scale process
development for any new chemical small molecule compound in the Field (other than an Excluded Product) with respect to which Amyris
proposes to develop for a Third Party after the Term;

 

(B)             
in the event Ginkgo declines to exercise its ROFR, such license shall be subject to the Supplier Restrictions;

 

(C)             
if Ginkgo exercises its ROFR, then Net Profits will be split between the parties in accordance with Section 6.2(a)(i) as though
such molecule or ingredient were a “Product” hereunder; if Ginkgo declines its ROFR, then the Net Profits will be split
as though such molecule or ingredient were a “Refused Product” hereunder where such molecule or ingredient uses the
other Party’s Intellectual Property that is licensed under this Agreement; and

 

(D)            
Amyris provides prompt written notice to Ginkgo for any such small molecule compounds for which Amyris will provide a ROFR pursuant
to Section 2.3(c)(ii)(A).

 

    	 

     

    

(iii)            
Rights of First Refusal Process.

 

(A)            
If a Party receives a bona fide offer subject to the ROFR in Section 2.3(c)(i) or 2.3(c)(ii) (each, an “Offer”),
and the Party receiving such offer (the “Developing Party”) intends to accept such offer, the Developing Party
shall provide the other Party with written notice of such offer (a “ROFR Notice”). The ROFR Notice shall identify
the Third Party making the Offer, the chemical small molecule compound, and all material terms and conditions of the Offer.

 

(B)             
In the case of a ROFR Notice delivered by Amyris, such ROFR Notice shall constitute an exclusive offer by Amyris for Ginkgo to
conduct strain engineering and small-scale process development for the applicable new chemical small molecule compound. In the
case of a ROFR Notice delivered by Ginkgo, such ROFR Notice shall constitute an exclusive offer by Ginkgo for Amyris to conduct
for scale-up and production for the applicable new chemical small molecule compound. Any such offer shall remain open and irrevocable
until expiration of fifteen (15) days after receipt of such ROFR Notice by the other Party (the “Offer Period”).
At any time prior to expiration of the Offer Period, the other Party shall have the right to accept the Developing Party’s
offer set forth in the ROFR Notice by giving a written notice of acceptance to the Developing Party.

 

(d)              
Rights of First Refusal upon Certain Terminations. If this Agreement is terminated by a Party pursuant to Section 7.2(a),
Section 7.2(b), Section 7.2(c) or Section 7.2(d), neither Party has any further obligation to offer the other Party a ROFR as provided
under Sections 2.3(c)(i)(A) and 2.3(c)(ii)(A), and any new products of either Party pertaining to chemical small molecule compounds
in the Field which use the other Party’s Intellectual Property that is licensed under this Agreement shall be treated as
a Refused Product hereunder. For clarity, nothing in this Section alters the licenses set forth in Section 2.3(c)(i) and 2.3(c)(ii).

 

(e)               
Escrows. Each Party agrees to maintain a Third Party escrow on the terms of the Escrow Agreement. Each Party shall update
its Third Party escrow whenever a new Product is commercialized and no less frequently than annually during the Term. Such Third
Party escrow shall include the applicable Party’s commercial strains and protocols (including but not limited to materials
lists and media recipes), Standard Operating Procedures, detailed process descriptions, and process flow diagrams pertaining to
manufacturing of Products.

 

(f)               
No Payment of Third Party Royalties or Fees. Notwithstanding anything herein to the contrary, none of the sublicenses granted
hereunder constitutes a covenant by the granting Party to pay any royalties or other fees that become due to a Third Party licensor
in respect of the practice of such Intellectual Property by the other Party.  Unless otherwise agreed by the Parties, each
Party shall be responsible for any such royalty obligations or other fees resulting from its practice of any Intellectual Property
sublicensed to it, except as provided in Section 2.3(g).‎ For clarity, any fees (i) under the licensing agreement between Amyris
and [*]

 

[*] Certain portions denoted with an asterisk have been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

    	 

     

    

[*].

 

(g)              
[*]

 

(h)              
No Other Licenses Granted. Other than as expressly provided for in this Agreement, no other licenses to any Intellectual
Property, including implied licenses, are granted between the Parties.

 

(i)                
Third Party Obligations. Each Party is responsible for identifying any Third Party obligations in its own agreements where
such Party does not have the rights necessary to grant the Intellectual Property rights and licenses granted or to be granted in
this Agreement (i.e., Intellectual Property that is not Controlled). The identifying Party will use commercially reasonable
efforts to remove such Third Party obligation(s) wherever possible and wherever no reasonable work-around solution exists that
would not require such Intellectual Property.

 

2.4             
Section 365(n).

 

(a)               
All rights and licenses granted under or pursuant to any section of this Agreement, including all rights to sublicense, are, and
shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the U.S. Code (the “Bankruptcy Code”),
licenses of rights to “intellectual property” as defined in Section 101(35A) of the Bankruptcy Code. The Parties shall
retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code. Each Party agrees that the
other Party, to the extent that it is a licensee of such rights under this Agreement, shall retain and may fully exercise all of
its rights and elections under the Bankruptcy Code, and that upon commencement of a bankruptcy proceeding by or against one Party
under the Bankruptcy Code, the other Party shall be entitled to a complete duplicate of, or complete access to (as such other Party
deems appropriate), any such Intellectual Property and all embodiments of such Intellectual Property; provided, that such
other Party continues to fulfill its obligations as specified herein in full. Such Intellectual Property and all embodiments thereof
shall be promptly delivered to the other Party (i) upon any such commencement of a bankruptcy

 

[*] Certain portions denoted with an asterisk have been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

    	 

     

    

proceeding upon written request therefor by the
other Party, unless the Party subject to such bankruptcy proceeding elects to continue to perform all of its obligations under
this Agreement or (ii) if not delivered under (i) above, upon the rejection of this Agreement by or on behalf of the Party
subject to such bankruptcy proceeding, upon written request therefor by the other Party. The foregoing is without prejudice to
any rights that either Party may have arising under the Bankruptcy Code, other applicable Law, or this Agreement.

 

(b)              
Nothing in this Section 2.4 shall be deemed any admission that this Agreement is an executory contract or that this Agreement or
any obligation hereunder is otherwise subject to rejection or disavowal in the bankruptcy, liquidation, reorganization, receivership,
assignment for the benefit of creditors, administration, insolvency, or similar proceeding or circumstance (an “Insolvency
Proceeding”) of any Party (the “Withdrawing Party”), nor any admission that upon any such proceeding
or circumstance involving a Party, or upon any such rejection or disavowal by a Party, the other Party (or any sublicensee thereof)
would lose or not be able to enforce or benefit from any right hereunder (or under any applicable sublicense).

 

(c)               
Each of the Parties agrees and acknowledges, as a licensor of Intellectual Property under this Agreement, in entering this Agreement
and granting the rights it respectively grants under this Agreement, and in its efforts to protect its own valuable Intellectual
Property, it has relied on the particular skills and business qualities of the other Party as recipient of such rights. Such skills
and business qualities include the expected future innovation of the other Party, and the particular market segments addressed
by the other Party in its business. Each of the Parties further agrees and acknowledges that upon the occurrence of any Insolvency
Proceeding, this Agreement is of the type described in Section 365(c)(1) and (e)(2) of the Bankruptcy Code, and under any other
applicable Law, for such reasons.

 

(d)              
In the event of an Insolvency Proceeding, the Party that is not the Withdrawing Party (the “Non-Withdrawing Party”)
shall have the right, but not the obligation, to purchase the Withdrawing Party’s interests hereunder (the “Withdrawing
Party’s Interest”), including any right to receive any future payments hereunder (whether for Net Profits, Incentive
Payments, or otherwise), any rights to exclusive ownership of any Intellectual Property that is owned jointly hereunder, and any
rights in the Withdrawing Party’s Customer Agreements. The purchase price for the Withdrawing Party’s Interest (the
“Withdrawing Purchase Price”) shall be fair market value, where such fair market value takes into consideration
future amounts payable under this Agreement, as well as all the additional development and manufacturing costs for Products that
a Third Party with standard manufacturing capacity would bear alone (as opposed to splitting with the Withdrawing Party), and shall
be determined by the applicable bankruptcy court overseeing the Insolvency Proceeding. In the event the Non-Withdrawing Party desires
to exercise to purchase the Withdrawing Party’s Interest for the Withdrawing Purchase Price, the Non-Withdrawing Party shall
deliver a written notice to the Withdrawing Party indicating the desire to exercise such right and setting a closing date for consummation
of the purchase of the Withdrawing Party’s Interest, which closing date shall be no earlier than seventy-five (75) days after
the date of such notice (the “Withdrawal Date”). Payment of the Withdrawing Purchase Price shall be made in
cash on the Withdrawal Date unless the parties agree otherwise, and, upon the Withdrawal Date, the Withdrawing Party shall, and
hereby does, assign all Intellectual Property that is owned jointly hereunder to the Non-Withdrawing Party, and the Withdrawing
Party further agrees to take all 

 

    	 

     

    

action and execute all documents in order to effectuate
the transfer of the Withdrawing Party’s Interest to the Non-Withdrawing Party thereafter.

 

Article
III.                     
COVENANTS

 

3.1             
Obligations of Amyris. Amyris agrees to do the following:

 

(a)               
Paying Agent Agreement. As soon as reasonably practicable after the date hereof, but no later than five (5) calendar days
following the Effective Date, Amyris and Citibank, N.A. (the “Paying Agent”) shall deliver to Ginkgo counterpart
signature pages to the Paying Agent Agreement, in substantially the form attached hereto as Exhibit 3.1(a) (the “Paying
Agent Agreement”).

 

(b)              
Amendment to Third Party Agreements. As of the Effective Date, Amyris shall have a plan mutually agreed upon by the Parties
in place for amending all Customer Agreements to require payments thereunder (other than Incentive Payments) to be delivered to
the Paying Agent, which plan Amyris shall follow in order to complete as soon as reasonably practicable after the Effective Date.

 

3.2             
Obligations of Ginkgo. Ginkgo agrees to do the following:

 

(a)               
Paying Agent Agreement. As soon as reasonably practicable after the date hereof, but no later than five (5) calendar days
following the Effective Date, Ginkgo and the Paying Agent shall deliver to Amyris counterpart signature pages to the Paying Agent
Agreement.

 

Article
IV.                     
OPERATIONS

 

4.1             
New Customers. The Parties shall collaborate to source prospective Customer Agreements in accordance with the guidelines
set forth by the Antitrust Committee; however, neither Party may enter into a proposed Ginkgo Customer Agreement or proposed Amyris
Customer Agreement during the Term except in compliance with the terms herein. The applicable Party shall attempt to determine
each prospective product to be developed under a proposed Customer Agreement (each, a “Prospective Product”)
and, for such Prospective Product, the target costs, estimated annual market volume, product specifications, and chemistry of such
Prospective Product. Thereafter, such Party shall cross-check the prospective customer and the Prospective Product against the
Excluded Products list in Table 5 on Exhibit  6.2(a), as may be amended from time to time. If the Prospective
Product is on such list, or if the Prospective Product is already being developed, manufactured, or commercialized pursuant to
an existing Customer Agreement under terms that would restrict one or both of the Parties from entering into such proposed Customer
Agreement, then the Prospective Product shall be abandoned and the proposed Customer Agreement shall be amended to remove any obligations
related to a Prospective Product; otherwise, if one or more Prospective Products are permitted under a proposed Customer Agreement,
such proposed Customer Agreement shall be referred to the JSC. The JSC, or a designated Subcommittee, shall draft a technical development
plan for each Prospective Product under a proposed Customer Agreement based on the form attached hereto as Exhibit 
4.1 (each, a “Technical Development Plan”), which shall be drafted in good faith by one or more appointees
of the JSC based on the most-recent information available at the time of the drafting of such Technical Development Plan. Each
Technical Development Plan shall be submitted to the JSC,

 

 

     

     

    

which may request amendments to the Technical
Development Plan or approve such Technical Development Plan in accordance with Section 4.2.

 

4.2             
Approval of Technical Development Plan.

 

(a)               
Joint Approval. If the JSC or the Executive Committee approves the Technical Development Plan, the applicable proposed Ginkgo
Customer Agreement or proposed Amyris Customer Agreement shall be executed and the development, manufacture, and commercialization
of each remaining Product under such Customer Agreement shall be considered a Program hereunder, and Table 1 on Exhibit 6.2(a)
shall be updated to include such Product and the relevant additional information specified therein. 

 

(b)              
Single Party Approval. If the JSC and Executive Committee are unable to approve a Technical Development Plan, but one Party
approves the Technical Development Plan, the applicable proposed Ginkgo Customer Agreement or Amyris Customer Agreement may be
executed, and the product thereunder shall be considered a Refused Product under this Agreement. 

 

(c)               
No Approval. If the JSC and Executive Committee are unable to approve a Technical Development Plan, and neither Party wishes
to pursue such Technical Development Plan, such Technical Development Plan and the proposed Ginkgo Customer Agreement or proposed
Amyris Customer Agreement shall be abandoned.

 

4.3             
Capital Expenditures. Except as provided herein, each Party shall be responsible for its Capital Expenditures required for
the development, manufacture and commercialization of Products under this Agreement.

 

4.4             
Manufacturing. Amyris shall expand its production facilities (the “BROTAS2 Facility”) to enable production
of Products hereunder, and Amyris shall consult Ginkgo in connection with such expansion and shall consider any of Ginkgo’s
comments or concerns in good faith. Products shall have Priority Access to manufacturing capacity at any of Amyris’ manufacturing
facilities. If Amyris is, as determined by the JSC in good faith, unable to meet scale-up needs, production needs, or timelines
for Products for technical reasons or other reasons, then (i) Amyris may manufacture as much of the Products as possible pursuant
to a manufacturing agreement to be entered into between Amyris and Ginkgo in accordance with the Amyris manufacturing terms set
forth on Exhibit 4.4(a), and, with the approval of the JSC, Amyris may outsource to a Third Party to manufacture
any remaining Products in accordance with the Third Party manufacturing terms set forth on Exhibit 4.4(b) (the “Supplier
Restrictions”) to meet such needs and timelines and until such time as Amyris is able to meet such needs and timelines
itself. Subject to approval of the JSC under the guiding principles that the Parties shall use reasonable efforts to attempt to
manufacture and commercialize a Product at the most efficient production location for such Product taking into account minimizing
Actual Cost of Goods Sold, the manufacturing location of other Products and/or Excluded Products, time and other relevant considerations,
Amyris reserves the right to utilize a CMO facility as the main and/or sole production site to manufacture one or more Products
including as a bundle with Excluded Products. Amyris shall take all reasonable steps to evaluate Strain performance prior to startup
of Product production. If a Product production issue is identified or is anticipated to result from the

 

    	 

     

    

production Strain, Ginkgo will assist Amyris and
provide the technical resources needed to troubleshoot and resolve the issue. 

 

4.5             
Cooperation. The Parties will reasonably cooperate in connection with the execution of any new Customer Agreement and the
development, manufacture, and commercialization of any new or existing Product hereunder including, without limitation, (a) Amyris
providing Ginkgo with its most up-to-date manufacturing cost models, which shall be updated at least once per Calendar Quarter
during the Term; (b) the Parties shall continue to establish and refine the template for technical development plans set forth
in Exhibit 4.1 to this Agreement; and (c) the business development teams from each Party shall meet periodically,
and no less frequently than at least once per year, to discuss customer needs and market conditions pertaining to the Field and
consistent with the guidelines developed by the Antitrust Committee.

 

Article
V. GOVERNANCE

 

5.1             
Executive Committee. The Executive Committee shall meet (a) at such times as required by this Agreement and (b) within ten
(10) days after the request of a Party for the Executive Committee to hold a meeting. Meetings of the Executive Committee shall
be effective only if at least one (1) representative of each Party is present or participating. The Executive Committee may meet
either (i) in person at either Party’s facilities in the United States or at such locations as the Parties may otherwise
agree or (ii) by audio or video teleconference.

 

5.2             
Partnership Joint Steering Committee.

 

(a)               
Establishment.  The Parties shall maintain a four-person partnership steering committee (“JSC”)
that will have the responsibilities set forth in Section 5.2(b) hereof.  Amyris appoints, and shall be entitled to remove
solely at their discretion, two (2) representatives to the JSC: (x) Joel Cherry and (y) Chuck Kraft; and Ginkgo appoints,
and shall be entitled to remove solely at their discretion, two (2) representatives to the JSC: (A) Kevin Madden and (B) Herve
Garant.  Each Party’s representatives and any substitute for a representative shall be bound by the obligations of confidentiality
set forth in Article X. The JSC shall be led by a chairperson (the “Chairperson”), who shall not have any greater
authority than any other representative on the JSC, but shall be responsible for the following activities: (i) calling meetings
of the JSC and preparing; (ii) preparing an agenda for each meeting and including any items requested by a member of the JSC
on such agenda; (iii) preparing and issuing minutes of each such meeting within thirty (30) days thereafter; (iv) ensuring
that any decision-making delegated to the JSC is carried out in accordance with this Article V; and (v) preparing and circulating
an agenda for the upcoming meeting; provided that the Chairperson shall include any agenda items proposed by the other Party.
Each Chairperson shall serve for six (6) month terms and appointment of the Chairperson shall rotate between the Parties, with
Amyris appointing the first Chairperson. Each Party shall be free to change its representatives on notice to the other Party or
to send a substitute representative to any JSC meeting; provided, however, that each Party shall ensure that at all times
during the existence of the JSC, its representatives on the JSC are appropriate in terms of expertise and seniority for the then-current
stage of development, manufacture or commercialization of the Products.

 

    	 

     

    

(b)              
Responsibilities.  The JSC shall have responsibility for:  (i) ensuring regular communication between the
Parties; (ii) ensuring the establishment of, and monitoring of progress of, Programs; (iii) monitoring, reviewing, and
reporting on the progress of any Products developed pursuant to this Agreement; and (iv) performing such other functions as
expressly set forth in this Agreement or appropriate to further the purposes of this Agreement, as mutually agreed upon by the
Parties in writing. The JSC has the authority to delegate any of these responsibilities as it sees fit. Each individual member
of the JSC shall be bound by the obligations of confidentiality set forth in Article X.  Each individual member of the JSC
shall not have any independent authority to act on behalf of the JSC unless such authority has been delegated to such individual
in advance by the JSC.

 

5.3             
Program Management Teams; Other Subcommittees.  The JSC shall establish a program management team (each, a “Program
Management Team”) for each Program and a project management team (each, a “Project Management Team”) for
each Product under a Program (each, a “Project”) unless otherwise agreed by the JSC (and, for clarity, the JSC may
instead determine that there should be different Project Management Teams for early stage vs. late stage activities for a Product
under a Program, or any other approach approved by the JSC). The JSC shall designate a program lead (each, a “Program
Lead”) from one Party and, if deemed appropriate by the JSC, a co-program lead (the “Co-Program Lead”)
from the other Party for each Program Management Team, who shall be responsible for monitoring each Program and reporting to the
JSC concerning status of each Program and the progress of any Products developed pursuant to this Agreement. The JSC shall also
designate a project lead (each, a “Project Lead”) from one Party and, if deemed appropriate by the JSC, a co-project
lead (the “Co-Project Lead”) from the other Party for each Project Management Team, who shall be responsible
for monitoring each Project under a Program and reporting to the JSC concerning status of each Project under a Program and the
progress of any Products developed pursuant to this Agreement. The Project Lead and Co-Project Lead shall use good faith efforts
to execute the applicable Project in accordance with its Technical Development Plan. The Project Lead for a given Project shall
be primarily responsible for (a) achieving any milestones under the Project; (b) commercializing the Product under a
given Project at scale; and (c) with reasonable consultation with the Co-Project Lead, developing and overseeing the Project,
including defining tasks, task dependencies and goals that leverage the capabilities of each Party to commercialize the Product
under the Program at scale; provided, the Project Lead shall use commercially reasonable efforts to allocate early stage
development work and later stage scale-up and manufacturing work, in each case, as appropriate based on capabilities and capacity
of each Party with the intention of maximizing speed to market for the Product; and provided, further, that the Party that
is a party to the applicable Customer Agreement shall be solely responsible for interfacing with the customer of such Program (including,
without limitation, serving on any steering or similar committee under the applicable Customer Agreement for such Program). In
the event that there is a dispute concerning a Program between a Program Lead and a Co-Program Lead or a Project between a Project
Lead and a Co-Project Lead, the JSC shall attempt to resolve such dispute in good faith and, if the JSC is unable to do so, such
dispute shall be resolved in accordance with Section 5.6. The JSC may establish and disband such other subcommittees as deemed
necessary by the JSC (each, a “Subcommittee”). Within 15 calendar days of the Effective Date, the JSC will establish
a Subcommittee responsible for handling all legal and intellectual property matters that may arise under the collaboration (“Legal
and Intellectual Property Subcommittee”). The responsibilities of the Legal and Intellectual Property Subcommittee shall
include addressing all freedom-to-operate issues that

 

    	 

     

    

arise during the course of the Term. Each Program
Management Team, Project Management Team and Subcommittee shall consist of the same number of representatives from each Party,
which number shall be mutually agreed by the JSC.  For the avoidance of doubt, either Party may designate the same representatives
to serve on multiple or all Program Management Teams (including as Program Lead and/or Co-Program Lead), Project Management Teams
(including as Project Lead and/or Co-Project Lead) or Subcommittees or on the JSC and any Program Management Team, Project Management
Team or Subcommittee. Each Party shall be free to change its representatives on notice to the other or to send a substitute representative
to any Program Management Team, Project Management Team or Subcommittee meeting; provided, however, that (x) the JSC
shall be required to approve each Program Lead, Co-Program Lead, Project Lead and Co-Project Lead, and (y) each Party shall
ensure that at all times during the existence of any Program Management Team, Project Management Team or Subcommittee, its representatives
on such Program Management Team, Project Management Team or Subcommittee are appropriate in terms of expertise and seniority for
the then-current stage of the development, manufacture and commercialization of a Product under the given Program. Each Party’s
representatives and any substitute for a representative shall be bound by the obligations of confidentiality set forth in Article
X.  No Program Management Team, Project Management Team or Subcommittee shall have the authority to bind the Parties hereunder
and each Program Management Team, Project Management Team or Subcommittee shall report to, and any decisions shall be made by,
the JSC.

 

5.4             
Committee Meetings.  The JSC and each of the Program Management Teams, Project Management Teams and Subcommittees
shall each hold at least one (1) meeting per Calendar Quarter at such times during such Calendar Quarter as the Chairperson elects
to do so.  Meetings of the JSC and each of the Program Management Teams, Project Management Teams or Subcommittees, respectively,
shall be effective only if at least one (1) representative of each Party is present or participating.  The JSC and each Program
Management Team, Project Management Team or Subcommittee may meet either (a) in person at either Party’s facilities
in the United States or at such locations as the Parties may otherwise agree or (b) by audio or video teleconference; provided
that no less than one (1) JSC meeting during each Calendar Year shall be conducted in person.  Other representatives of each
Party involved with the relevant Programs or Projects may attend meetings as non-voting participants, subject to the confidentiality
provisions set forth in Article X.  Additional meetings of the JSC, Program Management Teams, Project Management Teams or
Subcommittees may also be held with the consent of each Party, and neither Party shall unreasonably withhold its consent to hold
such additional meetings, or as required under this Agreement.  Each Party shall be responsible for all of its own expenses
incurred in connection with participating in all such meetings, and such expenses shall not be included in the calculation of Actual
Cost of Goods Sold hereunder.

 

5.5             
Authority.  The JSC, each Program Management Team, each Project Management Team and each Subcommittee shall have only
the powers assigned expressly to it in this Article V and elsewhere in this Agreement, and shall not have any power to amend, modify
or waive compliance with this Agreement.  In furtherance thereof, each Party shall retain the rights, powers and discretion
granted to it under this Agreement and no such rights, powers or discretion shall be delegated or vested in the JSC or any Program
Management Team or any Project Management Team or Subcommittee unless such delegation or vesting of rights is expressly provided
for in this Agreement or the Parties expressly so agree in writing.

 

    	 

     

    

5.6             
Decisions.

 

(a)               
Initial Dispute Resolution Procedures.  Subject to the provisions of this Article V, actions to be taken by the JSC
and each of the Program Management Teams, Project Management Teams or Subcommittees shall be taken only following a unanimous vote,
with each Party (through its representatives) having one (1) vote.  If any Program Management Team, Project Management Team
or Subcommittee fails to reach consensus on a matter before it for decision for a period in excess of thirty (30) days, either
Party shall have the right to refer the matter to the JSC.

 

(b)              
Final Decision-Making. If the JSC fails to reach unanimous agreement on a matter properly before it for decision for a period
in excess of ten (10) days, the matter shall be referred to the Executive Committee. If the Executive Committee fails to reach
unanimous agreement on a matter before it for decision for a period in excess of ten (10) days, the matter shall be resolved in
accordance with Section 11.2; provided, if the matter before the Executive Committee is approval of a Technical Development
Plan and the Executive Committee is unable to reach a consensus, the matter shall be resolved in accordance with Section 4.2.

 

5.7             
Conduct of Meetings; Future Adjustments in Governance. 

 

(a)               
Any meetings of the Executive Committee, JSC, a Program Management Team, a Project Management Team or a Subcommittee shall have
an agenda circulated in advance of such meeting. The Party responsible for preparing an agenda for any such meeting shall include
on the agenda any items suggested by the representatives of the other Party to be addressed at such meeting. Minutes will be taken
at each meeting by an individual appointed by the applicable committee, and circulated for review and approval of the same. Copies
of all final agendas and approved meeting minutes will be provided to each Party’s legal counsel. 

 

(b)              
The Parties may at any time by mutual written agreement create or delete governance committees or subcommittees or make other modifications
to the governance structures contemplated by this Agreement in order to promote the efficient operation of the Programs and/or
the Projects.

 

Article
VI.                     
FINANCIAL PROVISIONS

 

6.1             
BROTAS2 Fee. Subject to Amyris fully funding and breaking ground on the BROTAS2 Facility by March 30, 2017, Ginkgo shall
pay to Amyris a non-refundable fee of $[*] on or before March 31, 2017. For clarity, the Parties agree that the term “breaking
ground” means that Amyris has completed the following items: (A) proof of adequate funding; (B) engineering plans and layout
plans generated by a licensed and reputable engineer have been completed (with a copy provided to Ginkgo); (C) all necessary easements
or real property acquisitions necessary for BROTAS2 Facility have been secured; (D) all necessary approvals from the relevant authorities
to begin construction have been obtained (with a copy of such approval(s)

 

[*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

 

    	 

     

    

provided to Ginkgo); and (E) Amyris has begun
actual digging in the earth to start the construction of BROTAS2 Facility.

 

6.2             
Sharing of Net Profits.

 

(a)               
Allocation of Net Profits and Incentive Payments.

 

(i)                
New Contract for a Product. For any Products that are not Refused Products that are (A) developed under an Amyris Customer
Agreement or Ginkgo Customer Agreement or (B) listed on Table 1 in Exhibit 6.2(a), Net Profits plus any Incentive
Payments for such Products under such Customer Agreement shall be allocated fifty percent (50%) to each of Amyris and Ginkgo until
the development, manufacture, and commercialization of such Products under such Customer Agreement are permanently discontinued.

 

(ii)              
Existing Contract for a New Product. For any Products listed on Table 2 in Exhibit 6.2(a), Net Profits plus
any Incentive Payments less any Earned Incentive Payments for such Products under the applicable Customer Agreement shall be allocated
fifty percent (50%) to each of Amyris and Ginkgo until the development, manufacture, and commercialization of such Products under
such Customer Agreement are permanently discontinued. Earned Incentive Payments under a Customer Agreement for such Products shall
be allocated [*] to the Party indicated as “Sourcing Party” on such Table. Any extension after the Effective Date of
a Customer Agreement for a Product listed on Table 2 in Exhibit  6.2(a) (other than pursuant to the exercise
of a pre-existing renewal or extension option included in such Customer Agreement) shall be considered a new Customer Agreement
subject to Section 6.2(a)(i) hereof, unless such extension extends the term of the underlying Customer Agreement by no more than
six months from the termination date in effect on the Effective Date and does not otherwise materially alter the provisions of
such Customer Agreement. 

 

(iii)            
Existing Contract for a Product Under Development. For any Products listed on Table 3 in Exhibit  6.2(a),
Net Profits plus any Incentive Payments less any Earned Incentive Payments for such Products under the applicable Customer Agreement
shall be allocated fifty percent (50%) to each of Amyris and Ginkgo until the development, manufacture, and commercialization of
such Products under such Customer Agreements are permanently discontinued. Earned Incentive Payments under a Customer Agreement
for such Products shall be allocated [*] to the Party indicated as “Sourcing Party” on Table 3 in Exhibit 
6.2(a). Any extension after the Effective Date of a Customer Agreement listed on Table 3 in Exhibit  6.2(a)
(other than pursuant to the exercise of a pre-existing renewal or extension option included in such Customer Agreement) after the
Effective Date shall be considered a new Customer Agreement subject to Section 6.2(a)(i) hereof, unless such extension extends
the term of the underlying Customer Agreement by no more than six months from the termination date in effect on the Effective Date
and does not otherwise materially alter the provisions of such Customer Agreement. Any termination of a Customer Agreement listed
on Table 3 in Exhibit  6.2(a) after the Effective Date as a result of a conflict with a Customer Agreement of
the other Party shall result in the corresponding Customer Agreement of 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

    	 

     

    

such other Party, and any Products thereunder,
being treated as a new Customer Agreement subject to Section 6.2(a)(i) thereafter.

 

(iv)            
Existing Commercial Product. Table 4 in Exhibit 6.2(a) sets forth the Actual Cost of Goods Sold for each Product
currently being commercialized by Amyris. For each new Customer Agreement for such Products sourced by Ginkgo, Net Profits and
Incentive Payments under such new Customer Agreement for such Product shall be allocated between the Parties as though such Customer
Agreement is for a new Product subject to Section 6.2(a)(i). For each Customer Agreement for a Product listed in Table 4 in
Exhibit  6.2(a) originated by Amyris (whether before or after the Effective Date), Net Profits and Incentive
Payments under such Customer Agreement for such Product shall be allocated [*] to Amyris. Notwithstanding the foregoing, should
the Actual Cost of Goods Sold for a Product listed in Table 4 in Exhibit 6.2(a) be reduced from the amount set forth
in such Table, Ginkgo shall be entitled to receive a percentage of the savings as a result of such reduction in Actual Cost of
Goods Sold, with the specific percentage of the savings for such Product as set forth across from the name of such Product in Table
4 in Exhibit  6.2(a) (the “Ginkgo Cost Savings”). In the event that Ginkgo requests to help
Amyris improve its farnesene strain by providing a technical proposal to the Executive Committee, the Executive Committee will
approve any such reasonable technical proposal, and provided that Ginkgo performs work under such proposal, but regardless
of whether such work achieves any particular success or outcome (including production of any strain meeting any particular requirements)
or whether results of such work are incorporated into any production of any farnesene strains Product, Ginkgo shall be entitled
to receive [*]of the savings for any reduction in Actual Cost of Goods Sold for any farnesene sold thereafter as Ginkgo Cost Savings
hereunder. 

 

(v)              
Refused Products. In the event that one Party elects, at any time during the development of a Product, not to participate
in the development of such Product (such Party, the “Non-Participating Party”, and such Product, a “Refused
Product”), such Party shall provide written notice of such election to the other Party, and where such Product uses the
other Party’s Intellectual Property that is licensed under this Agreement, Net Profits for such Product shall be allocated
[*] to the Non-Participating Party and [*] to the other Party until the development, manufacture, and commercialization of such
Refused Product are permanently discontinued. The Parties agree that [*] shall be considered a Refused Product. In the event that
Ginkgo engages a Third Party manufacturer to manufacture a Refused Product, such manufacturing shall be subject to the Supplier
Restrictions set forth in Exhibit 4.4(b). For clarity, the Parties recognize that the decision not to participate
in the development of a Product shall cause any Intellectual Property created in connection with such development to be owned,
as between the Parties, solely by the developing Party; provided, however, that such Intellectual Property shall
be considered Foreground Intellectual Property for purposes of the license granted in Section 2.3(a)(ii).

 

(vi)            
Excluded Products. Notwithstanding anything in this Agreement to the contrary, the products listed in Table 5 in Exhibit 
6.2(a), which shall be amended with the approval of the JSC from time to time to reflect such chemical small molecule compound(s)
developed, manufactured, and/or commercialized in the Field that are outside 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

    	 

     

    

the scope of this Agreement, shall not
be considered Products hereunder (the “Excluded Products”), the development, manufacture, and commercialization
of such Excluded Products shall be outside the scope of this Agreement, and, absent any other agreement to the contrary, no Party
shall be obligated to make any payments to the other Party (whether directly or indirectly) for the development, manufacture, or
commercialization of any Excluded Products.

 

6.3             
Reporting. From and after the Effective Date, the Parties shall conduct a quarterly reconciliation of Net Profits, Incentive
Payments, Actual Cost of Goods Sold, and Ginkgo Cost Savings as follows, on a Product-by-Product basis:

 

(a)               
Within forty-five (45) days after the filing by Amyris of each Quarterly Report on Form 10-Q with the Securities and Exchange Commission,
and within thirty (30) days after the filing by Amyris of its Annual Report on Form 10-K with the Securities and Exchange Commission,
or, if Amyris is no longer making such filings with the Securities and Exchange Commission, within the applicable amount of time
after such filings would have been made, each Party shall submit to the JSC a written report setting forth, as applicable:

 

(i)                
actual revenues and expenses included in Net Profits, Incentive Payments, Earned Incentive Payments (if applicable), Actual Cost
of Goods Sold, and Ginkgo Cost Savings (if applicable) for such Product on a customer-by-customer basis for such Calendar Quarter,
including, as applicable:

 

(A)            
all sales in units, in Net Profits value, and any Incentive Payments received from a Customer during such Calendar Quarter; 

 

(B)             
the relevant Actual Cost of Goods Sold and, if applicable, Ginkgo Cost Savings for such Product incurred by each Party or its Affiliates
with respect to such Product during such Calendar Quarter, along with all ACOGS Invoices (as defined herein) delivered pursuant
to Section 6.4(c) during such Calendar Quarter; and 

 

(C)             
if applicable, any Earned Incentive Payments received from a Customer during such Calendar Quarter. 

 

(b)              
Within thirty (30) days after the receipt of the report pursuant to subparagraph (b) above, the Party then entitled to appoint
the JSC Chairperson shall submit to the JSC a written reconciliation report (the “Quarterly Payment Report”)
setting forth in reasonable detail the calculation of Net Profits, Incentive Payments, Earned Incentive Payments, Actual Cost of
Goods Sold, Ginkgo Cost Savings, Withholding Taxes, the calculation of the net amount owed by the Paying Agent to each of Amyris
and Ginkgo, as applicable, and the calculation of any Incentive Payments that need to be made from one Party to the other Party,
as applicable, in order to ensure compliance with Section 6.2 and the proper allocation of Withholding Taxes pursuant to Section
6.6.

 

(c)               
Each Party shall have ninety (90) days after delivery of a Quarterly Payment Report (the “Objection Period”)
to dispute the calculations therein by delivery of a written notice to the JSC of any objections thereto (the “Objection
Notice”). The Objection Notice shall set 

 

    	 

     

    

forth in reasonable detail the particulars of
such objections (the “Disputed Amount”). If no Objection Notice is delivered in the Objection Period, the Quarterly
Payment Report shall be considered final and binding on the Parties.

 

(d)              
If an Objection Notice is delivered, the JSC shall as soon as possible, and in any event no later than twenty (20) days after delivery
of the Objection Notice, negotiate in good faith to resolve any disputes related to the Quarterly Payment Report. If the JSC is
not able to resolve a dispute in such period, either Party may submit such dispute to, and such dispute shall be resolved fully,
finally, and exclusively through the use of, an Independent Accounting Firm. The fees and expenses of the Independent Accounting
Firm incurred in the resolution of such dispute shall be borne by the Parties in such proportion as is appropriate to reflect the
relative benefits received by each Party based on the final resolution of the Disputed Amount in accordance with this Section 6.3.
For example, if Party A challenges the calculation in the Quarterly Payment Report by an amount of $[*], but the Independent Accounting
Firm believes that Party A has a valid claim for only $[*], Party B shall bear [*] of the fees and expenses of the Independent
Accounting Firm and Party A shall bear [*] of the fees and expenses of the Independent Accounting Firm. The Independent Accounting
Firm shall determine (and written notice thereof shall be given to the Parties) as promptly as practicable, but in any event within
fifteen (15) days following its appointment and based solely on the written submissions detailing the disputed items submitted
to it by both Parties, the disputed items submitted to the Independent Accounting Firm. All negotiations pursuant to this Section
6.3 shall be treated as compromise and settlement negotiations for purposes of Rule 408 of the Federal Rules of Evidence and comparable
other laws including state rules of evidence, and all negotiations, submissions to the Independent Accounting Firm, and dispute
resolution proceedings under this Section 6.3(d) shall be treated as confidential information. The Independent Accounting Firm
shall be bound by a mutually agreeable confidentiality agreement. The determination of the Independent Accounting Firm shall be
final and binding on the Parties. The decision rendered pursuant to this Section 6.3(d) may be filed as a judgment in any court
of competent jurisdiction. Either Party may seek specific enforcement or take other necessary legal action to enforce any decision
under this Section 6.3(d). The other Party’s only defense to such a request for specific enforcement or other legal action
shall be fraud by or upon the Independent Accounting Firm. Absent such fraud, such other Party shall reimburse the Party seeking
enforcement for its expenses related to such enforcement.

 

(e)               
The final determination of each Quarterly Payment Report under this Section 6.3 shall not impair any other rights of a Party
under this Agreement including, without limitation, any rights to indemnification.

 

6.4             
Payment Mechanics.

 

(a)               
Each Customer Agreement shall require that all payments of invoices and purchase orders related to the sale of a Product issued
pursuant to such Customer Agreement shall be paid directly to the Paying Agent and the payment terms shall be net 30 days unless
otherwise approved by the Executive Committee. In the event a Party receives a payment of any invoice or purchase order issued
pursuant to a Customer Agreement, such Party shall promptly, and in any event no later than three (3) Business Days after receipt
of such payment, wire an amount equal to the amount of such payment to the Paying Agent.

 

 

 

[*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

 

    	 

     

    

(b)              
All payments of Incentive Payments, whether or not such Incentive Payments are Earned Incentive Payments, shall be made directly
to the Party named in the Customer Agreement to which such Incentive Payment relates, and any portion of the Incentive Payments
that are not Earned Incentive Payments allocable to the other Party shall be paid to the other Party no later than thirty (30)
days after the end of the applicable Calendar Quarter as payment of a fee for the services of the business development team of
the other Party during such Calendar Quarter. For any Incentive Payments that are not Earned Incentive Payments that have been
collected by a Party as of the Effective Date and are allocable to the other Party, including without limitation the Incentive
Payments collected under the [*], the portion allocable to the other Party shall be paid within thirty (30) days after the Effective
Date for the services of the business development team of the other Party prior to the date hereof.

 

(c)               
As soon as reasonably practicable following the shipping of any Products manufactured by or on behalf of a Party, such Party shall
send an invoice (an “ACOGS Invoice”) to the other Party in an amount equal to the product of (i) 1.1 and (ii)
the Actual Cost of Goods Sold for the Products reflected in such ACOGS Invoice. Within three (3) Business Days after payment by
a customer of any invoice or purchase order issued pursuant to a Customer Agreement, the Parties shall execute joint written instructions
to the Paying Agent to wire an amount equal to the amount set forth in the ACOGS Invoice corresponding to such invoice or purchase
order to the Party submitting such ACOGS Invoice to the other Party. Within three (3) Business Days after a Quarterly Payment Report
is deemed final and binding on the Parties: 

 

(i)                
If the final Quarterly Payment Report indicates that the payments a Party received pursuant to Section 6.4(c) during the applicable
Calendar Quarter were greater than an amount equal to the product of (i) 1.1 and (ii) the applicable Actual Cost of Goods Sold
for such Calendar Quarter, such Party shall pay the amount of any such excess payment, by wire transfer of immediately available
funds, to the Paying Agent for distribution in accordance with Section 6.4(c)(ii).

 

(ii)              
The Parties shall deliver joint written instructions to the Paying Agent instructing the Paying Agent to deliver to Amyris and
Ginkgo, as applicable, such Party’s share of the Net Profits, and Ginkgo Cost Savings set forth in the final Quarterly Payment
Report.

 

6.5             
Audits.  For a period beginning as of the Effective Date and ending on the date that is three (3) years following the
final payment of Net Profits and/or Incentive Payments under this Agreement, each Party shall keep, and shall cause its Affiliates
to keep, full, true and accurate books and records containing all particulars relevant to the calculation of Net Profits, Actual
Cost of Goods Sold, Ginkgo Cost Savings, Incentive Payments and Earned Incentive Payments in sufficient detail to enable the other
Party to verify the amounts payable by or to it under this Agreement. Each Party shall have the right, not more than once during
any Calendar Year and at its own expense, to have the books and records of the other Party and its Affiliates, as applicable, audited
by an Independent Accounting Firm. Audits under this Section 6.5 shall be conducted at the principal place of business of
the financial personnel with responsibility for preparing and maintaining such records, during normal business hours, upon at least
thirty (30) days’ prior written notice, and for the sole purpose of verifying amounts payable by or to such Party under

 

 

 

[*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

 

    	 

     

    

this Agreement. All information and data reviewed
in any audit conducted under this Section 6.5 shall be used only for the purpose of verifying amounts payable by or to a Party
under this Agreement and shall be treated as Confidential Information of the audited Party subject to the terms of this Agreement.
The auditing Party shall cause its accounting firm to enter into a reasonably acceptable confidentiality agreement with the audited
Party and its Affiliates, as applicable. The accounting firm shall disclose to the auditing Party only whether the calculation
of Net Profits, Actual Cost of Goods Sold, Ginkgo Cost Savings, Incentive Payments and Earned Incentive Payments, and payments
hereunder are correct or incorrect and the specific details concerning any discrepancies. If the audit demonstrates that the payments
owed under this Agreement have been understated, the audited Party shall pay the balance to the auditing Party, which shall be
paid together with interest in accordance with Section 6.8.  Further, if the amount of the understatement is greater
than [*] of the amount owed to the auditing Party with respect to the audited period, then the audited Party shall reimburse the
auditing Party for the reasonable out-of-pocket cost of the audit.  If the audit demonstrates that the payments owed under
this Agreement have been overstated, the audited Party shall be entitled to credit such amount against payments due to the auditing
Party.  All payments owed by or to a Party under this Section 6.5 shall be made within forty-five (45) days after the
results of the audit are delivered to the Parties.

 

6.6             
Tax Matters.  Any amounts payable by a Party or the Paying Agent (the “Payor”) to the other Party
(the “Payee”) pursuant to this Agreement (each a “Payment”) shall be made without deduction
or withholding for taxes except to the extent that any such deduction or withholding is required by Law in effect at the time of
the Payment. In the event that the Payor is required by applicable Law to deduct, withhold and pay over (collectively, “Withhold”)
any tax (a “Withholding Tax”) from or in respect of such Payment, the Payor shall (a) notify the Payee
of such requirement promptly upon first becoming aware thereof, and in no event less than five (5) days prior to Withholding, (b) Withhold
the full amount of such Withholding Tax to the relevant taxing authority as and when due and (c) pay the net after-Withholding
Tax amount of such Payment to the Payee, together with documentation confirming the amount and fact of the associated Withholding.
The amount of Withholding Tax required to be Withheld in respect of a Payment shall be (i) determined in the good-faith discretion
of the Payor, with due regard to any valid documentation previously provided to the Payor by or for the benefit of the Payee, in
form and substance reasonably satisfactory to the Payor, that supports a reduced rate of Withholding Tax in respect of the Payment,
and (ii) treated for all purposes of this Agreement as having been duly and timely paid by the Payor to or for the benefit
of the Payee. The Parties agree to cooperate in good faith to (x) minimize the amount of any Withholding Tax prior to Withholding,
and (y) permit a Payee to recover any excess Withholding Tax previously Withheld. On the date of execution of this Agreement, each
Party will deliver to the other an accurate and complete Internal Revenue Service Form W-9.

 

6.7             
Currency Exchange.  All payments to be made by a Party to the other Party shall be made in Dollars.  In the case
of Actual Cost of Goods Sold outside the United States, the average reasonable foreign exchange rates in effect when the transactions
occur as recorded in Amyris’ books and records for monthly external reporting will be used. In the case of any other payments
made pursuant to a Customer Agreement that are not in Dollars, the reasonable exchange rate used when the funds are converted to
Dollars shall be used as the conversion rate.

 

 

 

[*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

 

    	 

     

    

6.8             
Late Payments.  Without limiting any other rights or remedies available to a Party hereunder, if the paying Party does
not pay any amount due on or before the due date, the paying Party shall pay to such Party interest on any such amounts from and
after the date such payments are due under this Agreement at a rate per annum equal to the [*] in effect published in The Wall
Street Journal, Eastern Edition, plus [*] basis points, or the maximum applicable legal rate, if less, calculated on
the total number of days payment is delinquent; provided that with respect to any disputed payments, no interest payment
shall be due until such dispute is resolved and the interest which shall be payable thereon shall be based on the finally-resolved
amount of such payment, calculated from the original date on which the disputed payment was due through the date on which payment
is actually made.

 

6.9             
General Payment Provisions.  Notwithstanding anything to the contrary in this Agreement, (a) there shall be no
double-counting of expenses or revenue in the calculation of Net Profits, Actual Cost of Goods Sold, and Incentive Payments hereunder,
and (b) Net Profits, Actual Cost of Goods Sold, Ginkgo Cost Savings, Incentive Payments, and any components thereof shall
be determined from the books and records of the applicable Party and its Affiliates maintained in accordance with the Accounting
Principles.

 

Article
VII.                  
TERM AND TERMINATION

 

7.1             
Agreement Term.  The term of this Agreement shall commence on the Effective Date and shall continue for three (3) years
from the Effective Date unless terminated pursuant to Sections 7.2(a), 7.2(b), 7.2(c) or 7.2(d) below (the “Initial Term”).
The Agreement shall automatically be extended for successive one-year periods (each, a “Renewal Term” and, collectively
with the Initial Term, the “Term”) unless a Party delivers a written notice of non-renewal to the other Party
not less than ninety (90) days prior to a Renewal Term.

 

7.2             
Termination.

 

(a)               
Termination by Mutual Agreement. At any time during the Term, the Agreement may be terminated upon the mutual written consent
of the Parties.

 

(b)              
Termination for Material Non-Performance.  If, as of the eighteen (18) month anniversary of the Effective Date, the
Executive Committee, after receiving input from the members of the JSC, determines that a Party is repeatedly unable to perform
or meet commitments under its Customer Agreements or Technical Development Plans, the other Party shall have a right to terminate
the Agreement on thirty (30) days’ prior written notice. Notwithstanding the foregoing, if a Party disputes the termination,
then Section 7.2(e) shall apply.

 

(c)               
Termination for Material Breach.  If either Party (the “Non-Breaching Party”) believes that the
other Party (the “Breaching Party”) is in material breach of this Agreement, then the Non-Breaching Party may
deliver notice of such breach to the Breaching Party.  To the extent such breach is reasonably capable of being cured, if
the Breaching Party fails to cure such breach, or to initiate such steps as would be considered reasonable to effectively cure
such breach (and thereafter diligently pursues such cure), within thirty (30) days after receipt of such notice of breach, the
Non-Breaching Party may terminate this Agreement upon written notice

 

[*] Certain portions denoted with an asterisk have been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

    	 

     

    

to the Breaching Party.  Notwithstanding
the foregoing, if a Party disputes the termination, then Section 7.2(e) shall apply.

 

(d)              
Termination for Change in Control. A Party (the “Changed Party”) shall provide fifteen (15) days’
prior written notice (a “Change in Control Notice”) of any Change in Control of the Changed Party. The other
Party may terminate this Agreement in its sole and absolute discretion upon written notice given to the Changed Party not later
than ten (10) days after the receipt of such Change in Control Notice.

 

(e)               
Termination Disputes.  If a Party gives notice of non-performance, notice of breach or notice of termination under
Sections 7.2(b) or 7.2(c), and the other Party disputes whether such notice was proper, then the issue of whether or not such
non-performance or breach entitled the Party providing such notice to terminate this Agreement shall be resolved in accordance
with Section 11.2, and the Agreement shall remain in full force and effect until such dispute is resolved.  All cure periods
shall be tolled during such dispute resolution process. If, as a result of such dispute resolution process it is determined that
the notice of termination was proper, then the Breaching Party shall be entitled to the remainder of the relevant cure period and
such termination shall only be effective if the relevant breach is not cured or otherwise addressed in accordance with this Agreement
during such period.  On the other hand, if, as a result of the dispute resolution process, it is determined that the notice
of termination was improper, then no termination shall have occurred or shall occur as a result of such notice and this Agreement
shall remain in full force and effect.

 

7.3             
Effects of Termination.

 

(a)               
Upon termination of this Agreement for any reason:

 

(i)                
Ginkgo shall retain each Ginkgo Customer Agreement, Amyris shall retain each Amyris Customer Agreement, and the JSC shall determine
what the Parties shall do with respect to any Customer Agreement to which both Parties are a party;

 

(ii)              
Each Party shall return the other Party’s Confidential Information in accordance with Section 10.3; and

 

(iii)            
Subject to Section 7.3(d) below, each provision of this Agreement that does not expressly survive termination of this Agreement
or extend beyond the Term shall terminate and be of no further force and effect.

 

(iv)            
If during the Term:

 

(A)            
The Parties had determined that there are no restrictions on the Parties relating to (1) use of Amyris Background Intellectual
Property in the Flavors and Fragrances Market and/or (2) the manufacture of Products for the Flavors and Fragrances Market, then
for the Products listed in Table 2 of Exhibit 6.2(a) where Amyris is listed as the “Sourcing Party”, Ginkgo shall have
no rights and Amyris shall have no obligations to Ginkgo after the termination of this Agreement unless Amyris has been directed
to perform research or development on such Products prior to such termination by the relevant Third Party. 

 

    	 

     

    

(B)             
Amyris and/or Ginkgo was unable to use Amyris Background Intellectual Property for Products in the Flavors and Fragrances Market
and/or the Parties were unable to produce each Product in the Flavors and Fragrances Market under this Agreement for more than
one Third Party, Ginkgo shall be entitled after such termination to receive 50% of the Net Profits to make such Products in Table
2 of Exhibit 6.2(a), as well as other products not listed in Table 2 of Exhibit 6.2(a) for the relevant Third Party, regardless
of whether Ginkgo performed research or development on such Products prior to such termination.

 

(b)              
Termination of this Agreement shall be in addition to, and shall not prejudice, the Parties’ remedies at law or in equity,
including the Parties’ ability to receive legal damages and/or equitable relief with respect to any breach of this Agreement,
regardless of whether or not such breach was the reason for the termination. 

 

(c)               
Expiration or termination of this Agreement for any reason shall not release either Party from any obligation or liability which,
on the effective date of such expiration or termination, has already accrued to the other Party or which is attributable to a period
prior to such expiration or termination.

 

(d)              
Article I, Section 2.3(a)(i), Section 2.3(a)(iii), Section 2.3(e), Section 2.3(f), Section 2.4, Article VI, Section 7.3, Article
VIII, the last sentence of Section 9.5, Article X, and Article XI shall survive termination or expiration of this Agreement. Section
2.3(a)(ii) and Section 2.3(b) shall survive solely A) with respect to any updates and/or modifications to the Intellectual Property
provided under the Initial Strategic Partnership Agreement, to the extent and for such time as Section 2.1 survives as indicated
below, and (B) for any other Intellectual Property actually provided by the Parties prior to termination or expiration of this
Agreement in connection with the performance of activities under this Agreement for the Parties’ continued use of the existing
(as of such termination or expiration) Products or Refused Products with the existing (as of such termination or expiration) customers,
as the case may be. Notwithstanding the foregoing, (i) Section 2.3(c) shall survive subject to Section 2.3(d) and (ii) Section
2.1 shall survive solely to the extent applicable to Section 2.3(c) or in connection with the performance of activities under this
Agreement for the Parties’ continued use of the existing (as of such termination or expiration) Products or Refused Products
with the existing (as of such termination or expiration) customers, as the case may be. The Parties shall meet after such termination
or expiration of this Agreement to determine in good faith whether any changes should be made with respect to the Parties’
completion of any Products or Refused Products that are still under development as of such termination or expiration, taking into
account the best course of action for the customers of such products; any such changes must be mutually agreed to by the Parties,
and approval of such changes is not to be unreasonably withheld. Section 2.2 shall survive termination or expiration of this Agreement
in its entirety except that subpart (A) of Section 2.2(d)(ii) shall not survive.

 

Article
VIII.                INDEMNIFICATION;
LIMITATION OF LIABILITY

 

8.1             
By Amyris.

 

(a)               
Subject to Section 8.1(b), Amyris agrees, at Amyris’ cost and expense, to defend, indemnify and hold harmless Ginkgo and
its Affiliates, and their respective directors,

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

    	 

     

    

officers, employees and agents (the “Ginkgo
Indemnified Parties”) from and against any losses, costs, damages, fees or expenses (“Losses”) arising
out of any Action brought by a Third Party to the extent relating to (i) any breach by Amyris of any of its representations,
warranties or obligations pursuant to this Agreement; (ii) the negligence or willful misconduct of Amyris; (iii) any
infringement by Intellectual Property licensed from Amyris; (iv) any of Excluded Products developed, manufactured, or commercialized
by Amyris; or (v) except as otherwise provided in Section 8.3, actions taken solely by Amyris that serve as the sole basis
for such Action brought by a Third Party where such actions are inconsistent with the directions of the JSC.

 

(b)              
In the event of any such Action against any of the Ginkgo Indemnified Parties by any Third Party, Ginkgo shall promptly notify
Amyris in writing of the Action. Subject to Section 8.1(c), Amyris shall have the right, exercisable by notice to Ginkgo within
thirty (30) days after receipt of notice from Ginkgo of the Action, to assume direction and control of the Action (including the
right to settle the Action solely for monetary consideration) with counsel selected by Amyris and reasonably acceptable to Ginkgo. 
The Ginkgo Indemnified Parties shall cooperate with Amyris and may, at their option and expense, be separately represented in any
such action or proceeding.  Amyris shall not be liable for any Action costs or expenses incurred by the Ginkgo Indemnified
Parties without Amyris’ prior written authorization. In addition, Amyris shall not be responsible for the indemnification
or defense of any Ginkgo Indemnified Party to the extent arising from any negligent or intentional acts by any Ginkgo Indemnified
Party or the breach by Ginkgo of any representation, obligation or warranty under this Agreement, or any Actions compromised or
settled without its prior written consent. Notwithstanding the foregoing, Amyris shall not settle an Action brought by a Third
Party without the prior written consent of Ginkgo, if such settlement would impose any monetary obligation on Ginkgo or require
Ginkgo to submit to an injunction.

 

(c)               
Notwithstanding anything to the contrary above, (i) in the event of any such Action against a Ginkgo Indemnified Party brought
by a Governmental Entity or criminal action seeking an injunction against a Ginkgo Indemnified Party, or (ii) in the event
Amyris does not assume direction and control of the Action pursuant to Section 8.1(b), Ginkgo shall have the right to control
the Action at Amyris’ expense.

 

8.2             
By Ginkgo.

 

(a)               
Subject to Section 8.2(b), Ginkgo agrees, at Ginkgo’s cost and expense, to defend, indemnify and hold harmless Amyris and
its Affiliates and their respective directors, officers, employees and agents (the “Amyris Indemnified Parties”)
from and against any Losses arising out of any Action brought by a Third Party to the extent relating to (i) any breach by
Ginkgo of any of its representations, warranties or obligations pursuant to this Agreement; (ii) the negligence or willful
misconduct of Ginkgo; (iii) any infringement by Intellectual Property licensed from Ginkgo hereunder (iv) any of Excluded
Products developed, manufactured, or commercialized by Ginkgo; (v) except as otherwise provided in Section 8.3, actions taken
solely by Ginkgo that serve as the sole basis for such Action brought by a Third Party where such actions are inconsistent with
the directions of the JSC; or (vi) any Losses related to Ginkgo’s failure to make payments to SRD under Section 2.3(f). 

 

    	 

     

    

(b)              
In the event of any such Action against any of the Amyris Indemnified Parties by any Third Party, Amyris shall promptly notify
Ginkgo in writing of the Action. Subject to Section 8.2(c), Ginkgo shall have the right, exercisable by notice to Amyris within
thirty (30) days after receipt of notice from Amyris of the Action, to assume direction and control of the Action (including the
right to settle the Action solely for monetary consideration) with counsel selected by Ginkgo and reasonably acceptable to Amyris.
The Amyris Indemnified Parties shall cooperate with Ginkgo and may, at their option and expense, be separately represented in any
such action or proceeding.  Ginkgo shall not be liable for any Action costs or expenses incurred by the Amyris Indemnified
Parties without Ginkgo’s prior written authorization.  In addition, Ginkgo shall not be responsible for the indemnification
or defense of any Amyris Indemnified Party to the extent arising from any negligent or intentional acts by any Amyris Indemnified
Party, or the breach by Amyris of any representation, obligation or warranty under this Agreement, or any Actions compromised or
settled without its prior written consent.  Notwithstanding the foregoing, Ginkgo shall not settle an Action brought by a
Third Party without the prior written consent of Amyris, if such settlement would impose any monetary obligation on Amyris or require
Amyris to submit to an injunction.

 

(c)               
Notwithstanding anything to the contrary above, (i) in the event of any such Action against an Amyris Indemnified Party brought
by a Governmental Entity or a criminal action seeking an injunction against an Amyris Indemnified Party, or (ii) in the event
Ginkgo does not assume direction and control of the Action pursuant to Section 8.2(b), Amyris shall have the right to control
the Action at Ginkgo’s expense.

 

8.3             
Shared Claims. Any Losses arising out of any Action brought by a Third Party involving any actual or alleged death or bodily
injury arising out of or resulting from the development, manufacture or commercialization of any Product, to the extent that such
Losses exceed the amount (if any) covered by the applicable Party’s product liability insurance, shall be shared equally
by the Parties, except to the extent such Losses arise out of any Action brought by a Third Party based on (a) a Party’s
breach of any of its representations, obligations or warranties under to this Agreement, or (b) the negligence or intentional
act of a Party, its Affiliates, or their respective permitted sublicensees, or any of the respective officers, directors, employees
and agents of each of the foregoing entities, in the performance of obligations or exercise of rights under this Agreement.

 

8.4             
Limitation of Liability.  EXCEPT WITH RESPECT TO A BREACH OF Article VIII,
Article X, OR A PARTY’S LIABILITY PURSUANT TO Article
VIII OR Article X, NEITHER PARTY SHALL BE LIABLE FOR SPECIAL, INCIDENTAL,
CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR OTHER INDIRECT OR REMOTE DAMAGES, OR, EXCEPT WITH RESPECT TO A BREACH OF SECTIONS 2.1,
2.3(d) OR 2.3(e), FOR LOSS OF PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES, ARISING IN ANY WAY OUT OF THIS AGREEMENT OR THE EXERCISE
OF ITS RIGHTS HEREUNDER, WHETHER BASED UPON WARRANTY, CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSS.

 

    	 

     

    

Article
IX.                     
REPRESENTATIONS, WARRANTIES AND COVENANTS

 

9.1             
Representation of Authority; Consents.  Ginkgo and Amyris each represents and warrants, and covenants, as applicable,
to the other Party that, except as set forth on Schedule 9.1 of the Amyris Disclosure Schedules and the Ginkgo Disclosure Schedules:

 

(a)               
it has full right, power and authority to enter into this Agreement;

 

(b)              
its board of directors has determined that this business arrangement, and the structure of the resulting partnership, is in the
best interest of such party and its stockholders;

 

(c)               
this Agreement has been duly executed by such Party and constitutes a legal, valid and binding obligation of such Party, enforceable
in accordance with its terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization,
moratorium and other Laws relating to or affecting creditors’ rights generally and by general equitable principles and public
policy constraints (including those pertaining to limitations and/or exclusions of liability, competition Laws, penalties and jurisdictional
issues including conflicts of Laws); and

 

(d)              
except as otherwise contemplated in this Agreement, all necessary consents, approvals and authorizations of all government authorities
and other persons required to be obtained by such Party in connection with the execution, delivery and performance of this Agreement
have been and shall be obtained.

 

9.2             
No Conflict.  Each Party represents and warrants to the other Party that, except as set forth on Schedule 9.2 of the
Amyris Disclosure Schedules and the Ginkgo Disclosure Schedules, the execution and delivery of this Agreement and the performance
of such Party’s obligations hereunder (a) do not conflict with or violate such Party’s corporate organizational
documents or any requirement of applicable Laws and (b) do not conflict with, violate or breach or constitute a default or
require any consent under, any material oral or written contractual obligation of such Party.  Each Party agrees that it shall
not during the Term grant any right, license, consent or privilege to any Third Party or otherwise undertake any action, either
directly or indirectly, that would conflict with the rights granted to the other Party or interfere with any obligations of such
Party set forth in this Agreement.

 

9.3             
Intellectual Property. Each Party represents and warrants to the other Party, except as set forth on Schedule 9.3 of the
Amyris Disclosure Schedules and the Ginkgo Disclosure Schedules, and solely (other than subpart (e) or (f), below) with respect
to, as applicable, the Background Intellectual Property, Foreground Intellectual Property and Foundry Intellectual Property, as
follows:

 

(a)               
Such Party has the legal power to and such Party is not subject to any agreement which restricts or impairs its ability to convey
to the other Party all of the license rights for such Intellectual Property contemplated hereby; 

 

(b)              
Such Party does not pay or receive any royalty to or from anyone with respect to any of such Party’s Intellectual Property,
nor has such Party licensed anyone to commercially exploit any of such Party’s Intellectual Property;

 

    	 

     

    

(c)               
There are no pending or, to the knowledge of such Party, contemplated Actions relating to any of such Party’s Intellectual
Property, nor has such Party received written communication from any Person threatening the institution of any Action against such
Party relating to any of such Intellectual Property; 

 

(d)              
Except as contemplated by this Agreement, all rights of such Party in and to such Intellectual Property will be unaffected by this
Agreement and the other transactions contemplated hereunder;

 

(e)               
To the knowledge of such Party, neither the conduct of its business, nor the use of the technology it is providing pursuant to
this Agreement, interferes with, infringes, violates or misappropriates any rights under any valid and unexpired Intellectual Property
of any other Person; 

 

(f)               
Such Party has not received any notice alleging any such interference, infringement, violation or misappropriation (including any
such claim that such Party must license or refrain from using any such Intellectual Property); and

 

(g)              
To the knowledge of such Party, no Third Party has interfered with, infringed, violated or misappropriated, or is currently interfering
with, infringing, violating or misappropriating any rights under such Party’s Intellectual Property.

 

9.4             
Compliance with Laws. Each Party represents and warrants to the other Party that such Party is in compliance with all applicable
Laws applicable to it. Each Party shall comply in all material respects with all applicable Laws in connection with the development,
manufacture and commercialization of the Products.

 

9.5             
Insurance. Each Party represents and warrants that it is insured with financially sound and reputable insurance companies,
in such amounts, with such deductibles and covering such risks as are customarily carried by companies engaged in similar businesses.
Each Party shall not decrease or materially change its insurance policies for so long as this Agreement is in effect and for a
period of five years thereafter.

 

9.6             
No Other Molecules in the Field. Each Party represents and warrants that it has no rights to develop, manufacture or sell
any other molecules in the Field as of the date hereof that are not listed in one of the Tables on Exhibit 6.2(a).

 

9.7             
Disclaimer of Warranty.  EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY EXPRESSLY DISCLAIMS, WAIVES, RELEASES
AND RENOUNCES ANY WARRANTY, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT.

 

9.8             
Exclusivity.

 

(a)               
Each Party agrees that, during the Term, neither Party will collaborate, work with, or otherwise engage [*] or any of its Affiliates
within the Field. For clarity, 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

    	 

     

    

during the Term, neither party will license its
Intellectual Property to [*] or any of its Affiliates within the Field.

 

(b)              
During the Term, all future Amyris contracts pertaining to manufacturing of a [*] are subject to this Agreement except for the
following: (i) the agreement between [*]; (ii)  any agreement with a Governmental Entity; (iii) agreements related
to the [*]; and (iv) the agreements listed on Exhibit 1.5. For clarity and notwithstanding Section 9.8(b)(iv), [*].

 

(c)               
During the Term, all future Ginkgo contracts pertaining to manufacturing of a chemical small molecule compound in the Field where
the customer requires third party manufacturing of the molecule are subject to this Agreement except for the following: (i) any
agreement between Ginkgo and a Governmental Entity or (ii) certain aspects of existing Ginkgo agreements with both [*] (related
to the scale-up and manufacture of [*]) and [*] (related to the scale-up and manufacture of champignol and nonadienols/als); provided,
that process development and scale-up of such chemical small molecule compound shall remain subject to this Agreement. For the
avoidance of doubt, all agreements between Ginkgo and a Third Party for the development of strains or strain improvements only
(i.e., the agreement does not contemplate the industrial scale manufacture of chemical small molecule compounds) are not
subject to this Agreement and nothing herein shall prohibit the entry by Ginkgo into any such agreement.

 

(d)              
The Parties recognize and affirm that, in the event of a breach by a Party of this Section 9.8, money damages would be inadequate
and such Party would not have any adequate remedy at Law. Accordingly, the Parties agree that the non-breaching Party shall have
the right, in addition to any other rights and remedies existing in its favor, to enforce its rights and the breaching Party’s
obligations under this Section 9.8 by an action or actions for specific

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

    	 

     

    

performance, injunction or other equitable relief
against the breaching Party to enforce or prevent any violations, whether anticipatory, continuing or future, of the provisions
of this Section 9.8.

 

9.9             
Non-Solicitation. Each Party agrees that, during the Term, it will not, directly or indirectly, solicit the employment of
any officer or employee of the other Party. The foregoing will not prevent a Party from soliciting the employment of or from employing
any officer or employee of the other Party if such officer or employee of the other Party leaves the employment of the other Party
without any prior solicitation of employment of such officer or employee of the other Party by or on behalf of such Party. The
phrase “solicit the employment of” will not be deemed to include (a) general solicitations or advertisements of employment
not specifically directed towards officers or employees of the other Party, or from employing any such person who contacts such
Party in response to any of the foregoing, or (b) retaining and deploying recruiting firms and individuals to identify, seek and
solicit prospective employees on behalf of such Party so long as such recruiting firms and individuals are not directed, orally
or in writing, to solicit the employment of any officer or employee of the other Party, or from employing any such person who responds
to any recruiting efforts of the foregoing. For purposes of clarity, the provisions of this Section 9.9 will apply whether an officer
or employee of the other Party is employed on the date of this Agreement or hereafter.

 

Article
X. CONFIDENTIALITY

 

10.1         
Confidential Information. 

 

(a)               
In connection with the performance of their respective obligations under this Agreement, each Party (the “Disclosing Party”)
may, itself or through or its Affiliates, disclose certain Confidential Information to the other Party (the “Recipient”)
or its Affiliates. During the Term and at all times thereafter, the Recipient shall maintain all Confidential Information of the
Disclosing Party in strict confidence and shall not use such Confidential Information for any purpose, except that the Recipient
may disclose or permit the disclosure of any such Confidential Information to its Affiliates and permitted sublicensees, or its
or their respective directors, officers, employees, consultants, advisors and agents, and its Permitted Subcontractors, who in
each case are obligated to maintain the confidential nature of such Confidential Information on terms no less stringent than those
of this Article X. In addition, the Recipient may use or disclose Confidential Information of the Disclosing Party (i) in
exercising the Recipient’s rights and licenses granted hereunder (including exercising these rights to discuss with Third
Party sublicensing opportunities) or to fulfill its obligations and/or duties hereunder; provided that such disclosure is
made to a Person who is obligated to confidentiality and non-use obligations no less rigorous than those of this Section 10.1 and
(ii) subject to Section 10.1(c), in prosecuting or defending an Action, complying with applicable Law and/or submitting information
to tax or other Governmental Entities. For the purposes of this Agreement, “Confidential Information” shall
mean (x) any confidential or proprietary information related to the Products and (y) any confidential or proprietary information
relating to the Disclosing Party’s business, including without limitation trade secrets, processes, formulae, data and know-how,
improvements, inventions, chemical or biological materials, techniques, methods for making compounds, target compounds, product
development plans, marketing plans, strategies, customer lists or other information that has been created, discovered or developed
by the Disclosing Party, or has otherwise become known to the Disclosing Party, or for which proper rights have been 

 

    	 

     

    

assigned to the Disclosing Party, as well as any
other information and materials that are deemed confidential or proprietary to or by the Disclosing Party (including, without limitation,
all information and materials of the Disclosing Party’s customers and consultants and any other third party), regardless
of whether any of the foregoing are marked as “confidential” or “proprietary” or communicated to the Recipient
by the Disclosing Party in oral, written, graphic or electronic form.

 

(b)              
The obligations of confidentiality and non-use set forth above shall not apply to the extent that the Recipient can demonstrate
that the relevant Confidential Information of the Disclosing Party: (i) was publicly known prior to the time of its disclosure
under this Agreement or the Prior Confidentiality Agreement; (ii) became publicly known after the time of its disclosure under
this Agreement other than through acts or omissions of the Recipient, its Affiliates, potential sublicensees or permitted sublicensees
in violation of this Agreement; (iii) is or was disclosed to the Recipient or any of its Affiliates at any time, whether prior
to or after the time of its disclosure under this Agreement or the Prior Confidentiality Agreement, by a Third Party having no
fiduciary relationship with the Disclosing Party or any of its Affiliates and having no obligation of confidentiality with respect
to such Confidential Information; (iv) is independently developed by the Recipient or any of its Affiliates without access
to such Confidential Information as evidenced by written records; or (v) was known by the Recipient or any of its Affiliates
at the time of receipt from the Disclosing Party or any of its Affiliates as documented by the Recipient’s or any of its
Affiliates’ records.

 

(c)               
In addition, the Recipient or any of its Affiliates may disclose Confidential Information of the Disclosing Party to the extent
necessary to comply with applicable Laws or a court or administrative order; provided that the Recipient provides to the
Disclosing Party prior written notice of such disclosure, to the extent reasonably possible, and that the Recipient takes all reasonable
and lawful actions to obtain confidential treatment for such disclosure and, to the extent possible, to minimize the extent of
such disclosure.

 

(d)              
Notwithstanding the obligations in Section 10.1(a) and 10.1(c), a Party may disclose (and, in connection therewith, use) Confidential
Information of the other Party, if such disclosure:

 

(i)                
is made to Governmental Entities in order to obtain patent rights;

 

(ii)              
is made to its Affiliates, permitted sublicensees, agents, consultants or other Third Parties (including service providers) for
the development, manufacture or commercialization of Products as provided hereunder, or in connection with an assignment of this
Agreement, a licensing transaction related to products under this Agreement, a loan, financing or investment, or an acquisition,
merger, consolidation or similar transaction (or for such Persons to determine their interest in performing such activities or
entering into such transactions), in each case on the condition that any Third Parties to whom such disclosures are made agree
to be bound by confidentiality and non-use obligations no less rigorous than those contained in this Agreement; or

 

(iii)            
consists entirely of Confidential Information previously approved by the Disclosing Party for disclosure by the Recipient.

 

    	 

     

    

(e)               
Each Recipient shall be responsible for any breach of the obligations of this Section 10.1 by any Person to whom such Recipient
or its Affiliate disclosed the Disclosing Party’s Confidential Information.

 

10.2         
Publicity; Attribution; Terms of this Agreement; Non-Use of Names.

 

(a)               
The Parties shall issue a press release to announce the execution of this Agreement and describe the material financial and operational
terms of this Agreement. Such press release and the date of its issuance shall be mutually agreed to by the Parties. Except as
required by judicial order or applicable Law, or as set forth below, neither Party shall make any public announcement concerning
this Agreement without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed.
The Party preparing any such public announcement shall provide the other Party with a draft thereof at least three (3) Business
Days prior to the date on which such Party would like to make the public announcement. Neither Party shall use the name, trademark,
trade name or logo of the other Party or its employees in any publicity or news release relating to this Agreement or its subject
matter, without the prior express written permission of the other Party.

 

(b)              
Notwithstanding the terms of this Article X, either Party shall be permitted to disclose the existence and terms of this Agreement
to the extent required, based on the advice of such Party’s legal counsel, to comply with applicable Laws, including the
rules and regulations promulgated by the U.S. Securities and Exchange Commission (“SEC”) or any other Governmental
Entity. Notwithstanding the foregoing, before disclosing this Agreement or any of the terms hereof pursuant to this Section 10.2(b),
the Parties will consult with one another on the terms of this Agreement for which confidential treatment will be sought in making
any such disclosure. If a Party wishes to disclose this Agreement or any of the terms hereof in accordance with this Section 10.2(b),
such Party agrees, at its own expense, to seek confidential treatment of the portions of this Agreement or such terms as may be
reasonably requested by the other Party; provided that the disclosing Party shall always be entitled to comply with legal
requirements, including the requirements of the SEC.

 

(c)               
Either Party may also disclose the existence and terms of this Agreement in confidence to its attorneys and advisors, and to potential
acquirors (and their respective professional advisors), in connection with a potential merger, acquisition or reorganization and
to existing and potential investors or lenders of such Party, as a part of their due diligence investigations, or to existing and
potential sublicensees or to permitted sublicensees and assignees, or to any other Person described in Section 10.1(d)(ii), in
each case under an agreement to keep the terms of this Agreement confidential under terms of confidentiality and non-use substantially
no less rigorous than the terms contained in this Agreement and to use such information solely for the purpose permitted pursuant
to this Section 10.2(c) or Section 10.1(d)(ii).

 

(d)              
For purposes of clarity, either Party may issue a press release or public announcement or make such other disclosure if the content
of such press release, public announcement or disclosure has previously been made public other than through a breach of this Agreement
by the issuing Party or its Affiliates.

 

    	 

     

    

10.3         
Return of Confidential Information.  Subject to Section 7.3(a), upon the expiration or termination of this Agreement,
upon request, the Recipient shall return to the Disclosing Party or destroy all Confidential Information received by the Recipient
or any of its Affiliates from the Disclosing Party or any of its Affiliates (and all copies and reproductions thereof).  In
addition, the Recipient and its Affiliates shall destroy:  (a) any notes, reports or other documents prepared by the
Recipient which contain Confidential Information of the Disclosing Party; and (b) any Confidential Information of the Disclosing
Party (and all copies and reproductions thereof) which is in electronic form or cannot otherwise be returned to the Disclosing
Party.  Nothing in this Section 10.3 shall require the alteration, modification, deletion or destruction of archival
tapes or other electronic back-up media made in the ordinary course of business; provided that the Recipient and its Affiliates
shall continue to be bound by its obligations of confidentiality and other obligations under this Article X with respect to any
of the Disclosing Party’s Confidential Information contained in such archival tapes or other electronic back-up media. 
Any requested destruction of the Disclosing Party’s Confidential Information shall be certified in writing to the Disclosing
Party by an authorized officer of the Recipient supervising such destruction.  Notwithstanding the foregoing, (i) the
Recipient and its Affiliates may retain one copy of the Disclosing Party’s Confidential Information solely for the purpose
of determining the Recipient’s continuing obligations under this Article X and (ii) the Recipient and its Affiliates
may retain the Disclosing Party’s Confidential Information and its own notes, reports and other documents to the extent reasonably
required (x) to exercise the rights and licenses of the Recipient expressly surviving expiration or termination of this Agreement;
(y) to perform the obligations of the Recipient expressly surviving expiration or termination of this Agreement; or (z) for
regulatory or archival purposes.  Notwithstanding the return or destruction of the Disclosing Party’s Confidential Information,
the Recipient shall continue to be bound by its obligations of confidentiality and other obligations under this Article X.

 

Article
XI.                     
MISCELLANEOUS

 

11.1         
Governing Law.  This Agreement (and any Actions arising out of or related thereto or to the transactions contemplated
thereby or to the inducement of any Party to enter therein, whether for breach of contract, tortious conduct or otherwise and whether
predicated on common law, statute or otherwise) shall in all respects be governed by and construed in accordance with the laws
of the State of New York, USA, including all matters of construction, validity and performance, in each case without reference
to any conflict of law rules that might lead to the application of the laws of any other jurisdiction.

 

11.2         
Dispute Resolution.  Any Action arising out of or relating to this Agreement that is not subject to Article V shall
be settled, if possible, through good faith negotiations between the Parties.  If the Parties are unable to settle such dispute
within thirty (30) days or in accordance with the terms of Article V, as applicable, such Action arising out of or relating to
this Agreement, or the breach thereof, shall be resolved as follows:

 

(a)               
Such Action shall be settled by binding arbitration in Chicago, Illinois in accordance with the then current Commercial Arbitration
Rules of the American Arbitration Association and judgment upon the award rendered may be entered in any court having jurisdiction.
The arbitrator shall have the authority to grant any equitable and legal remedies that would be available in any judicial proceeding
subject to any limits set forth herein.

 

    	 

     

    

(b)              
Such arbitration shall be conducted by a single, independent arbitrator or, if the Parties are unable to agree on such arbitrator,
each Party shall appoint a single, independent arbitrator who must collectively agree on a Third Party, independent arbitrator
to serve as arbitrator hereunder. For clarity, the arbitrator can be either judicial or non-judicial, depending on the nature of
the dispute (i.e., if the dispute is technical in nature, the Parties may elect to agree upon an arbitrator who possesses
a relevant technical background).

 

(c)               
The arbitrator may rule upon motions to compel or limit discovery and shall have the authority to impose sanctions for discovery
abuses, including reasonable attorneys’ fees and costs, to the extent and upon the grounds available for such in the United
States District Courts for the District in which the arbitration is taking place.

 

(d)              
The decision of the arbitrator (the “Award”) as to any Action (including the validity and amount of any Action)
shall be final, binding, and conclusive upon the Parties. Such Award shall be written and shall be supported by written findings
of facts and conclusions. Within 30 days of issuance of an Award any payment required by the Award shall be made unless before
such date any Party shall commence legal action to vacate or modify the Award.

 

(e)               
The Parties to the arbitration may apply to a court of competent jurisdiction for a temporary restraining order, preliminary injunction
or other interim or conservatory relief, as necessary, including without limitation for breach of Section 9.8 or Article X
hereunder, without breach of this arbitration provision and without abridgment of the powers of the arbitrator.

 

(f)               
The Parties agree, and agree to direct the arbitrator, that the arbitration will be kept confidential and that the existence of
the proceeding and any proceedings therein, including without limitation any pleadings, briefs or other documents, any testimony
or other oral submissions and any Award, will not be disclosed beyond the arbitrator or arbitration tribunal, the Parties, their
counsel and any Person (including witnesses, if any) involved in the conduct of the proceeding, except (i) in any legal proceeding
concerning the arbitration, including without limitation any proceeding to compel or to stay arbitration or otherwise in aid of
arbitration, for other relief as described in Section 11.2(e), to vacate, modify or confirm an Award, or to enforce an Award or
any judgment based upon an Award, (ii) to the tax, legal, financial or other professional advisors of such Person who are obligated
to keep such information confidential, or (iii) as may be required by Law.

 

(g)              
Each Party shall pay its own costs and expenses (including counsel fees) of any such arbitration, except as may be awarded by the
arbitrator pursuant to Section 11.2(c) above. 

 

11.3         
General Release. Effective as of the effective date of the Initial Strategic Partnership Agreement, each Party voluntarily,
knowingly and irrevocably releases and forever discharge the other Party and its officers, directors, managers, employees and affiliates
from any and all actions, agreements, amounts, claims, damages, expenses, liabilities and obligations of every kind, nature or
description, known or unknown, arising or existing prior to the Effective Date, except for any rights of such Party under this
Agreement and any agreement entered into pursuant to this Agreement.

 

    	 

     

    

11.4         
Assignment. Neither Party may assign its rights and obligations under this Agreement without the prior written consent of
the other Party, except that either Party may make such assignment without the prior written consent of the other Party to an Affiliate
(so long as such Party shall remain jointly and severally liable with such Affiliate with respect to all obligations so assigned). 
Subject to a Party’s right to terminate this Agreement in connection with a Change in Control pursuant to Section 7.2(d),
any request for consent to assignment shall not be unreasonably withheld or delayed.  Any purported assignment in contravention
of this Section 11.3 shall, at the option of the non-assigning Party, be null and void and of no effect.  No assignment
shall release either Party from responsibility for the performance of any accrued obligation of such Party hereunder.  This
Agreement shall be binding upon and enforceable against the successor to or any permitted assignee from either of the Parties.

 

11.5         
Entire Agreement; Amendments.  This Agreement, the Letter Agreement executed between the Parties on August [__], 2016
and the Exhibits referred to in this Agreement constitute the entire agreement between the Parties with respect to the subject
matter hereof, and supersede all previous arrangements with respect to the subject matter hereof, whether written or oral, including
without limitation the Initial Strategic Partnership Agreement, and the Prior Confidentiality Agreement.  Any amendment or
modification to this Agreement shall be made in writing signed by both Parties.

 

11.6         
Notices.  All communications, notices, instructions and consents provided for herein or in connection herewith shall
be made in writing and be sent to the address below and will be (a) given in person, (b) sent by registered or certified mail,
return receipt requested, postage prepaid, or (c) sent by a reputable international overnight courier service. Any such communication,
notice, instruction or consent will be deemed to have been delivered: (i) on receipt if given in person; (ii) three (3) Business
Days after it is sent by registered or certified airmail, return receipt requested, postage prepaid within the same country as
the recipient’s address or five (5) Business Days after it is sent by registered or certified airmail, return receipt requested,
postage prepaid from another country; or (iii) one (1) Business Day after it is sent via a reputable international overnight courier
service.

 

Notices to Ginkgo shall be addressed to:

 

Ginkgo Bioworks, Inc.

27 Drydock Avenue, 8th Floor

Boston, MA 02210

Attention: CEO

Attention: General Counsel

and

 

Notices to Amyris shall be addressed to:

 

Amyris, Inc.

5885 Hollis Street, Ste. 100

Emeryville, CA 94608

Attention: CEO

Attention: General Counsel;

 

    	 

     

    

provided, however, that if either Party will have
designated a different address by notice to the other Party in accordance with this Section 11.6, then to the last address so designated.

 

11.7         
Force Majeure.  No failure or omission by either Party in the performance of any obligation of this Agreement shall
be deemed a breach of this Agreement or create any liability if the same shall arise from a Force Majeure Event; provided
that the Party affected by such cause promptly notifies the other Party and uses diligent efforts to cure such failure or omission
as soon as is practicable after the occurrence of one or more of the above mentioned causes.

 

11.8         
Compliance with Laws; Anti-Corruption Laws. 

 

(a)                     
Each Party shall perform its obligations under this Agreement in compliance with all applicable Laws. 

 

(b)                    
Anti-Corruption Laws. 

 

(i)                
Compliance with Anti-Corruption Law. In carrying out their responsibilities and exercising their rights under this Agreement,
the Parties shall, and shall ensure that their Permitted Subcontractors shall, comply with all applicable anti-corruption laws
in the countries where the Parties or such Permitted Subcontractors have their principal or other places of business and where
they conduct activities under this Agreement.

 

(ii)              
Certain Covenants regarding Anti-Corruption. Additionally, each Party represents and warrants to the other Party that neither
it nor any of its directors, employees, agents, Permitted Subcontractors or consultants will directly or indirectly pay or give
or promise to pay or give anything of value to any government official or a foreign public official for purposes of (a) influencing
any act or decision of any such person in his official capacity; (b) inducing such person to do or omit to do any act in violation
of the lawful duty of such official; (c) securing any improper advantage; or (d) inducing such person to use his position to affect
or influence any act or decision of government or any legislative, administrative, public agency or other public body, in all cases
with respect to any activities undertaken relating to this Agreement. Additionally, the Parties will make reasonable efforts to
comply with requests for information, including answering questionnaires and narrowly tailored audit inquiries, to enable the other
Party to ensure compliance with any applicable anti-corruption laws.

 

(iii)       Breach
of Anti-Corruption Covenants. The Parties agree that a breach of the anti-corruption commitments in this Section 11.7(b) shall
be considered a material breach of this Agreement by the relevant Party and that the other Party may immediately seek all remedies
available under law and equity including termination of this Agreement pursuant to Section 7.2(c) if the covenants under the anti-corruption
commitments in this Section 11.7(b) have been breached by a Party (including by its directors, employees, agents, Permitted Subcontractors
or consultants, as relevant), without owing to the other any damages or indemnification resulting solely from such termination.

 

11.9         
Independent Contractors.  It is understood and agreed that the relationship between the Parties is that of independent
contractors and that nothing in this Agreement shall be construed to create a joint venture or any relationship of employment,
agency or partnership

 

    	 

     

    

between the Parties to this Agreement.  Neither
Party is authorized to make any representations, commitments or statements of any kind on behalf of the other Party or to take
any action that would bind the other Party.  Furthermore, none of the transactions contemplated by this Agreement shall be
construed as a partnership for any tax purposes. Each Party shall select, employ, pay, supervise, direct and discharge all of its
personnel providing services on behalf of such Party, and each Party shall be solely responsible for the payment of all wages,
bonuses, benefits and any other direct or indirect compensation for such Party’s personnel, as well as worker’s compensation
insurance, employment taxes and other employer liabilities relating to such personnel.

 

11.10      No Implied
Waivers; Rights Cumulative.  No failure on the part of Ginkgo or Amyris to exercise, and no delay by either Party in exercising,
any right, power, remedy or privilege under this Agreement, or provided by statute or at law or in equity or otherwise, shall impair,
prejudice or constitute a waiver of any such right, power, remedy or privilege by such Party or be construed as a waiver of any
breach of this Agreement or as an acquiescence therein by such Party, nor shall any single or partial exercise of any such right,
power, remedy or privilege by a Party preclude any other or further exercise thereof or the exercise of any other right, power,
remedy or privilege.

 

11.11      Severability. 
If, under applicable Laws, any provision of this Agreement is invalid or unenforceable, or otherwise directly or indirectly affects
the validity of any other material provision(s) of this Agreement (such invalid or unenforceable provision, a “Severed
Clause”), this Agreement shall endure except for the Severed Clause.  The Parties shall consult one another and
use good faith efforts to agree upon a valid and enforceable provision that is a reasonable substitute for the Severed Clause in
view of the intent of this Agreement.

 

11.12      Execution
in Counterparts.  This Agreement may be executed in any number of counterparts, each of which shall be deemed an original,
and all of which together shall constitute one and the same instrument.  Signatures provided by facsimile transmission or
in AdobeTM Portable Document Format (.pdf) sent by electronic mail shall be deemed to be original signatures.

 

11.13      No Third
Party Beneficiaries.  No Person other than Amyris and Ginkgo (and their respective successors and permitted assignees)
shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement.

 

11.14      Performance
by Affiliates.  Either Party may use one or more of its Affiliates to perform its obligations and duties hereunder and
Affiliates of a Party are expressly granted certain rights herein; provided that each such Affiliate shall be bound by the
corresponding obligations of such Party and the Parties shall remain liable hereunder for the prompt payment and performance of
all their respective obligations hereunder.

 

11.15      Exhibits. 
In the event of inconsistencies between this Agreement and any Exhibit hereto, the terms of this Agreement shall control.

 

    	 

     

    

Article
XII.                  
ANTITRUST COMMITTEE

 

12.1         
Cooperation.

 

(a)               
The Parties have developed and agreed to the antitrust guidelines attached in Exhibit C (“the Antitrust Guidelines”)
under which the Parties shall operate and which Antitrust Guidelines are a part of this Agreement. The Parties shall establish
a Subcommittee within thirty (30) days after the Effective Date to, in conjunction with counsel, to advise the Parties on such
Antitrust Guidelines. If deemed appropriate by such Subcommittee, the Antitrust Guidelines may be amended.

 

(b)              
In addition to the foregoing, the Parties acknowledge that this Agreement relates to the operations of the Parties in the Field
only. The Parties further stipulate that they do not have any agreement on any topic outside the Field, and they shall not have
any agreement on any topic outside the Field unless such agreement is stated in writing, reviewed by the Antitrust Committee, and
approved by each Party’s counsel. 

 

 

 

 

 

 

 

[***Remainder of the Page Intentionally Left Blank; Signature
Page to Follow***]

 

 

 

    	 

     

    

IN WITNESS WHEREOF, the Parties have executed
this Agreement as of the Effective Date.

 

	 	
        AMYRIS, INC.

         

         

        By: /s/ John Melo                            

        John Melo

        Chief Executive Officer

         

	 	
         

        GINKGO
        BIOWORKS, INC.

         

         

        By: /s/ Jason Kelly                         

        Jason Kelly

        Chief Executive Officer

         

 

 

    	 

     

    

EXHIBIT 1.5

 

 

Per Section 1.5, any agreements entered between Amyris and a Third
Party before the Effective Date is not an Amyris Customer Agreement, because, by definition, they are not agreements entered during
the Term. These include, but are not limited to:

 

Services Agreement dated [*], between Amyris and [*].

 

Collaboration Agreement dated October 28, 2014, between Amyris and
Genome Compiler Corporation and Genome Compiler Israel Ltd. (acquired by Twist Bioscience)

 

GLS Inbound Services Agreement dated [*], between Amyris and [*]

 

Collaboration Agreement dated [*] between Amyris and [*]

 

Collaboration Agreement dated June 30, 2014 among Amyris, Amyris
Brazil, Braskem, S.A., Braskem America, Inc. and Manufacture Francaise Des Pneumatiques Michelin

 

Joint Development and License Agreement dated April 23, 2013 between
Amyris and International Flavors & Fragrances Inc.

 

Second Amended and Restated Collaboration Agreement dated March
28, 2014 between Amyris and Kuraray Co., Ltd.

 

Any agreement with a Governmental Entity (including the Technology
Investment Agreement between Amyris and DARPA concerning [*]; Agreement No.: HR0011-15-3-0001)

 

Development Agreement dated June 6, 2014 between Amyris and Takasago
International Corporation

 

Collaboration Agreement dated [*] between Amyris and [*]

 

Amended & Restated Jet Fuel License Agreement dated March 21,
2016 between Amyris and Total Amyris BioSolutions N.V.

 

License Agreement regarding Diesel Fuel in the EU dated March 21,
2016 between Amyris and Total Energies Nouvelles Activités USA

 

Technology License, Development, Research and Collaboration Agreement
dated June 21, 2010 between Amyris and Total Energies Nouvelles Activités USA (as assignee of Total Gas & Power USA
Biotech, Inc.)

 

Amended & Restated IP License Agreement dated July 19, 2016
between Amyris and Novvi LLC

 

Letter Agreement dated April 8, 2016 between Amyris and the Bill
& Melinda Gates Foundation

 

[*]

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

    	 

     

    

EXHIBIT 1.5

 

Research Collaboration Agreement dated June 6, 2016 between Amyris
and Janssen Biotech, Inc.

 

U.S. Master Services Agreement dated July 28, 2016 between Amyris
and Biogen, MA, Inc.

 

Any agreements between Amyris and a Third Party entered during the
Term that pertain primarily to the [*], are not Amyris Customer Agreements.

 

Any agreement between Amyris and a Third Party entered during the
Term under which Amyris and the Third Party are engaged in the [*] are not Amyris Customer Agreements.

 

Except for the Products included in Exhibit 6.2(a), any agreement
between Amyris and a Third Party entered during the Term, which is a [*], is not an Amyris Customer Agreement.

 

Any agreement between Amyris and a Third Party entered during the
Term under which Amyris and the Third Party are engaged in [*]

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

    	 

     

    

EXHIBIT 1.13 - AMYRIS

 

 

“Control” is limited by the restrictions set forth in
all agreements, each as amended from time-to-time, to which Amyris is a party as of the Effective Date, including without limitation
the following:

 

Collaboration Agreement dated March 13, 2013 between Amyris and
Firmenich SA

 

Supply Agreement dated September 26, 2014 between Amyris and Firmenich
SA

 

Collaboration Agreement dated June 23, 2016 between Amyris and Givaudan
International SA

 

Collaboration Agreement dated [*] between Amyris and [*]

 

Collaboration Agreement dated June 30, 2014 among Amyris, Amyris
Brazil, Braskem, S.A., Braskem America, Inc. and Manufacture Francaise Des Pneumatiques Michelin

 

Joint Development and License Agreement dated April 23, 2013 between
Amyris and International Flavors & Fragrances Inc.

 

Amended and Restated Research Agreement dated February 14, 2011
between Amyris and Givaudan Schweiz AG

 

Second Amended and Restated Collaboration Agreement dated March
28, 2014 between Amyris and Kuraray Co., Ltd.

 

Technology Investment Agreement between Amyris, Inc. and DARPA
concerning [*]; Agreement No.: HR0011-15-3-0001

 

Development Agreement dated June 6, 2014 between Amyris and Takasago
International Corporation

 

Collaboration Agreement dated [*] between Amyris and [*]

 

Research and Development Agreement dated April 3, 2014 between Amyris
and BASF SE

 

Amended & Restated Jet Fuel License Agreement dated March 21,
2016 between Amyris and Total Amyris BioSolutions N.V.

 

License Agreement regarding Diesel Fuel in the EU dated March 21,
2016 between Amyris and Total Energies Nouvelles Activités USA

 

Technology License, Development, Research and Collaboration Agreement
dated June 21, 2010 between Amyris and Total Energies Nouvelles Activités USA (as assignee of Total Gas & Power USA
Biotech, Inc.)

 

Amended & Restated IP License Agreement dated July 19, 2016
between Amyris and Novvi LLC

 

Letter Agreement dated April 8, 2016 between Amyris and the Bill
& Melinda Gates Foundation

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

    	 

     

    

EXHIBIT 1.13 - AMYRIS

 

 

[*]

 

Research Collaboration Agreement dated June 6, 2016 between Amyris
and Janssen Biotech, Inc.

 

U.S. Master Services Agreement and Statement of Work Number 1 dated
July 25, 2016 between Amyris and Biogen MA Inc.

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

    	 

     

    

EXHIBIT 1.13 - GINKGO

 

“Control” is limited by the restrictions set forth in
all agreements, each as amended from time-to-time, to which Ginkgo is a party as of the Effective Date, including without limitation
the following:

 

Non-Disclosure Agreement, dated March 6, 2012, between Ginkgo and
[*], as amended on June 9, 2012

 

Collaboration agreement, dated July 2, 2012, between Ginkgo and
[*], as amended on April 2, 2013, July 2, 2014, and February 10, 2016

 

Master Collaboration Agreement, dated July 4, 2014, between Ginkgo
and [*], as amended on August 12, 2014, and [*] dated August 12, 2014, May 1, 2015, and October 25, 2015 thereunder

 

Master Collaboration Agreement, dated October 22, 2014, between
Ginkgo and [*]

 

Chemical Commercialization Program Agreement, dated July 22, 2013,
between Ginkgo and [*]

 

Master Laboratory Study Agreement, dated February 1, 2014, between
Ginkgo and [*], and the [*] dated February 6, 2014 and October 27, 2014

 

Master Collaboration Agreement and [*] thereunder, dated February
27, 2014, between Ginkgo and [*].

 

Collaboration Agreement, dated November 28, 2014, between Ginkgo
and [*]

 

Evaluation Agreement, dated August 6, 2014, between Ginkgo and [*],
as amended on February 12, 2015

 

Collaboration Agreement, dated August 5, 2015, between Ginkgo and
[*]

 

Extension Agreement, dated August 5, 2016, between Ginkgo and [*]

 

Master Agreement for Services, dated January 9, 2014, between Ginkgo
and [*]

 

Master Agreement for Research Collaboration and Statement of Work
Number 1, dated December 10, 2014, between Ginkgo and [*], as amended on October 6, 2015

 

Professional Services Agreement, dated October 15, 2015, between
Ginkgo [*]

 

Collaboration and License Agreement, dated December 8, 2015, between
Ginkgo and [*]

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 

     

    

EXHIBIT 1.13 - GINKGO

 

Research Services Agreement, dated June 30, 2016 between Ginkgo
and [*]

 

Collaboration and License Agreement, dated June 1, 2016, between
Ginkgo and [*]

 

Collaboration and License Agreement, dated May 24, 2016, between
Ginkgo and [*]

 

Collaboration and License Agreement, dated May 2, 2016 between Ginkgo
and [*]

 

Collaboration Agreement, dated August 7, 2016 between Gingko and
[*]

 

Professional Service Agreement, dated July 28, 2016 between Ginkgo
and [*]

 

Collaboration and License Agreement, dated August 3, 2016 between
Ginkgo and [*]

 

Collaboration and License Agreement, dated June 10, 2016 between
Ginkgo and [*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 

     

    

EXHIBIT 1.13 - GINKGO

 

 

[*]

 

[*]

 

[*]

 

[*]

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

    	 

     

    

EXHIBIT 1.23

 

Per Section 1.23, any agreements entered between Ginkgo and a Third
Party before the Effective Date are not Ginkgo Customer Agreements, because, by definition, they are not agreements entered into
during the Term. These include, but are not limited to:

 

Collaboration agreement, dated July 2, 2012, between Ginkgo and
[*], as amended on April 2, 2013, July 2, 2014, and February 10, 2016

 

Master Collaboration Agreement, dated July 4, 2014, between Ginkgo
and [*], as amended on August 12, 2014, and [*] dated August 12, 2014, May 1, 2015, and October 25, 2015 thereunder (as it relates
to the scale-up and manufacture of [*])

 

Master Collaboration Agreement, dated October 22, 2014, between
Ginkgo and [*]

 

Chemical Commercialization Program Agreement, dated July 22, 2013,
between Ginkgo and [*]

 

Master Laboratory Study Agreement, dated February 1, 2014, between
Ginkgo and [*], and the [*] dated February 6, 2014 and October 27, 2014

 

Master Collaboration Agreement and the Ingredient Commercialization
Programs thereunder, dated February 27, 2014, between Ginkgo and [*]

 

Collaboration Agreement, dated November 28, 2014, between Ginkgo
and [*]

 

Collaboration Agreement, dated August 5, 2015, between Ginkgo and
[*]

 

Extension Agreement, dated August 5, 2016, between Ginkgo and [*]

 

Master Agreement for Services, dated January 9, 2014, between Ginkgo
and [*]

 

Master Agreement for Research Collaboration and Statement of Work
Number 1, dated December 10, 2014, between Ginkgo and [*], as amended on October 6, 2015.

 

Professional Services Agreement, dated October 15, 2015, between
Ginkgo and [*]

 

Collaboration and License Agreement, dated December 8, 2015, between
Ginkgo and [*]

 

Research Services Agreement, dated June 30, 2016 between Ginkgo
and [*]

 

Collaboration and License Agreement, dated June 1, 2016, between
Ginkgo and [*]

Collaboration and License Agreement, dated May 24, 2016, between
Ginkgo and [*]

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

    	 

     

    

EXHIBIT 1.23

 

 

Collaboration and License Agreement, dated May 2, 2016 between Ginkgo
and [*]

 

Collaboration Agreement, dated August 7, 2016 between Gingko and
[*]

 

Professional Service Agreement, dated July 28, 2016 between Ginkgo
and [*]

Collaboration and License Agreement, dated August 3, 2016 between
Ginkgo and [*]

 

Collaboration and License Agreement, dated June 10, 2016 between
Ginkgo and [*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

[*]

 

Any agreements between Ginkgo and a Third Party entered during the
Term that pertain primarily to the [*] are not Ginkgo Customer Agreements

 

Any agreements between Ginkgo and a Third Party entered during the
Term under which Ginkgo and the Third Party are engaged in the [*] are not Ginkgo Customer Agreements.

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

    	 

     

    

EXHIBIT 1.23

 

Any agreements between Ginkgo and a Third Party entered during the
Term under which Ginkgo and the Third Party are engaged in the [*].

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

    	 

     

    

EXHIBIT 1.34

 

“Non-Collaboration Intellectual Property” includes:

 

		1.	Intellectual Property conceived, discovered, developed or otherwise made or obtained for products
and/or activities primarily related to production of macromolecules, including without limitation, bioactive macromolecules, proteins,
nucleic acids, and polymers.

 

 

		2.	Intellectual Property conceived, discovered, developed or otherwise made or obtained for products
and/or activities related to any agreements between Amyris and a customer to produce any molecules in the Field using a program
developed through an agreement between Amyris and a Governmental Entity.

 

 

		3.	Intellectual Property conceived, discovered, developed or otherwise made or obtained from Amyris’s
work related to the development, manufacture, or commercialization of products that do not contemplate the use of microbial strains
and fermentation technologies, such as downstream chemical processing of compounds.

 

 

		4.	Intellectual Property conceived, discovered, developed or otherwise made or obtained from Amyris’s
valorization and/or co-production work related to spent microbial cells.

 

    	 

     

    

EXHIBIT 3.1

 

PAYING AGENT AGREEMENT

 

This
Paying Agent Agreement (this “Agreement”), dated as of [______], 2016, is by and among: (i) Ginkgo Bioworks,
Inc., a Delaware corporation (“Ginkgo”); (ii) Amyris, Inc., a Delaware corporation (“Amyris”
and together with “Ginkgo”, sometimes referred to individually as a “Party” and collectively as
the “Parties”); and (iii) Citibank, N.A as paying agent (the “Paying Agent”).

 

Introduction

 

Ginkgo
and Amyris have entered into a Collaboration Agreement, dated as of September 12, 2016 (the “Collaboration Agreement”),
which provides, among other things, for Ginkgo and Amyris to form an alliance in the Field, on the terms and conditions set forth
in the Collaboration Agreement. 

 

Ginkgo
and Amyris acknowledge that the Paying Agent is not a party to, is not bound by, and has no duties or obligations under, the Collaboration
Agreement, that all references in this Agreement to the Collaboration Agreement are for convenience, and that the Paying Agent
shall have no implied duties beyond the express duties set forth in this Agreement.

 

The
Paying Agent has agreed to hold and administer the Fund in accordance with the terms and conditions of this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual covenants and promises contained herein and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows:

 

 

 

AGREEMENT

 

1.                 
Definitions. Except as hereinafter defined, capitalized terms used in this Agreement will have the meanings assigned to
such terms in the Collaboration Agreement. As used herein, the following terms shall have the following respective meanings:

 

“Business Day” means any
day that is not a Saturday, Sunday, or other day in which the Paying Agent is authorized or obligated by law or executive order
to be closed.

 

“Deposit” means payment of
the entire amount of an invoice, which will equal the sum, minus any credits, of (i) the Actual Cost of Goods Sold for the Product
in the quantity purchased, (ii) ten percent (10%) of such Actual Cost of Goods Sold, (iii) 100% of any taxes owed, (iv) any fees
owed to Third Parties, and (v) any debits.

 

“Fund” means the amount held
by the Paying Agent pursuant to this Agreement.

 

“Joint Written Instructions”
means a written notice in substantially the form attached as Exhibit C hereto given to the Paying Agent directing the disbursement
of the Fund, or any

 

 

    	 

     

    

portion thereof, which shall be signed by an authorized
signer of each of Ginkgo and Amyris set forth on Exhibits A-1 and A-2 attached hereto.

 

2.                 
Appointment of the Paying Agent. Ginkgo and Amyris hereby designate and appoint Citibank, N.A. as the Paying Agent for the
purposes set forth herein, and the Paying Agent hereby accepts such appointment on the terms herein provided. The Paying Agent
shall constitute the agent of the Parties hereto solely to the extent required to execute its duties hereunder.

 

3.                 
Deposit(s); Commencement of Duties. Beginning on the date hereof, in accordance with the Collaboration Agreement, Ginkgo
and Amyris shall instruct their customers to make all payments of invoices (including any credit or debit memos thereto) issued
pursuant to the applicable Customer Agreement(s) directly to the Paying Agent in accordance with the wire instructions attached
hereto as Attachment A. The Paying Agent shall provide Ginkgo and Amyris with online access to the Paying Agent’s
reporting system to confirm Deposits made. Ginkgo and Amyris shall provide the Paying Agent with the appropriate documentation
for a customer that the Paying Agent may request to complete the identity verification process prior to such customer providing
a Deposit to the Fund. 

 

4.                 
Maintenance of Fund. During the term of this Agreement, the Paying Agent shall hold and safeguard the Fund in accordance
with this Agreement and shall disburse the Fund, or any portion(s) thereof, only in accordance with this Agreement. As between
Ginkgo and Amyris, the Fund shall not be subject to any lien, attachment, trustee process or any other judicial process of any
creditor of any Party except as otherwise provided in Section 28 below, and shall be held and distributed solely for the purposes
and in accordance with this Agreement.

 

5.                 
Investment of Fund; Tax and Other Reporting.

 

(a)               
No Permitted Investments. The Paying Agent shall maintain the Fund in a “noninterest-bearing deposit account”
insured by the Federal Deposit Insurance Corporation (“FDIC”) to the applicable limits.

 

(b)              
Tax Treatment. The Parties hereby represent to the Paying Agent no tax reporting of any kind is required giving rise to
this Agreement. 

 

(c)               
RESERVED . 

 

(d)              
Statements of Account. The Paying Agent shall provide Ginkgo and Amyris with monthly statements of the balance of the account(s)
in which the Fund is held showing, the beginning and ending balance for the applicable period, Deposits made into, and distributions
made from, the Fund during the applicable period.

 

6.                 
Distribution of Fund.

 

(a)               
Disbursements upon Joint Written Instructions. Ginkgo and Amyris may, at such times as required pursuant to the Collaboration
Agreement or at any other time, execute and deliver Joint Written Instructions to the Paying Agent setting forth payment instructions
for amounts to be distributed from the Fund, and the Paying Agent shall distribute the Fund, or

 

    	 

     

    

portion(s) thereof, in accordance therewith promptly
(and in any event, within one (1) Business Day) following receipt by the Paying Agent of each such Joint Written Instructions and
responses from the authorized representatives under the Agreement for security callbacks.

 

(b)              
Wire Transfers. Any distributions of all or any portion of the Fund made to a Party shall be made by wire transfer of immediately
available funds to such Party pursuant to wire instructions provided in writing to the Paying Agent by such Party. 

 

7.                 
Reliance by the Paying Agent; Liability of the Paying Agent.

 

(a)               
The Paying Agent may rely upon any written notice, request, waiver, consent, certificate, receipt, authorization or other paper
or document with respect to the Fund that the Paying Agent reasonably believes to be genuine and what it purports to be. The Paying
Agent may confer with its counsel in the event of any dispute or question as to the construction of any of the provisions hereof,
or its duties hereunder, and shall incur no liability and shall be fully protected in acting in accordance with the written opinions
of such counsel. The duties of the Paying Agent hereunder will be limited to the observance of the express provisions of this Agreement
and any Joint Written Instructions. The Paying Agent will not be subject to, or be obliged or entitled to recognize, any other
agreement between the parties hereto or directions or instructions not specifically set forth (or as provided for) herein. The
Paying Agent will not make any distribution of any portion of the Fund that is not expressly authorized pursuant to this Agreement.
The Paying Agent will not be liable to any party hereto for any action taken or not taken by it in good faith under the terms hereof
in the absence of gross negligence or willful misconduct on the part of the Paying Agent.

 

(b)              
The Paying Agent undertakes to perform only such duties as are expressly set forth herein or in this Agreement and no duties shall
be implied. The Paying Agent shall have no liability under and no duty to inquire as to the provisions of any agreement other than
this Agreement. The Paying Agent shall not be liable for any action taken or omitted by it in good faith except to the extent that
a court of competent jurisdiction finally adjudicates that the Paying Agent’s gross negligence or willful misconduct was
the primary cause of any loss to Ginkgo or Amyris. The Paying Agent’s sole responsibility with respect to the Fund shall
be for the safekeeping and disbursement of the Fund in accordance with the terms of this Agreement. The Paying Agent is obligated
only to perform the duties specifically set forth in this Agreement, which shall be deemed purely ministerial in nature. Under
no circumstance will the Paying Agent be deemed to be a fiduciary to any Party or any other person under this Agreement. The Paying
Agent shall have no implied duties or obligations and shall not be charged with knowledge or notice of any fact or circumstance
not specifically set forth herein or in Joint Written Instructions. The Paying Agent shall not be obligated to take any legal action
or commence any proceeding in connection with the Fund, any accounts in which the Fund is deposited, this Agreement, or to appear
in, prosecute or defend any such legal action or proceeding. The Paying Agent shall not be responsible or liable in any manner
for the performance by any other Party of such other Party’s obligations under the Collaboration Agreement nor shall the
Paying Agent be responsible or liable in any manner for the failure of any other Party to honor any of the provisions of this Agreement.
The Paying Agent may consult legal counsel selected by it in the event of any dispute or question as to the construction of any
of the provisions hereof or of any other agreement or of its duties hereunder, or relating to any

 

    	 

     

    

dispute involving any Party , and shall incur
no liability whatsoever in acting in good faith in accordance with the written opinion or written instruction of such counsel.
Ginkgo and Amyris shall be responsible to pay the reasonable fees of the Paying Agent’s outside counsel in accordance with
the provisions of Section 9 hereof; provided, however, solely as between Ginkgo and Amyris, each of Amyris, on the
one hand, and Ginkgo, on the other hand, agrees between them that it will pay 50% of such fees if any, and each of Amyris, on the
one hand, and Ginkgo, on the other hand, shall fully indemnify the other in the event that it pays the other such Party’s
portion of such amount.

 

(c)               
The Paying Agent shall not be liable, directly or indirectly, for any (i) damages, losses or expenses arising out of the services
provided hereunder, other than damages, losses or expenses which have been finally adjudicated to have directly resulted from the
Paying Agent’s gross negligence or willful misconduct or (ii) special, indirect, punitive, or consequential damages or losses
of any kind whatsoever (including without limitation lost profits), even if the Paying Agent has been advised of the possibility
of such losses or damages and regardless of the form of action.

 

8.                 
Indemnification of the Paying Agent. Ginkgo and Amyris, jointly and severally, hereby agree that each shall to the fullest
extent permitted by law, defend, indemnify and hold the Paying Agent and each director, officer, employee and agent of the Paying
Agent (the “Agent Indemnified Parties”) harmless from and against any and all actions, claims (whether or not
valid), losses, costs, liabilities, damages or expenses of any kind or nature whatsoever (including, but not limited to, reasonable
attorneys’ fees, costs and expenses) incurred by or asserted against the Agent Indemnified Parties from and after the date
hereof (a) in connection with the negotiation, preparation, execution, performance of this Agreement or any transactions contemplated
herein,; provided, however, that such Agent Indemnified Party shall not have the right to be indemnified hereunder for any liability
finally adjudicated by a court of competent jurisdiction, subject to no further appeal, to have the gross negligence or willful
misconduct of such Agent Indemnified Party; or (b) its following any joint instructions from Ginkgo and Amyris, except to the extent
that its following any such instruction or direction is expressly forbidden by the terms hereof. Each of the Agent Indemnified
Parties shall, in its reasonable discretion, have the right to select and employ separate counsel with respect to any action or
claim brought or asserted against it, and the reasonable fees of such outside counsel shall be paid upon presentation of evidence
thereof reasonably satisfactory to Ginkgo and Amyris in the form of customary invoices. The obligations of Amyris and Ginkgo under
this Section 8 shall survive any termination of this Agreement and the resignation or removal of the Paying Agent.

 

Solely as between the Parties, Ginkgo and Amyris
agree that the payment by Ginkgo or Amyris of any claim by the Paying Agent for indemnification hereunder shall not impair, limit,
modify or affect, as between Ginkgo, on the one hand, or Amyris, on the other hand, the respective rights and obligations of Ginkgo,
on the one hand, or Amyris, on the other hand, under the Collaboration Agreement.

 

9.                 
Fees and Expenses of the Paying Agent. Ginkgo, on the one hand, and Amyris, on the other, shall each pay 50% of the fees
and expenses of the Paying Agent owed to it on the date hereof for its services hereunder in accordance with the Fee Schedule attached
hereto as Exhibit B. The fee agreed upon for the services rendered hereunder is intended as full

 

    	 

     

    

compensation for the Paying Agent’s services
as contemplated by this Agreement. The Paying Agent is hereby granted the right to set off and deduct from the Fund any fees, expenses
and indemnification rights owed to the Paying Agent under this Agreement that remain unpaid, unreimbursed, and/or unsatisfied after
notice to Ginkgo and Amyris of such set-off and a reasonable opportunity to cure. Solely between Ginkgo and Amyris , each of Amyris,
on the one hand, and Ginkgo, on the other hand, agrees between them that it will pay 50% of all amounts payable under this Section
9, if any, and each of Amyris, on the one hand, and Ginkgo, on the other hand, shall fully indemnify the other in the event that
it pays the other such Party’s portion of such amount.

 

10.             
Resignation and Removal of the Paying Agent. The Paying Agent may resign from its duties hereunder by giving each of the
Parties not less than 30 days’ prior written notice of the effective date of such resignation. The Paying Agent may be removed
by joint written direction of Ginkgo and Amyris upon 30 days’ prior written notice. Ginkgo and Amyris shall appoint a substitute
Paying Agent prior to the effective date of a resignation or removal of the Paying Agent. The substitute Paying Agent shall fulfill
the duties of the Paying Agent hereunder for the remaining term of this Agreement and such substitute Paying Agent shall be a recognized
bank or trust company. Upon the effective date of such successor’s appointment, the Paying Agent will take all appropriate
action to transfer all funds and other property including notices or other written communications to such successor, who shall
thereafter be the “Paying Agent” under this Agreement. If a successor paying agent has not been appointed or has not
accepted such appointment by the end of such 30-day period, the Paying Agent may apply to a court of competent jurisdiction for
the appointment of a successor paying agent, and Ginkgo and Amyris shall each pay the reasonable and documented costs and expenses
(including reasonable attorneys’ fees) which are incurred in connection with such proceeding. Solely between Ginkgo and Amyris,
each of Amyris, on the one hand, and Ginkgo, on the other hand, agrees between them that it will pay 50% of all amounts payable
under this Section 10, if any, and each of Amyris, on the one hand, and Ginkgo, on the other hand, shall fully indemnify the other
in the event that it pays the other such Party’s portion of such amount. Until a successor paying agent has accepted such
appointment and the Paying Agent has transferred the Fund to such successor paying agent or an interpleader action has been commenced
with the payment of the Fund into a court of competent jurisdiction, the Paying Agent shall continue to retain and safeguard the
Fund until receipt of Joint Written Instructions or otherwise pursuant to the terms of this Agreement. Upon delivery of the Fund
to a successor paying agent in accordance with this Section 10, the Paying Agent shall thereafter be discharged from any further
obligations hereunder except for any liability accruing hereunder prior to such delivery. Any corporation or association into which
the Paying Agent may be merged or converted or with which it may be consolidated, or any corporation or association to which all
or substantially all of the escrow business of the Paying Agent’s line of business may be transferred, shall be the Paying
Agent under this Agreement without further act. 

 

11.             
Notices. All notices, demands or other communications hereunder shall be in writing and shall be deemed to have been duly
given if delivered in person, by e-mail with a signed PDF attachment or fax, by United States mail, certified or registered with
return receipt requested, or by a nationally recognized overnight courier service, or otherwise actually delivered:

 

 

    	 

     

    

If to Amyris, to:                                    Amyris,
Inc.

5885 Hollis Street, Ste. 100 

Emeryville, CA 94608 

Attn: [_________] 

Fax: 

Email:

 

 

 

If to Ginkgo, to:                                     Ginkgo
Bioworks, Inc.

27 Drydock Avenue, 8th Floor 

Boston, MA 02210 

Attn: CEO 

Attn: General Counsel 

Email:

 

 

 

If to the Paying Agent, to:                                  Citibank, N.A

153 East 53rd St, 21st Fl

New York, NY 10022

Attn:

Fax:

e-mail:

 

or at such other address as may have been furnished by such person
in writing to the other parties. Any such notice, demand or communication shall be deemed given on the date given, if delivered
in person, e-mailed or faxed or otherwise actually delivered, on the date received, if given by registered or certified mail, return
receipt requested or given by overnight delivery service, or three days after the date mailed, if otherwise given by first class
mail, postage prepaid.

 

 

12.             
Assignment. Neither this Agreement nor any of the rights or obligations hereunder may be assigned by any Party without the
prior written consent of the other parties. Subject to the preceding sentence, this Agreement shall be binding upon and inure to
the benefit of the Parties hereto and their respective successors and permitted assigns, and no other person shall have any right,
benefit or obligation under this Agreement as a third-party beneficiary or otherwise. Notwithstanding the preceding two sentences,
Ginkgo may (i) assign this Agreement and any of its interests, rights and obligations in, to and with respect to this Agreement
to any of Ginkgo’s affiliates or any Person acquiring a material portion of the assets, business or securities of the Company
or the Ginkgo, whether by merger, consolidation, sale of assets or securities or otherwise and/or (ii) collaterally assign its
rights and remedies under this Agreement to any agents and lenders (and their successors and assigns and whether current or future)
providing financing to Ginkgo or its affiliates; provided however, that Ginkgo shall provide the Paying Agent with reasonable advance
notice of any such assignment and cause such assignee(s) to comply with all reasonable requests for information by the Paying Agent
pursuant to Section 21 of this Agreement. The undersigned acknowledge and agree that, notwithstanding any such assignment, Ginkgo
shall remain liable under this Agreement to observe and perform all of the conditions and obligations herein contained to be observed
and performed by Ginkgo, and that neither a collateral assignment, nor any action taken pursuant thereto, shall cause the agents
or lenders providing the debt financing (or their affiliates, successors or assigns) to have any

 

    	 

     

    

obligation or liability in any respect whatsoever
to any party to this Agreement for the observance or performance of any of the representations, warranties, conditions, covenants,
agreements or terms contained in this Agreement. Any assignment of interest shall be noted in writing to the Paying Agent and such
new person or entity shall provide any necessary due diligence documentation to the Paying Agent as it may request. Notwithstanding
anything to the contrary in this Section 12, in no event shall the Paying Agent be obligated hereunder to (x) make any payments
from the Fund directly to any assignee of any rights under this Agreement, or (y) obey any written instructions delivered pursuant
hereto from any assignee of Ginkgo of any rights under this Agreement, unless, in the case of clauses (x) and (y), such assignee
has become a Party to this Agreement.

 

13.             
Amendment and Termination; Waiver. This Agreement may be amended by and upon written notice to the Paying Agent given by
both Ginkgo and Amyris, but the duties and responsibilities of the Paying Agent may not be modified in any way whatsoever without
its written consent. This Agreement will terminate on the date on which the entire Fund has been distributed, except such provisions,
including without limitation Section 8 and Section 9 hereof, which by their terms are intended to survive any such distribution.
No waiver by any party with respect to any condition, default or breach of covenant hereunder shall be deemed to extend to any
prior or subsequent condition, default or breach of covenant hereunder or affect in any way any rights arising prior or subsequent
to such occurrence.

 

14.             
Multiple Counterparts; Electronic Delivery. This Agreement may be executed in one or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument. Signatures to this Agreement transmitted
by facsimile transmission, electronic mail in “portable document format” (.pdf) or any other electronic means shall
have the same effect as physical delivery of the paper document bearing the original signature.

 

15.             
Invalidity. In the event that any one or more of the provisions contained in this Agreement shall, for any reason, be held
to be invalid, illegal or unenforceable in any respect, then to the maximum extent permitted by law, such invalidity, illegality
or unenforceability shall not affect any other provision of this Agreement.

 

16.             
Titles. The titles, captions or headings of the sections herein are for convenience of reference only and are not intended
to be a part of or to affect the meaning or interpretation of this Agreement.

 

17.             
Cumulative Remedies. All rights and remedies of any party hereto are cumulative of each other and of every other right or
remedy such party may otherwise have at law or in equity, and the exercise of one or more rights or remedies shall not prejudice
or impair the concurrent or subsequent exercise of other rights or remedies.

 

18.             
Choice of Law; Forum; WAIVER OF JURY TRIAL. This Agreement shall be governed by and construed in accordance with the laws
of the State of New York, without regard to conflicts of laws principles. Any proceeding arising out of or relating to this Agreement
shall be brought only in the federal courts located in the State of New York. The parties hereto consent to and agree (i) to submit
to the jurisdiction of any of the courts specified herein, (ii) to accept

 

    	 

     

    

service of process to vest personal jurisdiction
over them in any of these courts and (iii) that this provision may be filed with any court as written evidence of the knowing and
voluntary irrevocable agreement between the parties to waive any objections to jurisdiction, to venue or to convenience of forum.
EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED
AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN
RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT AND ANY OF THE DOCUMENTS DELIVERED
IN CONNECTION HEREWITH OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.

 

19.             
Specific Performance. In addition to any and all other remedies that may be available at law in the event of any breach
of this Agreement, Ginkgo and Amyris t shall be entitled to specific performance of the agreements and obligations of the Parties
and to such other injunctive or other equitable relief as may be granted by a court of competent jurisdiction.

 

20.             
Entire Agreement; Conflict. This Agreement constitutes the entire agreement among the parties with respect to the subject
matter hereof and supersedes any prior understandings, agreements or representations by or among the parties, written or oral,
with respect to the subject matter hereof; provided, that nothing in this Agreement shall or shall be deemed to modify or
alter the respective rights and obligations of the parties to the Collaboration Agreement as set forth in therein and, in furtherance
of the foregoing, the parties hereto agree and acknowledge that, as between the Parties, to the extent any terms and provisions
of this Agreement are in any way inconsistent with or conflict with any term, condition or provision of the Collaboration Agreement
(as between parties other than the Paying Agent), the Collaboration Agreement shall govern and control , the terms and conditions
of this Agreement shall control the actions of the Paying Agent. Unless and until the Paying Agent shall be notified in writing
that an inconsistency or a conflict exists between this Agreement and the Collaboration Agreement, it shall be entitled to assume
that no such inconsistency or conflict exists.

 

21.             
Patriot Act. To help the government fight the funding of terrorism and money laundering activities, federal law requires
all financial institutions to obtain, verify and record information that identifies each person who opens an account. For a non-individual
person such as a business entity, a charity, a trust or other legal entity, the Paying Agent may ask for documentation to verify
its formation and existence as a legal entity. The Paying Agent may also ask to see financial statements, licenses, identification
and authorization documents from individuals claiming authority to represent the entity, or other relevant documentation.

 

22.             
Force Majeure. No party shall be liable or responsible to the other parties, nor be deemed to have defaulted under or breached
this Agreement, for any failure or delay in fulfilling or performing any term of this Agreement, when and to the extent such failure
or delay is caused by or results from acts beyond the affected party’s reasonable control, including, without limitation:
(a) acts of God; (b) flood, fire or explosion; (c) war, invasion, riot or other civil unrest; (d) government order or law; (e)
embargoes or blockades in effect on or after the date of this Agreement; (f) action by any governmental authority; and (g) national
or regional emergency (each a “Force Majeure Event”).

 

    	 

     

    

26. Security Procedure For Funds Transfers.
The Paying Agent shall confirm each funds transfer instruction received in the name of a Party listed on Exhibit A-1 or Exhibit
A-2 attached hereto, which upon receipt by the Paying Agent shall become a part of this Agreement. Once delivered to the Paying
Agent, Exhibit A-1 or Exhibit A-2 may be revised or rescinded only by a writing signed by an authorized representative of the Party.
Such revisions or rescissions shall be effective only after actual receipt and following such period of time as may be necessary
to afford the Paying Agent a reasonable opportunity to act on it. If a revised Exhibit A-1 or A-2 or a rescission of an existing
Exhibit A-1 or A-2 is delivered to the Paying Agent by an entity that is a successor-in-interest to such Party, such document shall
be accompanied by additional documentation satisfactory to the Paying Agent showing that such entity has succeeded to the rights
and responsibilities of the Party under this Agreement. In the event a Joint Written Instruction is delivered to the Paying Agent,
whether in writing, by telecopier or otherwise, the Paying Agent is authorized to seek confirmation of such instruction by telephone
call back to the person or persons designated in Exhibits A-1 and or A-2 annexed hereto (the “Call Back Authorized Individuals”),
and the Paying Agent may rely upon the confirmations of anyone purporting to be a Call Back Authorized Individual. To assure accuracy
of the instructions it receives, the Paying Agent may record such call backs. If the Paying Agent is unable to verify the instructions,
or is not satisfied with the verification it receives, it will not execute the instruction until all such issues have been resolved.
The persons and telephone numbers for call backs may be changed only in writing, executed by authorized signers of the applicable
Party set forth on Exhibits A-1 and A-2 and actually received and acknowledged by the Paying Agent. Each of Ginkgo and Amyris understand
that the Paying Agent’s inability to receive or confirm funds transfer instructions pursuant to the security procedure selected
by such party may result in a delay in accomplishing such funds transfer, and agree that the Paying Agent shall not be liable for
any loss caused by any such delay.

 

27.       Use
of Citibank Name. No printed or other material in any language, including prospectuses, notices, reports, and promotional material
which mentions "Citibank" by name or the rights, powers, or duties of the Paying Agent under this Agreement shall be
issued by any other parties hereto, or on such party’s behalf, without the prior written consent of the Paying Agent.

 

28.Compliance with Court Orders.
In the event that the Fund shall be attached, garnished or levied upon by any court order, or the delivery thereof shall be stayed
or enjoined by an order of a court, or any order, judgment or decree shall be made or entered by any court order affecting the
property deposited under this Agreement, the Paying Agent is hereby expressly authorized, in its sole discretion, to obey and comply
with all writs, orders or decrees so entered or issued, which it is advised by legal counsel of its own choosing is binding upon
it, whether with or without jurisdiction, and in the event that the Paying Agent obeys or complies with any such writ, order or
decree it shall not be liable to any of the Parties hereto or to any other person, by reason of such compliance notwithstanding
such writ, order or decree be subsequently reversed, modified, annulled, set aside or vacated.

 

 

 

[Signature Page Follows]

 

    	 

     

    

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.

 

 

 

GINKGO BIOWORKS, INC.

 

By:______________________________

Name: Jason Kelly

Title: Chief Executive Officer

 

AMYRIS, INC.

 

By:______________________________

Name: John Melo

Title: Chief Executive Officer

 

CITIBANK, N.A.

 

By:______________________________

Name:

Title:

 

 

 

 

 

 

 

[ Signature Page to Paying Agent Agreement ]

    	 

     

    

Attachment A

 

 

[Note to draft: To be provided.]

 

 

 

 

 

 

 

 

 

 

 

 

    	 

     

    

EXHIBIT A-1

 

Certificate as to Amyris Authorized Signatures

 

 

 

The specimen signatures shown below are the specimen signatures
of the individuals who have been designated as authorized representatives of Amyris and are authorized to initiate and approve
transactions of all types for the accounts established under this Paying Agent Agreement, on behalf of Amyris. The below listed
persons (must list at least two individuals) have also been designated Call Back Authorized Individuals and will be notified by
Citibank N.A. upon the release of all or a portion of the Fund from the applicable account(s) unless an original “Standing
or Predefined Instruction” letter is on file with the Paying Agent.

 

	Name / Title /Telephone #	Specimen Signature
	
        ___ ________________

        Name

         

        ____ __________ _

        Title

         

        ____ __________ _

        Telephone #
	___________________________

Signature
	 	 
	
        ______________________________

        Name

         

        ______________________________

        Title

         

        ______________________________

        Telephone #
	_____________________________

Signature
	 	 
	
        ______________________________

        Name

         

        ______________________________

        Title

         

        ______________________________

        Telephone #
	_____________________________

Signature

 

    	 

     

    

EXHIBIT A-2

 

Certificate as to Ginkgo Authorized Signatures

 

 

 

The specimen signatures shown below are the specimen signatures
of the individuals who have been designated as authorized representatives of Ginkgo and are authorized to initiate and approve
transactions of all types for the accounts established under this Paying Agent Agreement, on behalf of Ginkgo. The below listed
persons (must list at least two individuals) have also been designated Call Back Authorized Individuals and will be notified by
Citibank N.A. upon the release of all or a portion of the Fund from the applicable account(s) unless an original “Standing
or Predefined Instruction” letter is on file with the Paying Agent.

 

	Name / Title /Telephone #	Specimen Signature
	
        ______________________________

        Name

         

        ______________________________

        Title

         

        ______________________________

        Telephone #
	_____________________________

Signature
	
         

         
	 
	
        ______________________________

        Name

         

        ______________________________

        Title

         

        ______________________________

        Telephone #
	_____________________________

Signature
	
         

         
	 
	
        ______________________________

        Name

         

        ______________________________

        Title

         

        ______________________________

        Telephone #
	_____________________________

Signature

 

 

 

    	 

     

    

Exhibit B

 

 

 

PAYING AGENT FEE SCHEDULE

 

Citibank, N.A., Paying Agent

 

Acceptance Fee

 

To cover the acceptance of the Paying Agency
appointment, the study of the Paying Agent Agreement, and supporting documents submitted in connection with the execution and delivery
thereof, and communication with other members of the working group:

 

Fee: WAIVED

 

Administration Fee

 

The annual administration fee covers maintenance
of the Fund including safekeeping of assets in the Fund, normal administrative functions of the Paying Agent, including maintenance
of the Paying Agent’s records, follow-up of the Paying Agent Agreement’s provisions, and any other safekeeping duties
required by the Paying Agent under the terms of the Paying Agent Agreement. Fee is based on Fund being deposited in a non-interest
bearing transaction deposit account, FDIC insured to the applicable limits.

 

Fee: $3,500.00 annually

 

Tax Preparation Fee

 

To cover preparation and mailing of Forms 1099-INT, if applicable
for the parties for each calendar year:

 

Fee: WAIVED

 

Transaction Fees

 

To oversee all required disbursements or release of property from
the Fund to any party, including cash disbursements made via check and/or wire transfer, fees associated with postage and overnight
delivery charges incurred by the Paying Agent as required under the terms and conditions of the Paying Agent Agreement:

 

Fee: WAIVED

 

    	 

     

    

Other Fees

 

 

 

Material amendments to the Paying Agent Agreement: additional fee(s),
if any, to be discussed at time of amendment

 

 

 

    	 

     

    

Exhibit C

 

 

 

 

 

FORM OF JOINT WRITTEN INSTRUCTION

 

    	 

     

    

EXHIBIT 4.1

  

TECHNICAL DEVELOPMENT PLAN

 

This Technical Development Plan (“TDP”) is dated (month) _(day)__
of (year). This TDP hereby incorporates by reference the terms and conditions of the Collaboration Agreement.

 

I.                  
Product and Product Application (e.g. field of use from contract)

Include name, InChl and FEMA and/or CAS numbers when possible

 

 

 

II.       Product(s) Specification

 

Include as much detail as possible

 

 

 

III.       Product Projections

 

Include:

 

	Production organism
	Maximum stoichiometric yield
	Productivity
	Target yield
	Manufacturing volume (Product tonnage): volume projections for the next 5 years, assuming
success.
	Cost of goods range:
	Selling price estimate:

 

 

		IV.	Background and Opportunity Summary

 

		V.	Project Outline

Include description of:

 

	Key tasks (strain and process development)
	Major deliverables (strain and process development)
	Major project risks
	Description of major resource requirements
	Gantt chart mapping tasks and deliverables onto a timeline
	R&D capital expenditures required

 

    	 

     

    

EXHIBIT 4.1

 

VI.       Additional Process and Manufacturing
Plan Information

 

Include description of:

 

	Block flow diagram for projected end to end manufacturing process
	Brief description of envisioned physical assets required for manufacturing and any key
regulatory or permitting requirements

	Include statement about compatibility with existing Amyris facilities or other manufacturing
options and whether significant capital expenditures may be necessary

	Summary page of cost model for the Product opportunity

	Include estimates for required rate, titer, yield (on major substrate), yield (Product
recovery), and Product purity

	Description of path from lab-scale validation to commercial production

		o	Packaging requirements envisioned (bulk truck, drum, totes, etc.).

		o	List of ingredients/raw materials required.

		o	Capital improvement requirements, if any

		o	EH&S evaluation of molecule and process for production

	Is it TSCA listed? Reference number:
	Detailed description of anticipated host strain (for CTNBio approval):
	Anticipated process hazards of additional chemicals used in production:
	Safety Data Sheet for the product, if available
	Anticipated waste generated:
	Air emissions anticipated:
	Additional safety data for assessment, as requested

 

Remainder of page left intentionally blank.

 

    	 

     

    

EXHIBIT 4.1

 

IN WITNESS WHEREOF, the parties hereby have caused this Exhibit
4.1 Technical Development Plan to be included as part of the Collaboration Agreement between Amyris and Ginkgo as of the date
first written above.

 

 

 

Amyris       

 

By: ________________________________

 

Name: ______________________________

 

Title: ______________________________

 

 

Ginkgo

 

 

By: ________________________________

 

Name: ______________________________

 

Title: _______________________________

 

    	 

     

    

EXHIBIT 4.4(a)

 

Manufacturing Terms

 

This Exhibit 4.4(a) sets forth the manufacturing terms and conditions
(collectively, the “Manufacturing Terms”) for all Products that Amyris shall produce for a customer under an Amyris
Customer Agreements or a Ginkgo Customer Agreements (“Customer”). Amyris and Ginkgo shall ensure that all provisions
relating to the supply of Products under their respective Customer Agreements are consistent with the Manufacturing Terms, and
that all of the Manufacturing Terms that are expressly designated for inclusion in their respective Customer Agreements are so
included

 

		1)	The following definitions and other terms shall be included in all supply agreements between Amyris
and Ginkgo for Customer Agreements (each a “Supply Agreement”):

		a.	Supplier: Amyris

		b.	Purchaser: Customer

		c.	Product(s): Product to be produced by Amyris for the Customer.

		d.	Product Specification(s): As set forth by the applicable Technical Development Plan.

		e.	Delivery Terms: As specified by the approved Joint Steering Committee.

		f.	Price: The Product price agreed to with the Customer and approved by the Joint Steering Committee.

		g.	Payment Terms: Not more than 30 days upon invoice.

		h.	Term of Supply Agreement: As approved by the Joint Steering Committee.

 

		2)	In the event that Product volumes for a given Customer Agreement exceed the top end of the volume
estimate for such Product provided to Amyris in the most recent Product forecast, Amyris shall use commercially reasonable efforts
to accommodate the production and delivery of the additional volume by the Customer’s expected delivery date. Amyris will
provide an estimate for additional costs, if any, to meet the delivery date for the additional volume and will not commence work
prior to receipt of Customer’s approval.

 

		3)	The Customer will provide Amyris with a rolling forecast for Product volumes. Each such forecast
shall include quarterly volume forecasts for the next four (4) calendar quarters. Unless otherwise agreed in advance by the JSC,
the volumes indicated for the first two (2) quarters of each forecast shall constitute a binding commitment to purchase such volumes
in such quarters. For avoidance of doubt, once a binding forecast is provided by the Customer for a given calendar quarter, such
forecast may not be amended without the prior written consent of Amyris.

 

		4)	Rights and limitations on use (e.g., for Program markets) consistent with the Agreement, shall
be included in (or cross-referenced by) the Supply Agreement.

 

		5)	Amyris and Ginkgo obligations under the Agreement with respect to Strain engineering, if any, and
up-scaling that is covered under Incentive Payments, concludes at the delivery of a technical transfer package that has been validated
by at least one Pilot Run that is Successful. After this step, any work Amyris or Ginkgo performs is deemed part of its Product
manufacturing work. 

		a.	“Pilot Run” is defined as fermentation at a maximum 300 liter tank capacity and associated
downstream processing. Such downstream processing will include any necessary steps to achieve a result from which the final Product
can be derived. For clarity, any final chemical processing steps that are industry standard and proven may be excluded from a Pilot
Run.

		b.	“Successful” in connection with a Pilot Run means that Amyris has demonstrated the
ability to produce the Product within the defined final Product specifications or the defined specifications needed to complete
the remaining downstream processing steps.

    	 

     

    

EXHIBIT 4.4(a)

 

		6)	Amyris shall be responsible for indirect costs associated with the startup of production of a Product,
including without limitation licenses, approvals, and permits necessary for performance

 

 

 

 

 

 

 

 

 

 

    	 

     

    

EXHIBIT 4.4(a)

 

of services, up to a maximum aggregate amount of $[*] per
Product. Any amounts above $[*]will be billed to the Customer.  

 

		7)	The Parties agree that the Customer shall be responsible for any licenses, authorizations, approvals,
permits, and the like required for the distribution and sale of the Product.

 

		8)	Amyris shall be responsible for all procurement and personnel required for the production of a
Product.

 

		9)	Amyris shall provide Ginkgo with a standard supply agreement template for reference and use by
Ginkgo and Amyris in the negotiation of Customer Agreements.

 

		10)	Ginkgo shall involve Amyris in the negotiation and approval of any manufacturer liabilities, representations
and warranties for a Ginkgo Customer Agreement to the extent that any such provisions deviate from the standard provisions included
in the template described in paragraph 9, above.

 

		11)	If for any reason a Product under a Customer Agreement is to be no longer supplied by Amyris, the
Customer will purchase all Product that is currently in production and all Product in Amyris’ owned inventory, to the extent
such current production or inventory was based on any binding estimates or purchase orders. If the Product is also sold to another
customer, Amyris will deduct the forecasted demand for that Product from the amount the Customer will be required to purchase from
Amyris.

 

		12)	In the event a Customer requests a change in production of a Product under an existing Customer
Agreement that increases production costs, Amyris will provide a cost estimate for the Customer to approve prior to implementing
the change.

 

		13)	Ginkgo will manage and maintain the manufacturing Strain banks for all Products under a Ginkgo
Customer Agreement and demonstrate standard QC checks for such Strain banks. The standard test protocol for such Strain banks is
as follows:

[*]

		14)	Amyris will manage and maintain the manufacturing Strain banks for all Products under an Amyris
Customer Agreement and demonstrate standard QC checks for such Strain banks. The standard test protocol for such Strain banks is
as follows:

[*]

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

    	 

     

    

EXHIBIT 4.4(b)

 

Supplier Restrictions

 

In the event that Amyris engages a Third Party to manufacture Products
under Section 4.4 of the Agreement or Ginkgo engages a Third Party to manufacture Products under Section [6.2(a)(v)] of the Agreement
(Amyris or Ginkgo, as applicable, the “Contracting Party” and the Third Party, the “Permitted Manufacturer”),
the Contracting Party shall include in any agreement with the Permitted Manufacturer (the “Third Party Manufacturing Agreement”)
the following substantive terms and provisions:

 

1. Permitted Manufacturer will confine its manufacturing of the
Product to the following geographic territories: [*] and any other countries, or territories as may be agreed in writing by the
Parties’ respective Executive Officers from time to time.

 

2. The Party that is not the Contracting Party (the “Non-Contracting
Party”) will have the right, upon reasonable prior notice and during normal business hours, to accompany the Contracting
Party on an inspection of the facility at which the Product is manufactured (the “Permitted Facility”) at least once
per year.

 

3. The Non-Contracting Party will be named as a third party beneficiary
to the agreement between Contracting Party and the Permitted Manufacturer, with the express right to pursue claims against the
Permitted Manufacturer in the event of a breach of any of the provisions set forth in this Exhibit 4.4 (b)

 

4. As between the Parties, The Contracting Party will have the primary
right to pursue actions required to protect the Strain used for production of the applicable Product(s) and related intellectual
property vis-a-vis the Permitted Manufacturer.

 

5. Permitted Manufacturer will agree to (a) hold Confidential Information
(including, but not limited to, process technology, confidential information related to the Strain, know-how and other confidential
information and technology of the Parties) in confidence and take all reasonable precautions to protect such Confidential Information
(subject to customary exceptions) and (b) subject to customary exceptions, not divulge any such Confidential Information or any
information derived therefrom to any Third Party.

 

6. Permitted Manufacturer covenants not to reverse engineer the
applicable Strain used in production, not to engineer any strains from such Strain, not to use such Strain except to manufacture
and supply the Product to the Contracting Party as permitted under the Agreement and pursuant to the Third Party Manufacturing
Agreement, and not to distribute, disclose or transfer such Strain or any related intellectual property to any Third Party or to
any location or facility that is not a Permitted Facility, and in the event of such transfer, the Contracting Party shall notify
the Non-Contracting Party in writing at least thirty (30) days in advance of the transfer.

 

7. Permitted Manufacturer shall represent and warrant that its manufacture
and supply of the Product to the Contracting Party will be conducted in accordance with agreed commercial specifications and manufactured
in accordance with the reasonable instructions provided by the Contracting Party and with all applicable Laws.

 

8. Permitted Manufacturer shall maintain insurance of the type,
minimum rating and in amounts not less than is customary for similarly situated manufacturers.

 

9. The Contracting Party shall use its best efforts to cause Permitted
Manufacturer to grant each Party a non-exclusive royalty-free license to use any process improvements with respect to the manufacture
of the Product that are conceived, discovered, developed or otherwise made by Permitted Manufacturer.

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 

     

    

EXHIBIT 4.4(b)

 

10. In the event that Permitted Manufacturer ceases to use any Strain
for production of the Product under the Third Party Manufacturing Agreement, or in the event of a termination or expiration of
the Third Party Manufacturing Agreement, Permitted Manufacturer shall promptly return any such Strain or, at the Contracting Party’s
election, destroy such Strain.

 

11. Permitted Manufacturer will defend, indemnify and hold harmless
the Parties for any direct losses incurred by the Parties or any Amyris Indemnified Party or Ginkgo Indemnified Party, as applicable,
arising from or as a result of its willful misconduct or gross negligence or a breach of any provision of the Third Party Manufacturing
Agreement, including any representation, warranty or covenant thereunder.

 

 

 

 

 

    	 

     

    

Table 1

	Product	Sourcing Party	Customer Agreement	 
	[*]	Amyris	[*]	 
	[*]	Amyris	[*]	 
	[*]	Amyris	[*]	 
	[*]	Amyris	[*]	 
	[*]	Amyris	[*]	 
	[*]	Amyris	[*]	 
	[*]	Amyris	[*]	 
	[*]	Ginkgo	No contract signed as of the Effective Date	 
	[*]	Ginkgo	No contract signed as of the Effective Date	 
	[*]	Ginkgo	No contract signed yet as of the Effective Date	 
	[*]	Ginkgo	No contract signed yet as of the Effective Date
	[*]	Ginkgo	No contract signed yet as of the Effective Date
	[*]	Ginkgo	No contract signed yet as of the Effective Date
	[*]	Ginkgo	No contract signed yet as of the Effective Date
	[*]	Ginkgo	No contract signed yet as of the Effective Date
	[*]	Ginkgo	No contract signed yet as of the Effective Date
	Molecules stemming from [*]	Amyris	No contract signed as of the Effective Date	 
	 	 	 	 	 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

Table 2

	Product	Sourcing Party	Customer Agreement
	[*]	Amyris	[*]
	[*]	Amyris	[*]
	[*]	Amyris	[*]
	[*]	Amyris	[*]
	[*]	Amyris	[*]
	[*]	Amyris	[*]
	[*]	Amyris	[*]
	[*]	Amyris	[*]
	beta-pinene (IFF)	Amyris	Joint Development and License Agreement dated April 23, 2013 between Amyris and International Flavors & Fragrances Inc.
	

    	 

     

    

	duct	Sourcing Party	Customer Agreement
	[*]	Amyris	[*]
	other [*]	Amyris	[*]

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

    	 

     

    

Table 3

	Product 	Sourcing Party	Customer Agreement
	[*]	Amyris	[*]
	[*]	Amyris	[*]
	[*]	Amyris	[*]
	[*]	Ginkgo	[*]
	[*]	Ginkgo	[*]
	[*]	Ginkgo	[*]
	[*]	Ginkgo	[*]
	[*]	Ginkgo	[*]
	[*]	Ginkgo	[*]

 

 

Table 4

	Existing Commercial Product	Percentage of COGS Savings	COGS Model for Calculating COGS Savings
	[*]	[*]	See file “Copy of BGT'16 Mfg Model - 8-26-16 v0.xlsx”
	[*]	[*]	See file “AA cost model 2016_08_26.xlsx”
	[*]	[*]	See file “Copy of BGT'16 Mfg Model - 8-26-16 v0.xlsx”
	[*]	[*]	See file “Copy of BGT'16 Mfg Model - 8-26-16 v0.xlsx”
	[*]	[*]	See file “Manatee_2016_08_26_v2.xlsx”

 

 

Within 30 days of the Effective Date, the JSC will proscribe a method for calculation
of COGS savings using the listed COGS models.

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

 

 

 

    	 

     

    

Table 5

	Amyris Excluded Product	Ginkgo Excluded Product
	[*]	[*]
	 	[*]
	 	[*]
	 	[*]
	 	[*]
	 	[*]
	 	Chemical small molecule compounds in the Field for which the customer does not require Third Party manufacturing.

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 

     

    

EXHIBIT A

 

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS
CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED
(I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY,
THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 UNDER SAID ACT.
NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING
ARRANGEMENT SECURED BY THE SECURITIES.

 

WARRANT TO PURCHASE COMMON STOCK

 

	Company:	Amyris, Inc., a Delaware corporation
	Warrant Certificate:	GW-1
	Number of Shares:	5,000,000
	Class of Stock:	Common Stock
	Warrant Price:	$0.50 per share
	Issue Date:	August 4, 2016
	Expiration Date:	The 1st anniversary of the Issue Date

 

 

THIS WARRANT CERTIFIES THAT, for good and valuable
consideration, GINKGO BIOWORKS, INC. (together with any registered holder from time to time of this Warrant or any holder of the
shares issuable or issued upon exercise of this Warrant, “Holder”) is entitled to purchase the number of fully
paid and nonassessable shares of the class of securities of the Company at the Warrant Price, all as set forth above and as adjusted
pursuant to Article 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant.

 

ARTICLE
1 EXERCISE.

·     Exercise. This Warrant shall be exercisable for 5,000,000 shares of the Company’s common stock, par value $0.0001
per share (the “Common Stock”) (the “Shares”). The number of Shares and the Warrant Price
are subject to adjustment as provided herein, and all references to “Shares” and “Warrant Price” herein
shall be deemed to include any such adjustment or series of adjustments.

·     Method of Exercise.

·     Mechanics. This Warrant may be exercised by the Holder at any time on or after the Issue Date (an “Exercise
Date”), in whole or in part, by delivery (whether via facsimile or otherwise) of a written notice, in the form attached
hereto as Exhibit A (the “Exercise Notice”), of the Holder’s election to exercise this Warrant. Within
one (1) Trading Day following an exercise of this Warrant as aforesaid, the Holder shall deliver payment to the Company of an amount
equal to the Warrant Price in effect on the date of such exercise multiplied by the number of Shares as to which this Warrant was
so exercised (the “Aggregate Warrant Price”) in cash or via wire transfer of immediately available funds if
the Holder did not notify the Company in such Exercise Notice that such exercise was made pursuant to a Cashless Exercise (as defined
in Section 1.3). The Holder shall not be required to deliver the original of this Warrant in order to effect an exercise hereunder.
Execution and delivery of an Exercise Notice with respect to less than all of the Shares shall have the same effect as cancellation
of the original of this Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Shares.

    	 

     

    

Execution and delivery of an Exercise Notice for all of the then-remaining Shares shall have the same effect as cancellation of
the original of this Warrant after delivery of the Shares in accordance with the terms hereof. On or before the later of the third
(3rd) Trading Day following the date on which the Company has received such Exercise Notice and one (1) Trading Day after the Company’s
receipt of the Aggregate Warrant Price (or valid notice of a Cashless Exercise) (such later date, the “Share Delivery
Deadline”), the Company shall, (X) provided that the Company’s Common Stock transfer agent (the “Transfer
Agent”) is participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer
Program, upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled
pursuant to such exercise to the Holder’s or its designee’s balance account with DTC through its Deposit/Withdrawal
at Custodian system, or (Y) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, upon
the request of the Holder, issue and deliver (via reputable overnight courier) to the address as specified in the Exercise Notice,
a certificate, registered in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder
shall be entitled pursuant to such exercise. Upon delivery of an Exercise Notice, the Holder shall be deemed for all corporate
purposes to have become the holder of record of the Shares with respect to which this Warrant has been exercised, irrespective
of the date such Shares are credited to the Holder’s DTC account or the date of delivery of the certificates evidencing such
Shares (as the case may be). If this Warrant is submitted in connection with any exercise pursuant to this Section 1 and the number
of Shares represented by this Warrant submitted for exercise is greater than the number of Shares being acquired upon an exercise
and upon surrender of this Warrant to the Company by the Holder, then the Company shall as soon as practicable and in no event
later than three (3) business days after any exercise and at its own expense, issue and deliver to the Holder (or its designee)
a new Warrant representing the right to purchase the number of Shares purchasable immediately prior to such exercise under this
Warrant, less the number of Shares with respect to which this Warrant is exercised. No fractional shares of Common Stock are to
be issued upon the exercise of this Warrant, but rather the number of shares of Common Stock to be issued shall be rounded down
to the nearest whole number. The Company shall pay any and all transfer, stamp, issuance and similar taxes, costs and expenses
(including, without limitation, fees and expenses of the Transfer Agent) that may be payable with respect to the issuance and delivery
of Shares upon exercise of this Warrant. Notwithstanding the foregoing, the Company’s failure to deliver Shares to the Holder
on or prior to Share Delivery Deadline shall not be deemed to be a breach of this Warrant, provided that the Company is in compliance
with the other provisions of this Warrant, including without limitation Section 1.2(b).

 

·                    
Company’s Failure to Timely Deliver Securities. If the Company shall fail, for any reason or for no reason,
on or prior to the Share Delivery Deadline, if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer
Program, to issue and deliver to the Holder (or its designee) a certificate for the number of Shares to which the Holder is entitled
and register such Shares on the Company’s share register or, if the Transfer Agent is participating in the DTC Fast Automated
Securities Transfer Program, to credit the balance account of the Holder or the Holder’s designee with DTC for such number
of Shares to which the Holder is entitled upon the Holder’s exercise of this Warrant (as the case may be), and if on or after
such Share Delivery Deadline the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver
in satisfaction of a sale by the Holder of all or any portion of the number of shares of Common Stock issuable upon such exercise
that the Holder anticipated receiving from the Company (a “Buy-In”), then, in addition to all other remedies
available to the Holder, the Company shall, within three (3) business days after the Holder’s request and in the Holder’s
discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including brokerage
commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including, without limitation,
by any other Person in respect, or on behalf, of the Holder) (the “Buy-In Price”), at which point the Company’s
obligation to so issue and deliver such certificate (and to issue such shares of Common Stock) or credit the balance account of
such Holder or such Holder’s designee, as applicable, with DTC for the number of Shares to which the Holder is entitled upon
the Holder’s exercise hereunder (as the case may be) (and to issue such Shares) shall terminate and the applicable Exercise
Notice shall be disregarded as if never submitted by the Holder, or (ii) promptly honor its obligation to so issue and deliver
to the Holder a certificate or certificates representing such Shares or credit the balance account of such Holder or such Holder’s
designee, as applicable, with DTC for the number of Shares to which the Holder 

    	 

     

    

is entitled upon the Holder’s exercise hereunder
(as the case may be) and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product
of (A) such number of Shares multiplied by (B) the average closing price of the Common Stock across all Trading Days during the
period commencing on the date of the applicable Exercise Notice and ending on the date of such issuance and payment under this
clause (ii). Nothing shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in
equity, including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s
failure to timely deliver certificates representing shares of Common Stock (or to electronically deliver such shares of Common
Stock) upon the exercise of this Warrant as required pursuant to the terms hereof.

 

·                    
Cashless Exercise Right. In lieu of exercising this Warrant by making the cash payment otherwise contemplated to
be made to the Company upon such exercise in payment of the Aggregate Warrant Price pursuant to Article 1.2, Holder may elect instead
to receive upon such exercise the “Net Number” of shares of Common Stock determined according to the following formula
(a “Cashless Exercise”):

Net Number = (A x B) - (A x C)

B

 

For purposes of the foregoing formula:

 

A= the total number of shares with respect to which this Warrant
is then being exercised.

 

B= the fair market value of each Share, which shall be
(i) the average for the five Trading Days immediately prior to the date of determination thereof of the last reported sale price
regular way on each such day, (ii) in the case no such sale takes place on any such day, the average of the reported closing bid
and asked prices regular way of the shares of Common Stock on such day, in each case as quoted on the Principal Market, as reported
by Bloomberg or such other principal securities exchange or inter-dealer quotation system on which the shares of Common Stock are
then traded, or (iii) in the case the shares of Common Stock are not traded publically on the Principal Market, the value mutually
agreed up by the Company and the Holder.

 

C= the Warrant Price then in effect for the applicable Shares at the time
of such exercise.

 

·                    
Delivery of Certificate and New Warrant. Promptly after Holder exercises or converts this Warrant, and, if applicable,
the Company receives payment of the aggregate Warrant Price, the Company shall deliver to Holder certificates for the Shares acquired
and, if this Warrant has not been fully exercised or converted and has not expired, a new Warrant representing the Shares not so
acquired. Holder shall be deemed to own and have all of the rights associated with any Shares or other securities or property to
which it is entitled pursuant to this Warrant upon the exercise or conversion of the Warrant in accordance with this Article 1.

·                    
Replacement of Warrants. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction
or mutilation of this Warrant and in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory
in form and amount to the Company or, in the case of mutilation on surrender and cancellation of this Warrant, the Company shall
execute and deliver, in lieu of this Warrant, a new warrant of like tenor.

·                    
Treatment of Warrant Upon Acquisition of Company.

    	 

     

    

·                    
“Acquisition”. For the purpose of this Warrant, “Acquisition” shall mean the occurrence
of any of the following: (i) the consolidation of the Company with, or the merger of the Company with or into, another “person”
(as such term is used in Rule 13d-3 and Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)),
or the sale, lease, exclusive license, transfer, conveyance or other disposition, in one or a series of related transactions, of
all or substantially all of the assets of the Company and its Subsidiaries taken as a whole, or the consolidation of another “person”
with, or the merger of another “person” into, the Company, other than in each case pursuant to a transaction in which
the “persons” that “beneficially owned” (as such term is defined in Rule 13d-3 and Rule 13d-5 under the
Exchange Act), directly or indirectly, the Voting Shares (as defined below) of the Company immediately prior to the transaction
“beneficially own”, directly or indirectly, Voting Shares representing at least a majority of the total voting power
of all outstanding classes of voting stock of the surviving or transferee person; (ii) the adoption by the Company of a plan
relating to the liquidation or dissolution of the Company; (iii) the consummation of any transaction (including, without limitation,
any merger or consolidation) the result of which is that any “person” becomes the “beneficial owner” directly
or indirectly, of more than 50% of the Voting Shares of the Company (measured by voting power rather than number of shares); or
(iv) during any period of 24 consecutive months, a majority of the members of the Company’s Board of Directors cease to be
composed of individuals (A) who were members of the Board of Directors on the first day of such period, (B) whose election, nomination
or appointment to the Board of Directors was approved by at least a majority of the individuals referred to in clause (A) above
or (C) whose election, nomination or appointment to the Board was approved by at least a majority of the individuals referred to
in clauses (A) and (B) taken together. For the purposes of this Article 1.6.1, “Voting Shares” of any person
shall mean capital shares or capital stock of such person which ordinarily has voting power for the election of directors (or persons
performing similar functions) of such person.

·                    
Notice of Acquisition. The Company shall provide Holder with written notice of an Acquisition (together with
such reasonable information as Holder may request in connection with such contemplated Acquisition giving rise to such notice),
which is to be delivered to Holder not less than ten (10) days prior to the closing of the proposed Acquisition.

·                    
Treatment of Warrant at Cash/Public Acquisition. In the event of an Acquisition in which the consideration to be
received by the Company’s stockholders consists solely of cash, solely of Marketable Securities or a combination of cash
and Marketable Securities (a “Cash/Public Acquisition”), and the fair market value of one Share as determined
in accordance with Section 1.3 above would be greater than the Warrant Price in effect on such date immediately prior to such
Cash/Public Acquisition, and Holder has not exercised this Warrant pursuant to Article 1 above as to all Shares, then this Warrant
shall automatically be deemed to be exercised as a Cashless Exercise pursuant to Section 1.3 above as to all Shares effective
immediately prior to and contingent upon the consummation of a Cash/Public Acquisition. In the event of a Cash/Public Acquisition
where the fair market value of one Share as determined in accordance with Section 1.3 above would be less than the Warrant
Price in effect immediately prior to such Cash/Public Acquisition, then this Warrant will expire immediately prior to the consummation
of such Cash/Public Acquisition, unless the Holder elects to exercise the Warrant prior to the consummation of such Cash/Public
Acquisition.

·                    
Treatment of Warrant at Acquisition other than Cash/Public Acquisition. Upon the closing of any Acquisition other
than a Cash/Public Acquisition, unless Holder agrees otherwise in writing (but without obligation to do so), the acquiring, surviving
or successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same
securities and/or other property as would have been paid for the Shares issuable upon exercise of the unexercised portion of this
Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time
to time in accordance with the provisions of this Warrant.

    	 

     

    

·                    
Insufficient Authorized Shares. If at any time while the Warrant remains outstanding the Company does not have a
sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation to reserve for issuance upon exercise
of the Warrant at least a number of shares of Common Stock equal to 100% (the “Required Reserve Amount”) of
the number of shares of Common Stock as shall from time to time be necessary to effect the exercise of the Warrant then outstanding,
then the Company shall immediately take all action necessary to increase the Company’s authorized shares of Common Stock
to an amount sufficient to allow the Company to reserve the Required Reserve Amount for the Warrant then outstanding.

·                    
 ADJUSTMENTS TO THE SHARES.

·                    
Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on the Shares payable in common stock of
the Company, or other securities, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost
to Holder, the total number and kind of shares of common stock of the Company to which Holder would have been entitled had Holder
owned the Shares of record as of the date the dividend occurred. If the Company subdivides the Shares by reclassification or otherwise
into a greater number of shares or takes any other action which increases the amount of stock for which this Warrant is exercisable,
the number of Shares subject to the Warrant shall be proportionately increased and the Warrant Price shall be proportionately decreased.
If the outstanding shares are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant
Price shall be proportionately increased and the number of Shares subject to the Warrant shall be proportionately decreased.

·                    
Reclassification, Exchange, Combinations or Substitution. Upon any reclassification, exchange, substitution, reorganization,
recapitalization or other event that results in a change of the number and/or class of the securities issuable upon exercise or
conversion of this Warrant (other than an Acquisition which is subject to the provisions of Article 1.6), Holder shall be entitled
to receive, upon exercise or conversion of this Warrant the number and kind of securities and property that Holder would have received
for the Shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution, or other event.
The Company or its successor shall promptly issue to Holder an amendment to this Warrant setting forth the number and kind of such
new securities or other property issuable upon exercise or conversion of this Warrant as a result of such reclassification, exchange,
substitution or other event that results in a change of the number and/or class of securities issuable upon exercise or conversion
of this Warrant. The amendment to this Warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable
to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price and to the number
of securities or property issuable upon exercise of the new Warrant. The provisions of this Article 2.2 shall similarly apply to
successive reclassifications, exchanges, substitutions, or other events.

 

·                    
Other Adjustment Events. If any event occurs of the type contemplated by the provisions of this Article 2 but not
expressly provided for by such provisions, then the Company’s Board of Directors will make an appropriate adjustment in the
Warrant Price and the number of Warrant Shares so as to protect the rights of the Holder; provided that no such adjustment pursuant
to this Article 2.4 will increase the Warrant Price or decrease the number of Shares as otherwise determined pursuant to this Article
2.

·                    
No Impairment. Without the consent of the Holder, the Company shall not by amendment of its Certificate of Incorporation
or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities or any other
voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this
Warrant by the Company, but shall at all times in good faith assist in carrying out of all 

    	 

     

    

the provisions of this Article 2 and
in taking all such action as may be necessary or appropriate to protect Holder’s rights under this Article 2 against impairment.

·                    
Fractional Shares. No fractional Shares shall be issuable upon exercise or conversion of this Warrant and the number
of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise
or conversion of the Warrant, the Company shall eliminate such fractional share interest by paying Holder in cash equivalent to
the amount computed by multiplying the fractional interest by the fair market value of a full Share (as determined pursuant to
Section 1.3 of this Warrant).

·                    
Certificate as to Adjustments. Upon each adjustment of the Warrant Price and Shares, the Company shall promptly notify
Holder in writing, and, at the Company’s expense, promptly compute such adjustment, and furnish Holder with a certificate
of its Chief Financial Officer, Corporate Secretary or a senior financial officer setting forth such adjustment and the facts upon
which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant
Price and Shares in effect upon the date thereof and the series of adjustments leading to such Warrant Price and Shares.

·                    
 REPRESENTATIONS AND COVENANTS OF THE COMPANY. The Company represents,
warrants and covenants to the Holder as follows:

·                    
Representations and Warranties. The Company represents and warrants and covenants to the Holder as follows: All corporate
action required to be taken by the Company’s Board of Directors and stockholders in order to authorize the Company to enter
into this Warrant, and to issue the Shares upon exercise thereof, has been taken. All Shares which may be issued upon the exercise
of the purchase right represented by this Warrant shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable,
and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and
state securities laws. The issuance of this Warrant, or the Shares issuable thereunder, will not trigger any anti-dilution adjustment,
preemptive rights, rights of first refusal or other similar rights of third parties other than as have been waived prior to the
issuance of this Warrant. The Company will at all times reserve and keep available, out of its authorized but unissued share of
Common Stock, solely for the purpose of providing the exercise or conversion of this Warrant, the aggregate number of Shares issuable
upon exercise or conversion of this Warrant. The Company will use its reasonable best efforts to ensure that the Shares may be
issued without violation of any law or regulation applicable to the Company or of any requirement of any securities exchange applicable
to the Company on which the Shares are listed or traded.

·                    
All corporate action required to be taken by the Company’s Board of Directors and stockholders in order to authorize
the Company to enter into this Warrant, and to issue the Shares at the closing, has been taken or will be taken prior to the closing.
All action on the part of the officers of the Company necessary for the execution and delivery of this Warrant, the performance
of all obligations of the Company under this Warrant to be performed as of the closing, and the issuance and delivery of the Shares
has been taken or will be taken prior to the closing. This Warrant, when executed and delivered by the Company, shall constitute
valid and legally binding obligations of the Company, enforceable against the Company in accordance with their respective terms
except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of
general application relating to or affecting the enforcement of creditors’ rights generally or (ii) as limited by laws relating
to the availability of specific performance, injunctive relief, or other equitable remedies.

·                    
No Stockholder Rights. Except as provided in this Warrant, and other than with regard to shares of the Company’s
Common Stock acquired by Holder other than pursuant to the exercise of this Warrant, the Holder will not have any rights as a stockholder
of the Company until the exercise of this Warrant.

    	 

     

    

·                    
Charges, Taxes and Expenses. Issuance of certificates for Shares to the Holder or the credit of the Shares to the
Holder or the Holder’s designee with DTC upon the exercise or conversion of this Warrant shall be made without charge to
the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificates, all of which
taxes and expenses shall be paid by the Company.

·                       
Notice of Certain Events. If the Company proposes at any time to:

(a) declare any dividend or distribution upon
the outstanding shares of Common Stock, whether in cash, property, stock, or other securities and whether or not a regular cash
dividend;

 

(b) offer for subscription or sale pro rata
to the holders of the outstanding shares of the Common Stock any additional shares of any class or series of the Company’s
capital stock (other than pursuant to contractual pre-emptive rights);

 

(c) effect any reclassification, exchange,
combination, substitution, reorganization or recapitalization of the outstanding shares of Common Stock; or

 

(d) effect an Acquisition or to liquidate,
dissolve or wind up;

 

then, in connection with each such event, the Company shall give
Holder:

 

(1) in the case of the matters referred
to in (a) and (b) above, at least seven (7) business days prior written notice of the earlier to occur of the effective date thereof
or the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on
which the holders of outstanding shares of Common Stock will be entitled thereto) or for determining rights to vote, if any; and

 

(2) in the case of the matters referred
to in (c) and (d) above at least seven (7) business days prior written notice of the date when the same will take place (and specifying
the date on which the holders of outstanding shares of Common Stock will be entitled to exchange their shares for the securities
or other property deliverable upon the occurrence of such event and such reasonable information as Holder may reasonably require
regarding the treatment of this Warrant in connection with such event giving rise to the notice).

 

The Company will also provide information requested by Holder that
is reasonably necessary to enable Holder to comply with Holder’s accounting or reporting requirements.

 

·                    
 REPRESENTATIONS, WARRANTIES OF THE HOLDER. The Holder represents
and warrants to the Company as follows:

·                    
Purchase for Own Account. This Warrant and the securities to be acquired upon exercise or conversion of this Warrant
by the Holder will be acquired for investment for the Holders account, not as a nominee or agent, and not with a view to the public
resale or distribution within the meaning of the Securities Act of 1933, as amended (the “Securities Act”),
and the Holder has no present intention, and upon exercise or conversion will have no intention, of selling or engaging in any
public distribution of the same except pursuant to a registration or exemption. Holder also represents that the Holder has not
been formed for the specific purpose of acquiring this Warrant or the Shares.

·                    
Disclosure of Information. The Holder has received or has had full access to all the information it considers necessary
or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities.
The Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions
of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed
such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to the
Holder or to which the Holder has access.

    	 

     

    

·                    
Investment Experience. The Holder understands that the purchase of this Warrant and its underlying securities involves
substantial risk. The Holder has experience as an investor in securities of companies in the development stage and acknowledges
that the Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and
has such knowledge and experience in financial or business matters that the Holder is capable of evaluating the merits and risks
of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with
the Company and certain of its officers, directors or controlling persons of a nature and duration that enables the Holder to be
aware of the character, business acumen and financial circumstances of such persons.

·                    
Accredited Investor Status. The Holder is an “accredited investor” within the meaning of Regulation D
promulgated under the Securities Act.

·                    
Securities Act. The Holder understands that this Warrant and the Shares issuable upon exercise or conversion hereof
have not been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon,
among other things, the bona fide nature of the Holder’s investment intent as expressed herein. The Holder understands that
this Warrant and the Shares issued upon any exercise or conversion hereof must be held indefinitely unless subsequently registered
under the Securities Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification
are otherwise available. The Holder further understands that settlement of this Warrant is to be made in Shares and, for the elimination
of doubt, the fact that the Shares delivered on exercise of this Warrant will not be registered under the Securities Act (as defined
below) will not in any way require the Company to settle this Warrant otherwise than in Shares, including without limitation, that
there is no circumstance that would require the Company to settle this Warrant in cash.

·                    
 MISCELLANEOUS.

·                    
Term. This Warrant will be exercisable in whole or in part at any time and from time to time on or before the Expiration
Date.

·                    
Automatic Cashless Exercise upon Expiration. In the event that, upon the Expiration Date, the fair market
value of one Share as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date,
then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to Section 1.3 above as to all
Shares for which it shall not previously have been exercised.

·                    
Legends. This Warrant and the Shares shall be imprinted with a legend in substantially the following form:

NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT
BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM
REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD
PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE
MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

    	 

     

    

·                    
Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant may
not be transferred or assigned in whole or in part without compliance with applicable federal and state securities laws by the
transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions
reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide
an opinion of counsel if the transfer is to any affiliate of the Holder, provided that any such transferee is an “accredited
investor” as defined in Regulation D under the Securities Act; provided, however, in any such transfer the transferee shall
agree to be bound by the terms of this Warrant as if an original holder hereof. Additionally, the Company shall also not require
an opinion of counsel if there is no material question as to the availability of Rule
144 promulgated under the Securities Act.

·                    
Notices. All notices and other communications from the Company to the Holder, or vice versa, shall be deemed delivered
and effective when given personally or mailed by first-class registered or certified mail, postage prepaid (or on the first business
day after transmission by facsimile), at such address as may have been furnished to the Company or the Holder, as the case may
be, in writing by the Company or such Holder from time to time. Effective upon receipt of the fully executed Warrant, all notices
to the Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer
or otherwise:

Ginkgo Bioworks, Inc.

27 Drydock Avenue, 8th Floor

Boston, MA 02210

Attn: CEO

Attn: General Counsel

 

With a copy (which shall not constitute notice) to:

 

Latham & Watkins LLP

1000 Winter Street Suite 3700

Waltham, MA 02451

Attn:

Facsimile:

 

 

 

Notice to the Company shall be addressed as follows until the Holder receives notice
of a change in address:

 

Amyris, Inc.

5885 Hollis Street, Suite 100

Emeryville, CA 94608

Attn: General Counsel

Facsimile:

 

With a copy (which shall not constitute notice) to:

 

Shearman & Sterling LLP

535 Mission Street, 25th Floor

San Francisco, CA 94105

Attn:

Facsimile:

 

    	 

     

    

·                    
Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in
writing signed by the parties against which enforcement of such change, waiver, discharge or termination is sought.

 

·                    
Counterparts. This Warrant may be executed in counterparts, all of which together shall constitute one and the same
agreement.

·                    
Amendment. This Warrant may be amended and the observance of any term of this Warrant may be waived only with the
written consent of the Company and the Holder.

·                    
Binding Effect. This Warrant shall be binding upon any successors or assigns of the Company.

·                    
Governing Law. This Warrant, and the provisions, rights, obligations, and conditions set forth herein, and the legal
relations between the parties hereto, including all disputes and claims, whether arising in contract, tort, or under statute, shall
be governed by and construed in accordance with the laws of the State of Delaware without giving effect to its conflict of law
provisions.

·                 
 CERTAIN DEFINITIONS.

“Bloomberg” means Bloomberg
Financial Markets.

 

“Principal Market” means
The NASDAQ Stock Market.

 

“Trading Day” means any day
on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market for
the Common Stock, then on the principal securities exchange or securities market on which the Common Stock is then traded; provided
that “Trading Day” shall not include any day on which the Common Stock is scheduled to trade on such exchange or market
for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such exchange
or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market,
then during the hour ending at 4:00 p.m., New York time).

 

“Marketable Securities” means securities meeting all
of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d)
of the Exchange Act and is then current in its filing of all required reports and other information under the Act and the Exchange
Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the
Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded in a trading market, and (iii)
following the closing of such Acquisition, Holder would not be restricted from publicly re-selling all of the issuer’s shares
and/or other securities that would be received by Holder in such Acquisition were Holder to exercise this Warrant in full on or
prior to the closing of such Acquisition, except to the extent that any such restriction (x) arises solely under federal or state
securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing of such Acquisition.

 

[Balance of Page Intentionally Left Blank]

 

 

 

 

 

    	 

     

    

“COMPANY”

 

Amyris, Inc.

 

 

 

By: ___________________________________

John Melo, Chief Executive Officer

 

	AGREED AND ACKNOWLEDGED:
	“HOLDER” 
	 
	Ginkgo Bioworks, Inc. 
	 
	
        By: _________________________________

        Jason Kelly, Chief Executive Officer

	 

 

 

 

 

 

[Signature Page to Warrant]

    	 

     

    

ARTICLE
2Exhibit A

ARTICLE
3EXERCISE NOTICE

ARTICLE
4TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS

WARRANT TO PURCHASE COMMON STOCK

ARTICLE
5AMYRIS, INC.

ARTICLE
6The undersigned holder hereby exercises the right to purchase _________________ of the shares of Common Stock (“Shares”)
of Amyris, Inc., a Delaware corporation (the “Company”), evidenced by Warrant to Purchase Common Stock No. GW-1
(the “Warrant”). Capitalized terms used herein and not otherwise defined shall have the respective meanings
set forth in the Warrant.

ARTICLE
71.Form of Warrant Price. The Holder intends that payment of the Aggregate Warrant Price shall be made as:

		____________	a “Cash Exercise” with respect to _________________ Shares; and/or

 

		____________	a “Cashless Exercise” with respect to _______________ Shares.

 

ARTICLE
82.Payment of Warrant Price. In the event that the Holder has elected a Cash Exercise with respect to some
or all of the Shares to be issued pursuant hereto, the Holder shall pay the Aggregate Warrant Price in the sum of $___________________
to the Company in accordance with the terms of the Warrant.

ARTICLE
93.Delivery of Shares. The Company shall deliver to Holder, or its designee or agent as specified below,
__________ Shares in accordance with the terms of the Warrant. Delivery shall be made to Holder, or for its benefit, as follows:

ARTICLE
10[_]Check here if requesting delivery as a certificate to the following name and
to the following address:

	Issue to:	 
	 	 
	 	 

ARTICLE
11 

		[_]	Check here if requesting delivery by Deposit/Withdrawal at Custodian as follows: 

	DTC Participant:	 
	DTC Number:	 
	Account Number:	 
	 	 
	 	 	 

 

	
        Date: _____________ __, ___

         

         _______________________

Name of Registered Holder

         

         

         

	

    	 

     

    

	
        By: __________________________________

        Name:

        Title:

        

         

        Tax ID:____________________________

         

        Facsimile:__________________________

         

        E-mail Address:_____________________

         

         

         

         

 

 

 

    	 

     

    

EXHIBIT B

 

ESCROW AGREEMENT

 

This Escrow Agreement (the “Agreement”)
is entered into as of [●] (the “Effective Date”), by and among Amyris, Inc., a Delaware corporation, having
its place of business at 5885 Hollis Street, Suite 100, Emeryville, California 94608 (the “Amyris”), Ginkgo
Bioworks, Inc., a Delaware corporation having its principal office at 27 Drydock Avenue, 8th Floor, Boston, MA 02210 (the “Ginkgo”),
and [●] (“Escrow Agent”). Amyris, Ginkgo, and Escrow Agent may be referred to individually as a “Party”
or collectively as the “Parties” throughout this Agreement.

 

RECITALS

 

WHEREAS, Amyris and Ginkgo
have entered into that certain Collaboration Agreement dated [●] (the “Collaboration Agreement”);

 

WHEREAS, pursuant to the
Collaboration Agreement, Amyris and Ginkgo are required to establish and maintain a third party escrow of each Party’s materials
described on Exhibit A (the “Escrowed Materials”);

 

WHEREAS, capitalized terms
used but not defined herein shall have the meanings set forth in the Collaboration Agreement; and

 

WHEREAS, Amyris and Ginkgo
desire to appoint Escrow Agent as escrow agent with respect to the Escrowed Materials, and Escrow Agent desires to act in such
capacity, in each case in accordance with the terms and conditions of this Agreement.

 

NOW, THEREFORE, in consideration
of the respective representations, warranties, covenants and agreements contained herein, and for other valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows.

 

		1.	Depositor Responsibilities

 

		(a)	Each of Amyris and Ginkgo, as a “Depositor”, shall make an initial deposit of the Escrowed
Materials to Escrow Agent within three (3) months of the Effective Date. In conjunction with such deposit, the applicable Depositor
will submit an itemized list of the initial Escrowed Materials to the other Party that is not the Escrow Agent, as the applicable
“Beneficiary”. From time to time in accordance with the Collaboration Agreement, each Depositor may deposit additional
or updated versions of the Escrowed Materials together with any applicable written instructions regarding return or destruction
of any replaced Escrowed Materials (such instructions, the “Replacement Instructions”). In conjunction with any Replacement
Instructions, such Depositor will submit to the applicable Beneficiary an updated itemized list of the Escrowed Materials resulting
from such Replacement Instructions.

 

		(b)	Prior to or in conjunction with the initial deposit of Escrowed Materials by a Depositor, such
Depositor shall provide Escrow Agent with written instructions regarding the storage, handling & shipping conditions for the
Depositor’s Escrowed Materials (the “Storage, Handling & Shipping Instructions”). Such Depositor may supplement
or revise the Storage, Handling & Shipping Instructions at any time upon written notice to Escrow Agent. In conjunction with
providing or updating any Storage, Handling & Shipping Instructions to Escrow Agent, such Depositor will also simultaneously
provide a copy of such Storage, Handling & Shipping Instructions to the applicable Beneficiary.

 

    	 

     

    

EXHIBIT B

 

		(c)	In the event of a dispute between Ginkgo and Amyris regarding the contents of the Escrowed Materials,
either (i) upon the initial deposit of such Escrowed Materials or (ii) following the delivery of any Replacement Instructions or
Storage, Handling & Shipping Instructions, then such dispute shall be resolved between them in accordance with the applicable
provisions of the Collaboration Agreement.

 

		2.	Beneficiary Acknowledgment

 

		(a)	Each of Ginkgo and Amyris acknowledge that, except as set forth in Section 3 below, Escrow Agent
has no obligations hereunder with respect to the sufficiency or functionality of the Escrowed Materials for any purpose.

 

		3.	Escrow Agent Responsibilities

 

		(a)	Escrow Agent shall store the Escrowed Materials at its facility located at [●] in two separate
escrows, one with Amyris as Depositor, Ginkgo as Beneficiary and containing Amyris’ Escrowed Materials (“Amyris’
Escrow”), and the other with Ginkgo as Depositor, Amyris as Beneficiary and containing Ginkgo’s Escrowed Materials
(“Ginkgo’s Escrow”) (Amyris’ Escrow and Ginkgo’s Escrow, each an “Escrow” and collectively
the “Escrows”). The Escrows shall at all times be (i) controlled by Escrow Agent (by ownership, lease or otherwise),
(ii) covered by all and amounts of insurance required by applicable Law and /or as is necessary to fully protect Ginkgo and Amyris
from and against any and all loss, damage, or destruction of the Escrowed Materials, including those set forth in the Storage,
Handling & Shipping Instructions and (iii) accessible only to employees and agents of Escrow Agent authorized to carry out
Escrow Agent’s obligations under this Agreement and, pursuant to the terms and conditions of Section 3(d) or Section 7(a),
to such limited other individuals who may be permitted to access the Escrowed Materials under those sections. Escrow Agent shall
not transfer the Escrowed Materials to any other facility without the prior written consent of Ginkgo and Amyris.

 

		(b)	Escrow Agent shall immediately notify Ginkgo and Amyris in writing upon its receipt of the initial
deposit and any subsequent deposits or updates of Escrowed Materials.

 

		(c)	Escrow Agent shall at all times store and handle all Escrowed Materials in accordance with the
terms hereof and the Storage, Handling & Shipping Instructions and in compliance with applicable Laws. Escrow Agent will immediately
acknowledge receipt of new or revised Storage, Handling & Shipping Instructions in writing to both Ginkgo and Amyris. Escrow
Agent shall at all times segregate (i) the Escrowed Materials contained in Amyris’ Escrow from the Escrowed Materials contained
in Ginkgo’s Escrow and (ii) all Escrowed Materials from any other materials of Ginkgo or Amyris that are then being stored
with Escrow Agent.

 

    	 

     

    

EXHIBIT B

 

		(d)	Escrow Agent shall permit the authorized representatives of Ginkgo and Amyris access to the Escrow
Agent’s facilities, at reasonable times during Escrow Agent’s normal business hours upon notice to Escrow Agent, and
provide each of Ginkgo and Amyris, individually and collectively, all cooperation and assistance as may be necessary or reasonably
useful for Ginkgo and Amyris, together or individually, to inspect and audit the Escrow Agent’s deposit facilities and any
records, information, and other materials comprising or relating to the Escrowed Materials, to determine Escrow Agent’s compliance
herewith; provided, that no such inspection and audit will be unduly disruptive of the Escrow Agent's business or operations.

 

		(e)	Escrow Agent shall, subject to Section 1(c), comply with any Replacement Instructions delivered
by a Depositor in connection with any deposit by such Depositor of additional or updated versions of the Escrowed Materials. Escrow
Agent shall (i) immediately notify Ginkgo and Amyris in writing upon receipt of any Replacement Instructions and (ii) subject to
Section 1(c), comply with such Replacement Instructions at all times.

 

		(f)	Escrow Agent shall comply with the provisions of Exhibit B with respect to the release of Escrowed
Materials to Beneficiary.

 

		4.	Payment

 

		(a)	As entire compensation for the services to be performed by Escrow Agent hereunder, (i) Ginkgo,
as Beneficiary, shall pay to Escrow Agent the fees and expenses set forth in Exhibit C with respect to Amyris’ Escrow and
(ii) Amyris, as Beneficiary, shall pay to Escrow Agent the fees and expenses set forth in Exhibit C with respect to Ginkgo’s
Escrow. All payments shall be made in U.S. currency within sixty (60) days after the date of the applicable undisputed invoice.
If the applicable Beneficiary wishes to dispute an invoiced amount, it must provide written notice to Escrow Agent within ten (10)
days of receipt of the applicable invoice. All invoices must be addressed to the applicable Beneficiary at its address set forth
at the signature page or such other address as may be notified by the applicable Beneficiary from time to time, with a copy to
the other Parties at their applicable address.

 

		5.	Term and Termination

 

		(a)	The term of this Agreement is for a period of one (1) year from the Effective Date and, if not
terminated earlier, shall automatically renew each anniversary of the Effective Date for additional one (1) year periods (the initial
one (1) year period and any subsequent renewal period, collectively, the “Term”). This Agreement shall continue in
full force and effect until (i) Ginkgo and Amyris provide Escrow Agent with joint written notice of the termination of this Agreement,
in which case termination shall be effective twenty (20) days after the date of such notice; (ii) not more than ninety (90), nor
less than sixty (60) days, prior to the expiration of the then-current Term, Escrow Agent provides Ginkgo and Amyris written notice
of the termination of this Agreement, in which case termination shall be effective upon the expiration of the Term; (iii) this
Agreement is terminated by Escrow Agent pursuant to Section 5(b); (iv) this Agreement is terminated upon the release of all Escrowed
Materials in accordance with Exhibit B; or (v) this Agreement is terminated under Section 8(g).

 

    	 

     

    

EXHIBIT B

 

		(b)	In the event of the nonpayment of any undisputed fees owed to Escrow Agent, Escrow Agent shall
provide Ginkgo and Amyris with written notice thereof. If the undisputed fees are not paid in full by the non-paying Party within
thirty (30) days of the date of such written notice, then Escrow Agent shall have the right to terminate the Escrow to which the
non-paying Party is the Beneficiary upon ten (10) days’ written notice to the non-paying Party and either return to the Depositor
of such Escrow or destroy the applicable Escrowed Materials (unless such fees are paid during such period).

 

		(c)	Unless otherwise agreed in writing by Ginkgo and Amyris, upon any termination of this Agreement
(other than under clauses (iii) or (iv) of Section 5(a)), Escrow Agent shall, as instructed by the other Parties, either (i) return
the Escrowed Materials to each applicable Depositor or (ii) destroy the Escrowed Materials and certify to the other Parties in
writing that Escrow Agent has completed such destruction.

 

		(d)	Expiration or termination of this Agreement will not affect the rights and obligations of the Parties
accrued prior to the date of expiration or termination. In addition, termination of this Agreement is not a Party’s sole
or exclusive remedy for another Party’s breach of this Agreement.

 

		6.	Indemnification and Limitation of Liability

 

		(a)	Escrow Agent shall not, by reason of its execution of this Agreement, assume any responsibility
or liability for any transaction between Ginkgo and Amyris. However, each Party shall indemnify and hold harmless each other Party
and their respective affiliates from any and all liability, damages, costs, or expenses, including reasonable attorney’s
fees, that shall be sustained or incurred by such other Party (“Losses”) to the extent that such Losses are attributable
to such indemnifying Party’s intentional misconduct or gross negligence in connection with the performance of its obligations
under this Agreement or its breach of any provision of this Agreement. As between Ginkgo and Amyris, in the case of a conflict
between this Article 6 and any indemnification provisions set forth in the Collaboration Agreement, the provisions in the Collaboration
Agreement shall prevail solely to the extent necessary to avoid such conflict.

 

		(b)	EXCEPT IN THE CASE OF A PARTY’S GROSS NEGLIGENCE, INTENTIONAL MISCONDUCT, FRAUD, LIABILITY
WHICH CANNOT BE EXCLUDED UNDER LAW OR BREACH OF A PARTY’S OBLIGATIONS UNDER SECTION 7, IN NO EVENT SHALL ANY PARTY BE LIABLE
TO ANOTHER PARTY UNDER THIS AGREEMENT FOR ANY INCIDENTAL, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR LOST PROFITS, WHETHER ARISING
IN CONTRACT, TORT OR OTHERWISE, EVEN IF THE POSSIBILITY THEREOF MAY BE KNOWN IN ADVANCE.

 

		7.	Confidential Information

 

		(a)	Escrow Agent shall maintain and protect the Escrowed Materials as valuable proprietary and confidential
information, using at least the same high level of care that it would use to protect its own valuable confidential information
or trade secrets and in no event less than a reasonable degree of care. Except as required to perform its obligations under this
Agreement, Escrow Agent shall not use the Escrowed Materials for any purpose and shall not disclose or otherwise make available
the Escrowed Materials to any third party other than its employees and agents to the extent required for performing its obligations
under this Agreement; provided, that such employees and agents are subject to confidentiality obligations at least as restrictive
as those set forth herein. Notwithstanding the foregoing, if Escrow Agent receives a subpoena or similar order from a court of
competent jurisdiction requiring the disclosure or release of the Escrowed Materials, Escrow Agent may comply in good faith with
such order; provided, that Escrow Agent, to the extent not legally prohibited, gives Ginkgo and Amyris reasonable notice
prior to such disclosure or release, and cooperates with any reasonable efforts of Ginkgo and Amyris to limit or restrict such
disclosure or release.

 

    	 

     

    

EXHIBIT B

 

		(b)	Escrow Agent acknowledges and agrees that any breach or threatened breach of Section 7(a) may result
in irreparable injury to any other Party for which there will be no adequate remedy at law. Notwithstanding anything herein to
the contrary, in the event of any such breach or threatened breach, any other Party shall be entitled to enforce the provisions
of this Agreement by injunction and seek other equitable relief in any court of competent jurisdiction. Escrow Agent irrevocably
and unconditionally waives any requirement that such other Party (i) post a bond or other security as a condition for obtaining
any such relief or (ii) show irreparable harm, balancing of harms, consideration of the public interest or inadequacy of monetary
damages as a remedy in connection with such relief.

 

		8.	General

 

		(a)	Supplementary to the Collaboration Agreement. As between Ginkgo and Amyris, this Agreement
shall be considered supplementary to the Collaboration Agreement. In the event of any conflict between the terms and provisions
of this Agreement and those of the Collaboration Agreement, the terms and conditions of the Collaboration Agreement shall control
the rights, obligations, and relationship between Ginkgo and Amyris.

 

		(b)	Choice of Law. This Agreement (and any Actions arising out of or related thereto or to the
transactions contemplated thereby or to the inducement of any Party to enter therein, whether for breach of contract, tortious
conduct, or otherwise and whether predicated on common law, statute or otherwise) shall in all respects be governed by and construed
in accordance with the laws of the State of New York, USA, including all matters of construction, validity and performance, in
each case without reference to any conflict of law rules that might lead to the application of the laws of any other jurisdiction

 

		(c)	Right to Rely on Instructions. Escrow Agent may act in reliance upon any written instruction,
instrument, or signature reasonably believed by Escrow Agent to be genuine and from an authorized representative of a Party. Escrow
Agent may assume that any representative of a Party who gives any written notice, request, or instruction has the authority to
do so. Escrow Agent will not be required to inquire into the truth of, or evaluate the merit of, any statement or representation
contained in any notice or document reasonably believed to be from such a representative.

 

		(d)	Force Majeure. No failure or omission by either Party in the performance of any obligation
of this Agreement shall be deemed a breach of this Agreement or create any liability if the same shall arise from a Force Majeure
Event; provided that the Party affected by such cause promptly notifies the other Party and uses diligent efforts to cure
such failure or omission as soon as is practicable after the occurrence of one or more of the above mentioned causes.

 

    	 

     

    

EXHIBIT B

 

		(e)	Notices. Any notices or other written communications permitted or required under this Agreement
shall be given by facsimile transmission (with transmission confirmed) or internationally recognized delivery service that maintains
records of delivery, addressed to a Party at its address set forth on the signature page hereto or to such other address as the
Party to whom notice is to be given may have provided to each other Party in accordance herewith. Such notice shall be deemed to
have been given as of the date (if a Business Day, otherwise the next Business Day) transmitted by facsimile (with transmission
confirmed) or on the third (3rd) Business Day (at the place of delivery) after deposit with an internationally recognized delivery
service. Any notice delivered by facsimile will be confirmed by a hard copy delivered as soon as practicable thereafter.

 

		(f)	Assignment. Neither Ginkgo nor Amyris shall assign this Agreement or any of its rights or
obligations hereunder without the prior written consent of Escrow Agent, which shall not be unreasonably withheld or delayed. Escrow
Agent shall not assign this Agreement or any of its rights or obligations hereunder without the prior written consent of Ginkgo
and Amyris.

 

		(g)	Severability. In the event any of the terms of this Agreement become or are declared to
be illegal or otherwise unenforceable by any court of competent jurisdiction, such term(s) shall be null and void and shall be
deemed deleted from this Agreement. All remaining terms of this Agreement shall remain in full force and effect. If this paragraph
becomes applicable and, as a result, the value of this Agreement is materially impaired for any Party, as determined by such Party
in its sole discretion, then the affected Party may terminate this Agreement by thirty (30) days’ written notice to each
other Party.

 

		(h)	Independent Contractor Relationship. Ginkgo and Amyris understand, acknowledge, and agree
that Escrow Agent’s relationship with Ginkgo and Amyris will be that of an independent contractor and that nothing in this
Agreement is intended to or should be construed to create a partnership, joint venture, or employment relationship. No Party has
any right or authority hereunder to assume or create any obligation of any nature whatsoever on behalf of any other Party or bind
any other Party in any respect.

 

		(i)	Disputes. Any dispute solely between Ginkgo and Amyris concerning the construction, meaning,
effect or implementation of this Agreement or the rights or obligations of any Party hereunder shall be resolved in accordance
with the applicable terms of the Collaboration Agreement. Any other dispute among the Parties concerning the construction, meaning,
effect or implementation of this Agreement or the rights or obligations of any Party hereunder that cannot be settled by good faith
negotiation within thirty (30) Business Days after the first notice of such dispute shall be finally settled by binding arbitration
in Chicago, Illinois in accordance with the then current Commercial Arbitration Rules of the American Arbitration Association and
judgment upon the award rendered may be entered in any court having jurisdiction. The arbitrator shall have the authority to grant
any equitable and legal remedies that would be available in any judicial proceeding subject to any limits set forth herein. Such
arbitration shall be conducted by a single, independent arbitrator or, if the Parties are unable to agree on such arbitrator, each
Party shall appoint a single, independent arbitrator who must collectively agree on a Third Party, independent arbitrator to serve
as arbitrator hereunder. For clarity, the arbitrator can be either judicial or non-judicial, depending on the nature of the dispute
(i.e., if the dispute is technical in nature, the Parties may elect to agree upon an arbitrator who possesses a relevant technical
background). The arbitrator may rule upon motions to compel or limit discovery and shall have the authority to impose sanctions
for discovery abuses, including reasonable attorneys’ fees and costs, to the extent and upon the grounds available for such
in the United States District Courts for the District in which the arbitration is taking place. The decision of the arbitrator
(the “Award”) as to any Action (including the validity and amount of any Action) shall be final, binding, and conclusive
upon the Parties. Such Award shall be written and shall be supported by written findings of facts and conclusions. Within thirty
(30) days of issuance of an Award any payment required by the Award shall be made unless before such date any Party shall commence
legal action to vacate or modify the Award. The Parties to the arbitration may apply to a court of competent jurisdiction for a
temporary restraining order, preliminary injunction or other interim or conservatory relief, as necessary, without breach of this
arbitration provision and without abridgment of the powers of the arbitrator. The Parties agree, and agree to direct the arbitrator,
that the arbitration will be kept confidential and that the existence of the proceeding and any proceedings therein, including
without limitation any pleadings, briefs or other documents, any testimony or other oral submissions and any Award, will not be
disclosed beyond the arbitrator or arbitration tribunal, the Parties, their counsel and any Person (including witnesses, if any)
involved in the conduct of the proceeding, except (i) in any legal proceeding concerning the arbitration, including without limitation
any proceeding to compel or to stay arbitration or otherwise in aid of arbitration, for other relief as described in the immediately
prior sentence, to vacate, modify, or confirm an Award, or to enforce an Award or any judgment based upon an Award, (ii) to the
tax, legal, financial or other professional advisors of such Person who are obligated to keep such information confidential, or
(iii) as may be required by Law. Each Party shall pay its own costs and expenses (including counsel fees) of any such arbitration,
except as may be awarded by the arbitrator pursuant to this Section.

 

    	 

     

    

EXHIBIT B

 

		(j)	No Third Party Rights. This Agreement is made solely for the benefit of the Parties to this
Agreement and their respective permitted successors and assigns, and no other person or entity shall have or acquire any right
by virtue of this Agreement.

 

		(k)	Entire Agreement. The Parties agree that this Agreement (together with the Collaboration
Agreement and any existing confidentiality agreement (to the extent in effect), including any amendments to either of them, with
regard to Ginkgo and Amyris) is the complete agreement among the Parties concerning the subject matter of this Agreement and replaces
any prior or contemporaneous oral or written communications among the Parties. There are no conditions, understandings, agreements,
representations, or warranties, expressed or implied, which are not specified herein. Each Party represents and warrants that the
execution, delivery, and performance of this Agreement by such Party has been duly authorized and that this Agreement has been
duly executed by an authorized representative of such Party. This Agreement may not be modified except by written agreement of
all the Parties. No waiver of any right under this Agreement by any Party shall constitute a subsequent waiver of that or any other
right under this Agreement.

 

    	 

     

    

EXHIBIT B

 

		(l)	Counterparts. This Agreement may be executed in any number of counterparts, each of which
shall be an original, but all of which together shall constitute one instrument.

 

		(m)	Survival. Sections 5(b), (c) and (d), 6, 7 and 8 shall survive any expiration or termination
of this Agreement.

 

[Remainder of page left intentionally blank; signature page follows]

 

 

 

    	 

     

    

IN
WITNESS WHEREOF, the Parties have duly executed this Agreement as of the Effective Date by their authorized representatives:

 

	GINKGO	AMYRIS
	Signature	 	Signature	 
	Print Name	 	Print Name	 
	Title	 	Title	 
	Address for Notices	
         

         

         

         

         

         

         

         

         

         

         

         
	Address for Notices	 
	 	 	 	 
	ESCROW AGENT	 	 
	Signature	 	 	 
	Print Name	 	 	 
	Title	 	 	 
	Address for Notices	
         

         

         

         

         

         

         

         

         

         

         

         
	 	 

 

 

    	 

     

    

Exhibit A

Escrowed Materials

 

All items, materials, and other Intellectual
Property required to be deposited pursuant to Section 2.3(e) of the Collaboration Agreement.

 

 

 

 

 

 

 

 

 

    	 

     

    

Exhibit B

Release of Escrowed
Materials

 

Escrow
Agent shall use the following procedures to process any request by a Beneficiary to release any Escrowed Materials to such Beneficiary
(“Release Request”):

 

		1.	Release Conditions.

 

A
Beneficiary may submit a Release Request to Escrow Agent upon the occurrence of any one or more of the following (the “Release
Conditions”):

 

		(a)	The Collaboration Agreement expires or is terminated pursuant to Section 7.2(a);

 

		(b)	The Collaboration Agreement is terminated pursuant to Section 7.2(b), Section 7.2(c), or Section
7.2(d); provided, that only the non-breaching may submit a Release Request;

 

		(c)	If Amyris, as Depositor, permanently withdraws
from its business of manufacturing and commercializing chemical small molecule compounds using microbial strains
and fermentation technologies;

 

		(d)	If Ginkgo, as Depositor, permanently withdraws from its business of strain engineering and small-scale
process development of chemical small molecule compounds in the Field; or

 

		(e)	the applicable Depositor becomes the subject of
an Insolvency Proceeding.

 

		2.	Release Request.

 

Each of Ginkgo and Amyris, as Beneficiary, agrees that
a Release Request shall be made solely in accordance with the Release Conditions. Any Release Request shall be submitted by such
Beneficiary to the Escrow Agent in writing, shall cite the triggering Release Condition, and shall specify the Escrowed Materials
to be released. Promptly upon receipt of the Release Request, Escrow Agent shall send a copy thereof to the applicable Depositor.

 

		3.	Contrary Instructions.

 

From the date of delivery by Escrow Agent of notice of
the Release Request, the applicable Depositor shall have a period of fifteen (15) days to deliver to Escrow Agent written notice
of any dispute regarding the occurrence of the Release Conditions (“Contrary Instructions”). Upon receipt of
any Contrary Instructions, Escrow Agent shall promptly send a copy thereof to the applicable Beneficiary. In the event the applicable
Depositor timely delivers Contrary Instructions to Escrow Agent, Escrow Agent shall continue to store the applicable Escrowed Materials
without release pending the earlier of (i) joint written instructions from Ginkgo and Amyris to release the applicable Escrowed
Materials; (ii) written notice from the applicable Depositor withdrawing the Contrary Instructions; or (iii) receipt by the Escrow
Agent of an order from a court of competent jurisdiction requiring release of the applicable Escrowed Materials.

 

    	 

     

    

EXHIBIT B

 

		4.	Release of Escrowed Materials.

 

If the applicable Depositor does not timely deliver Contrary
Instructions to Escrow Agent, Escrow Agent shall release the applicable Escrowed Materials to the applicable Beneficiary in accordance
with any written instructions pertaining to the delivery of such Escrowed Materials provided by such Beneficiary, subject to the
terms and conditions of the Collaboration Agreement.

 

		5.	Right to Use Following Release.

 

Upon any release of Escrowed Materials in accordance with
this Exhibit B, such Beneficiary shall have the right to use the Escrowed Materials solely in accordance with the terms and conditions
of the Collaboration Agreement.

 

 

 

    	 

     

    

Exhibit C

Fees and Expenses

 

Monthly Storage Fee:

 

$[●] per cubic foot per month.

 

Shipping or Destruction Costs:

 

Any shipping or destruction expenses incurred by Escrow
Agent related to the applicable Escrowed Materials will be to the applicable Beneficiary at cost plus [●] percent ([●]%).

 

    	 

     

    

EXHIBIT C

 

Antitrust
Guidelines

 

		I.	Scope

 

These antitrust guidelines (“Guidelines”)
shall govern the operation of the Collaboration formed between Amyris, Inc. (“Amyris”) and Ginkgo Bioworks, Inc. (“Ginkgo”)
(each a “Party” or collectively the Parties) on September 12, 2016 (the “Collaboration Agreement”). It
is the policy of the Parties to comply fully with all U.S. and international antitrust laws, and all other laws applicable to its
operations.

 

The purpose of these Guidelines is to
assure that opportunities falling outside the scope of the Collaboration, and/or opportunities subject to a defined exclusion,
will be explored by either Party on an individual basis only (except as provided for in certain circumstances below), while opportunities
within the scope of the Collaboration will be pursued by the Collaboration. Thus, this document provides guidance for your day-to-day
conduct. Whenever you have any questions about the possible application of the antitrust laws to any of your activities, you should
consult with your company’s General Counsel (See Section IX below).

 

		II.	Background

 

In order to compete in modern markets,
competitors sometimes need to collaborate. Competitive forces are driving firms toward complex collaborations to achieve goals
such as expanding into different markets, funding expensive innovation efforts, and lowering production and other costs. Such collaborations
often are not only benign but procompetitive. The Field of the Collaboration is defined as activities related to the development,
scale-up, and manufacture of a chemical small molecule compound(s) whose manufacture is enabled at least in part by the use of
microbial strains and fermentation technologies. The Parties formed the present Collaboration in recognition of the likely benefits
of developing a biotechnology platform in the Field, which would generate additional possibilities to expand each of their businesses
and stimulate innovation in the Field, as well as improve the ability of the Parties to serve the emerging demands of many current
and potential end-use sectors by offering solutions relying upon compounds within the Field.

 

The Parties have worked together to
provide guidance to the business development teams within both Amyris and Ginkgo (collectively “Collaboration BD Team”;
individually “Amyris BD Team” or “Ginkgo BD Team”) on how best to source opportunities and to work collaboratively
and cohesively under the Collaboration without triggering certain antitrust issues. These Guidelines are intended to describe the
analytical framework that will assist the Collaboration BD Team in sourcing and evaluating proposed transactions with greater understanding
of possible antitrust implications.

 

		III.	Exclusions from the Collaboration

 

The Collaboration excludes specific
contractual relationships of the Party as outside the Field, as well as excluding certain Party-specific commercial areas (hereinafter
referred to as an “Exclusion” or collectively “Exclusions”; when specific to one Party, it shall be referred
to as either a Ginkgo Exclusion or Amyris Exclusion) and are enumerated in Table 1 below.

 

 

    	 

     

    

Table 1:

	Amyris Exclusions	Ginkgo Exclusions
	[*]	Any agreement with a customer that does not require Third Party manufacturing.
	Agreements related to the pharmaceuticals market, including without limitation agreements relating to Amyris’ [*] platform	Any agreement with a customer relating solely to the [*]
	Agreements listed in Section 1.5 and Exhibit 1.5.	Certain aspects of the existing agreement with [*] related to the scale-up and manufacture of [*]
	 	Certain aspects of the existing agreement with [*] related to the scale-up and manufacture of [*]
	 	Agreements with a Governmental Entity
	 	Agreements listed in Exhibit 1.23.

 

		IV.	Opportunities Within the Collaboration

 

If a party sources an opportunity that
falls within the scope of the Collaboration (as defined by the Field above) and that is not an Exclusion, the Parties may work
together to share any information necessary to structure a potential Customer Agreement in accordance with the Collaboration Agreement.
For example, the Parties may jointly develop: (i) a unified business strategy that includes a common pricing structure, (ii) a
go-to market position for the Collaboration, (iii) product pricing strategies, (iv) a market, customer and/or geographic allocation
as between the Parties, and (v) common forms or templates for use in the Collaboration.

 

		V.	Opportunities Outside the Collaboration

 

If a party sources an opportunity that
falls outside the scope of the Collaboration (as defined by the Field above) and is not subject to an Exclusion (which is addressed
separately below), the Parties may not work together or share any information related to such opportunities.

 

		VI.	Ambiguous Opportunities or Opportunities Relating to One Party’s Exclusions

 

In the event of ambiguity as to whether:
(i) an opportunity is within the Collaboration, (ii) is outside the Collaboration, or (iii) is subject to any Exclusion, the opportunity
should be summarized accurately but generically in order to describe: (a) the name of the third party with which the opportunity
lies, (b) the subject matter of the opportunity, and (c) any other information that may be useful to the Parties in determining
whether such opportunity falls within the Collaboration. The summary should be disclosed promptly to the JBDSC (as defined in the
Collaboration Agreement) once complete. The JBDSC, with input and guidance from the Executive Committee (as deemed necessary by
the JBDSC), will then make a determination if the opportunity falls within the Collaboration, outside of the Collaboration or is
subject to an Exclusion and, if subject to an Exclusion, whether any Products encompassed by such opportunity shall be deemed Refused
Products under Section 6.2(a)(v) of the Collaboration Agreement.

 

		VII.	General Dos & Don’ts

 

		1.	DO exercise independent judgment and, to the extent possible, avoid even the appearance of collusion
on opportunities outside the scope of the Collaboration.

		2.	DO make all pricing decisions independently of the other Party on opportunities that fall outside
the Collaboration.

 

[*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

 

 

    	 

     

    

		3.	DO NOT make statements—orally or in writing—which exaggerate your company's or the
Collaboration’s competitive power or which might suggest a predatory intent.

		4.	DO NOT suggest that due to your company’s participation in the Collaboration, enhances its
ability to exclude competitors; it is all right to suggest truthfully that these factors enhance your company's ability to do things
for customers.

		5.	DO NOT enter into any discussion with the other Party on opportunities that fall outside the scope
of the Collaboration – if you are not sure it falls outside, talk to your General Counsel.

		6.	DO NOT remain at any meetings with the other Party (including informal social gatherings) where
opportunities outside the Collaboration are discussed.

		7.	DO NOT provide business information to the other Party regarding opportunities outside the scope
of the Collaboration.

		8.	DO document the source of any sensitive information you may obtain about an opportunity outside
the scope of the Collaboration to avoid any later inference that the information was improperly obtained; if you obtain this information
from customers or other third-party sources, document where you obtained the information.

		9.	DO keep these guidelines in mind as you prepare your day-to-day business correspondence and memoranda,
including electronic mail. When matters arise which are related to any of the subjects discussed, consult with the General Counsel
in advance to determine how to prepare the necessary documentation.

		10.	DO consult with your General Counsel immediately if you have any concerns about discussions you
may have had with a Party, at a trade association or elsewhere.

		11.	DO seek guidance from the General Counsel immediately if you receive an inquiry from any government
agency, or from any lawyer who purports to represent a customer, competitor, supplier or other third party with a grievance.

 

		VIII.	Conclusion

 

As mentioned at the beginning, these
Guidelines are not intended to make you experts in the antitrust laws and cannot cover all the problems that may arise. You should
consult with your manager and/ or the General Counsel when you are in doubt about the legality of any business activity.

 

		IX.	Contacts

 

 

	
        Ginkgo Bioworks, Inc.:

        Shelby J. Walker

        General Counsel

         
	
        Amyris, Inc.:

        Chris Jaenike

        General Counsel, Interim

         

 

    	 

     

    

Amyris’ Disclosure Schedules

 

Information contained in any section of these disclosure schedules shall be deemed to
be disclosed for purposes of all other sections of the disclosure schedule to the extent that the relevance of any such disclosure
to any other section of the disclosure schedules is reasonably apparent on the face of such disclosure.

 

Section 9.2

 

For the avoidance of doubt, it is understood by the Parties that certain provisions of
the agreements in Exhibit 1.13 limit the rights and obligations of Amyris granted pursuant to Article II of the Agreement.

 

Section 9.3(a)

 

With respect to section 9.3(a), scheduled exceptions are as follows:

 

Security Interest Granted to Stegodon. Under the
certain Loan and Security Agreement dated as of March 29, 2014, as amended on June 12, 2014, March 31, 2015, October 12, 2015,
November 30, 2015, May 9, 2016, June 24, 2016 and June 29, 2016 by and between Amyris and Stegodon Corporation, a Delaware corporation,
as assignee of Hercules Capital, Inc.(“Stegodon”) (the “Loan and Security Agreement”), Amyris has granted
Stegodon a security interest in certain of Amyris’s intellectual property and other collateral.

 

Ordinary Course Licenses and Sublicenses Granted.
All licenses and rights granted by Amyris under the Agreement and all of Amyris’s obligations under the Agreement are subject
to and qualified by the exclusive and/or non-exclusive licenses and the covenants not to compete that Amyris and its subsidiaries
have granted to Third Parties (including the U.S. government in some cases) as of the Effective Date.

 

Section 9.3(b)

 

Regarding payment of royalty

 

Amyris has paid a one-time licensing fee under License Agreement dated [*]
between Amyris and the [*].

 

Amyris pays an annual licensing fee under the following agreements with the
[*]:

 

Amended and Restated License Agreement effective [*].

 

 

 

Amended and Restated Exclusive Patent and Non-Exclusive Know-how License [*]

 

Amyris pays an annual licensing fee under License Agreement dated [*] between
Amyris and [*].

 

Amyris pays an annual licensing fee under the Agreement dated [*] between Amyris
and [*].

 

 

[*] Certain portions denoted with an asterisk have been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 

     

    

Amyris has paid a one-time licensing fee under the Agreement on [*] between
Amyris and [*] dated [*], Amyris must pay a fee of [*] provided to a third party [*].

 

Regarding receipt of royalty payment

 

Amyris and/or its subsidiaries, in return for the licenses and covenants that
Amyris and its subsidiaries have granted to Third Parties as of the Effective Date, receive compensation in various forms from
such Third Parties.

 

Regarding licensing to commercially exploit any of Amyris’s Intellectual
Property

 

See Section 9.3(a) and response in 9.3(b) regarding receipt of royalty payment

 

Section 9.3(c)

 

During the ordinary course of business, Amyris has ongoing examinations, prosecutions,
and appeal proceedings for patent and trademark applications with the U.S. Patent & Trademark Office and foreign counterpart
offices or government entities.

 

[*]

 

 

 

[*]

 

Section 9.3 (e)

 

[*]

 

 

 

Section 9.6

 

The molecules contemplated by (i) the Intellectual Property (A) excluded from the definition
of Non-Collaboration Intellectual Property in Section 1.34 and (B) listed on Exhibit 1.34, and (ii) the agreements listed (A) in
the definition of Amyris Customer Agreement in Section 1.5 and (B) on Exhibit 1.5.

 

 

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

    	 

     

    

SCHEDULE 9.1

 

Ginkgo’s Disclosure Schedules

 

Information contained in any section of these disclosure schedules shall be deemed to
be disclosed for purposes of all other sections of the disclosure schedule to the extent that the relevance of any such disclosure
to any other section of the disclosure schedules is reasonably apparent on the face of such disclosure.

 

Section 9.2

 

For the avoidance of doubt, it is understood by the Parties that certain provisions of
the agreements in Exhibit 1.13 limit the rights and obligations of Ginkgo granted pursuant to Article II of the Agreement.

 

Section 9.3(a)

 

With respect to section 9.3(a), scheduled exceptions are as follows:

 

Ordinary Course Licenses and Sublicenses Granted. All licenses and rights
granted by Ginkgo under the Agreement and all of Ginkgo’s obligations under the Agreement are subject to and qualified by
the exclusive and/or non-exclusive licenses and the covenants not to compete that Ginkgo and its affiliates have granted to Third
Parties (including the U.S. government in some cases) as of the Effective Date.

 

Section 9.3(b)

 

Regarding receipt of royalty payment

 

Ginkgo and/or its affiliates, in return for the licenses and covenants that
Ginkgo and its affiliates have granted to Third Parties as of the Effective Date, receive compensation in various forms from such
Third Parties.

 

Regarding licensing to commercially exploit any of Ginkgo’s Intellectual
Property

 

See Section 9.3(a) and response in 9.3(b) regarding receipt of royalty payment

 

Section 9.3(c)

 

During the ordinary course of business, Ginkgo has ongoing examinations, prosecutions,
and appeal proceedings for patent and trademark applications with the U.S. Patent & Trademark Office and foreign counterpart
offices or government entities.Exhibit

Exhibit 10.1

23 August 2016
	
			
	CIBER INTERNATIONAL B.V.
(as the Seller)
and
EXPERIS AS
(as the Purchaser)

	 
	AGREEMENT
	 

	 
	for the sale and purchase of the entire share capital of 
Ciber Norge AS
	 

	 

CONTENTS
            Clause                                                                                                         Page 	
			
	 
	 
	 

	1.
	Sale and Purchase
	1

	2.
	Price
	1

	3.
	Conditions to Closing
	2

	4.
	Pre‐Closing Seller Undertakings
	4

	5.
	Closing
	4

	6.
	Seller Warranties
	5

	7.
	Purchaser Warranties
	6

	8.
	Conduct of Purchaser Claims
	6

	9.
	Escrow
	7

	10.
	No Rights of Rescission or Termination
	8

	11.
	Trademark license
	8

	12.
	Transitional Services
	8

	13.
	Tax
	8

	14.
	Insurance
	9

	15.
	Payment of Inter-Company Debt
	10

	16.
	Protective Covenants Post-closing
	10

	17.
	Post‐Closing Undertakings
	11

	18.
	Payments
	13

	19.
	Announcements
	14

	20.
	Confidentiality
	14

	21.
	Assignment
	16

	22.
	Further Assurances
	16

	23.
	Costs
	16

	24.
	Notices
	17

	25.
	Conflict with other Agreements
	17

	26.
	Whole Agreement
	18

	27.
	Waivers, Rights and Remedies
	18

	28.
	Effect of Closing
	18

	29.
	Counterparts
	18

	30.
	Variations
	18

	31.
	Invalidity
	18

	32.
	Third Party Enforcement Rights
	18

	33.
	Mitigation
	19

	34.
	Governing Law and Jurisdiction
	19

	Schedule 1 Seller Warranties
	19

	Schedule 2 Limitations on Liability
	32

	Schedule 3 Purchaser Warranties
	35

	Schedule 4 Conduct of the Company Pre‐Closing
	36

	Schedule 5 Closing Arrangements
	39

	Schedule 6 Trademark License Agreement
	42

- 2 -

	
			
	Schedule 7 Transitional Services Agreement
	43

	Schedule 8 Inter-Company Debt
	44

	Schedule 9 Post‐Closing Financial Adjustments
	45

	Schedule 10 Client Adjustment Amount
	49

	Schedule 11 Data room index
	52

	Schedule 12 Disclosure Letter
	53

	Schedule 13 Accounting Review
	54

	Schedule 14 Definitions and Interpretation
	56

EXHIBITS REFERRED TO IN THIS AGREEMENT
Description    Clause/Schedule
EXHIBIT 1    FINANCIAL ADJUSTMENTS    
Amounts for Estimated Working Capital, Target Working Capital, Estimated Cash and Estimated External Debt    
Closing Statement Format    
Working Capital Breakdown    

- 3 -

THIS AGREEMENT is made on 23 August 2016 by and between:
PARTIES:
		
	1.
	CIBER INTERNATIONAL B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid), with corporate seat (statutaire zetel) in Amsterdam, the Netherlands and its office address at Vredeoord 105, 2e verdieping, 5621CX Eindhoven, the Netherlands, registered with the Trade Register of the Dutch Chamber of Commerce under number 24257040 (the Seller); and

		
	2.
	EXPERIS AS, a private company with limited liability (Norwegian: Aksjeselskap), with corporate seat in Oslo, Norway and its office address at Tordenskiolds gate 2, 0160 Oslo, registered at the Norwegian Register of Business Enterprises under number 982 683 955 (the Purchaser),

(each a party in this Agreement and, together, the parties).
Capitalised terms used in this Agreement shall be interpreted in accordance with Schedule 14.
WHEREAS:
(A)    As at the date hereof, the Seller owns the Shares.
(B)    The Seller has agreed to sell and transfer the Shares and the Purchaser has agreed to purchase and accept transfer of the Shares on the terms of this Agreement and any other Transaction Document, with effect from Closing.
IT IS AGREED:

1.SALE AND PURCHASE
1.1    The Seller shall sell, and the Purchaser shall purchase, the Shares with effect from Closing with all rights then attaching to them including the right to receive all distributions and dividends declared, paid or made in respect of the Shares after Closing. 
1.2    The Shares shall be sold free from all Third Party Rights and ownership and risk in them shall (except as otherwise set out in this Agreement) pass to the Purchaser with effect from Closing.

2.    PRICE
2.1    The price for the Shares (the Final Price) shall be the amount which results from taking NOK 57,377,049 (the Debt Free/Cash Free Price) and:
		
	(a)
	subtracting the aggregate of the External Debt;

		
	(b)
	adding the aggregate of the Cash; and

		
	(c)
	adding the amount of the difference between the aggregate Working Capital and the Target Working Capital if that aggregate Working Capital is greater than the Target Working Capital (or subtracting the amount of such difference if that aggregate Working Capital is less than the Target Working Capital).

2.2    At Closing, the Purchaser shall pay:
		
	(a)
	a sum of NOK 5,737,705 (the Escrow Amount) to the Escrow Agent into the Escrow Account; and

		
	(b)
	the Initial Price less the Escrow Amount to the Seller in United States Dollars, converted from NOK to United States Dollars at the US Exchange Rate,

where the Initial Price is the Debt Free/Cash Free Price (i) minus the aggregate of the Estimated External Debt (ii) plus the aggregate of the Estimated Cash (iii) plus or minus, as the case may be, the difference between the amount of the Estimated Working Capital and the Target Working Capital, as set out in Exhibit 1.
2.3    The Final Price shall be calculated after Closing on the basis set out in Schedule 9.  Any payments required to be made under the Financial Adjustments shall be treated as adjusting the Initial Price, thus resulting after such adjustment in the Final Price.  The Final Price shall (subject to any further adjustment, if applicable, pursuant to clause 2.4) be adopted for all Tax reporting purposes.
2.4    Any payment made in satisfaction of a liability arising under a Seller Obligation (including, for the avoidance of doubt, any obligation to pay the Client Adjustment Amount in accordance with this Agreement) or a Purchaser Obligation shall adjust the price paid for the Shares.

3.    CONDITIONS TO CLOSING
3.1    Closing shall be conditional on the following Conditions having been fulfilled or waived in writing in accordance with the terms of this Agreement:
		
	(a)
	the Competition Authority of Norway has, under the applicable merger control laws:

		
	(i)
	given the approval, consent or clearances required under relevant law for completion of the Proposed Transaction, either unconditionally or subject to conditions, obligations, undertakings or modifications accepted by the Purchaser;

		
	(ii)
	rendered a decision that no approval, consent or clearance is required under relevant law for completion of the Proposed Transaction; or

		
	(iii)
	failed to render a decision within the applicable waiting period under law and such failure is considered under such law to be a grant of all requisite consents or clearances under such law or referred the Proposed Transaction or any part thereof to another Governmental Entity in accordance with law and one of the requirements listed in items (i) through (ii) above has been fulfilled in respect of such other Governmental Entity.

- 2 -

		
	(b)
	the Seller and its Affiliates having obtained from Wells Fargo Bank, N.A. as Lender and Agent under the Credit Agreement (the Credit Agreement) entered into as of May 7, 2012 by and among the lenders identified in the signature pages to the Credit Agreement, Wells Fargo Bank, N.A. (as Agent, and such other capacities as described in the Credit Agreement) and Ciber Inc. and certain of its subsidiaries as set forth in the Credit Agreement the written consent for the entering into and consummation of the transaction contemplated by this Agreement;

		
	(c)
	there shall not have occurred any Material Adverse Change or any events or circumstances that, individually or in the aggregate, could reasonably be expected to cause a Material Adverse Change; and

		
	(d)
	the conclusion of the Purchaser’s legal, financial and tax due diligence in respect of the Company being concluded to the reasonable satisfaction of the Purchaser.

3.2    The Purchaser shall, at its own cost, use reasonable efforts to ensure that the Condition in clause 3.1(a) is fulfilled promptly after the date of this Agreement. The Purchaser and the Seller shall, each at its own cost, use reasonable efforts to ensure that the other Conditions are fulfilled to the reasonable satisfaction of the Purchaser as soon as reasonably practicable. The Seller and Purchaser shall cooperate in obtaining all consents, approvals or actions of any Governmental Entity which are required in order to satisfy any relevant Condition and shall take all steps as are reasonable for that purpose (including making appropriate submissions, notifications and filings, in consultation with the other, on or before the date of this Agreement).  The Seller and Purchaser shall for this purpose:
		
	(a)
	promptly (but in any case within 2 Business Days) notify the other party (and provide copies or, in the case of non-written communications, details) of any communications with any such Governmental Entity relating to any such consent, approval or action, save to the extent such communications contain commercially sensitive information of a party or any of its Affiliates;

		
	(b)
	keep the other informed of any communication (whether written or oral) with any such Governmental Entity; 

		
	(c)
	take into account any reasonable comments and requests of the other party and its advisers; and

		
	(d)
	regularly review with the other party the progress of any notifications or filings with a view to obtaining the relevant consent, approval or action from any Governmental Entity at the earliest reasonable opportunity.

3.3    The Seller shall, to the extent legally permissible, provide any Governmental Entity and, save to the extent such information contains commercially sensitive information of the Seller or any member of the Seller Group, the Purchaser and its legal advisers with any necessary information and documents reasonably required for the purpose of making any submissions, notifications and filings to any such Governmental Entity.
3.4    If a Governmental Entity is prepared to grant its consent or approval only subject to compliance with specific conditions or obligations to be imposed upon the Purchaser, the Purchaser shall have the sole and absolute discretion whether or not to accept the imposition of such conditions and obligations.

- 3 -

3.5    The Condition in clause 3.1(c) may be waived by notice in writing from the Purchaser. The Conditions in clauses 3.1(a) and (b) may only be waived by written agreement between the Seller and the Purchaser.
3.6    The Seller and the Purchaser shall each notify the other promptly (but in any event within 2 Business Days) upon becoming aware that any of the Conditions have been fulfilled.  The first Business Day on or by which all Conditions have been fulfilled (or waived in accordance with clause 3.5) is the Unconditional Date.
3.7    If the Unconditional Date has not occurred on or before the day that is 45 days after the date of this Agreement (the Longstop Date) (or such later date as the parties may agree in writing), this Agreement shall automatically terminate (other than in respect of the Surviving Provisions).  In such event, neither party (nor any of its Affiliates) shall have any claim under the Transaction Documents of any nature whatsoever against the other party (or any of its Affiliates) except in respect of any rights and liabilities which have accrued before termination or under any of the Surviving Provisions.

4.    PRE‐CLOSING SELLER UNDERTAKINGS
To the extent permissible under applicable law, from the date of this Agreement until Closing, the Seller shall (except as may be approved in writing by the Purchaser) ensure that the business of the Company is carried on in all material respects only in the ordinary course of business and shall comply with the obligations set out in Schedule 4. For the avoidance of doubt, the Purchaser accepts the creation of the Excluded Inter-Company Debt and Day-to-day Inter-Company Debt Balances. 

5.    CLOSING
5.1    Closing shall, where possible, take place by electronic communication and, to the extent not possible, take place in Oslo, at the offices of Advokatfirmaet Selmer DA (or at such other location(s) as the parties may agree) on the second Business Day after the Unconditional Date (provided that all the Conditions (other than those which have been waived in accordance with clause 3) remain fulfilled at that date) or such other date as the parties may agree in writing (the Closing Date).
5.2    At Closing each of the Seller and the Purchaser shall deliver or perform (or ensure that there is delivered or performed) all those documents, items and actions respectively listed in relation to that party or any of its Affiliates in Schedule 5.
5.3    If the Seller (on the one hand) or the Purchaser (on the other) fails to comply with any material obligation in Schedule 5, then the other party shall be entitled (in addition to and without prejudice to other rights and remedies available) by written notice to the party in default on the date Closing would otherwise be due to take place, to:
		
	(a)
	require Closing to take place so far as practicable having regard to the defaults which have occurred; or

- 4 -

		
	(b)
	notify the party in default of a new date for Closing (being not more than 5 Business Days after the original date for Closing) in which case the provisions of this clause 5 (other than this clause 5.3) and Schedule 5 shall apply to Closing as so deferred; or

		
	(c)
	terminate this Agreement (other than the Surviving Provisions).

5.4    If this Agreement is so terminated, neither party nor any of its Affiliates shall have any claim under this Agreement of any nature against the other party or its Affiliates (except in respect of any rights and liabilities which have accrued before termination or under any of the Surviving Provisions).

6.    SELLER WARRANTIES
6.1    The Seller represents and warrants to the Purchaser that on the date of this Agreement and at Closing each and every one of the statements set forth in Schedule 5 is true and accurate.
6.2    The Warranties are given subject to the limitations set out in this clause 6, clause 8 and Schedule 2.
6.3    None of the limitations in Schedule 2 shall apply to any Claim to the extent that the Claim (or the delay in discovery of it) is the consequence of, or is increased as a consequence of, dishonest or deliberate misstatement or concealment or other fraud or fraudulent misrepresentation by the Seller or any director, officer or employee (or former officer or employee) of the Seller or any other member of the Seller Group.
6.4    Except in the case of fraud, wilful intent or gross negligence and as against any individual or entity who has acted fraudulently, the Seller agrees and undertakes with the Purchaser that neither it nor any other member of the Seller Group has any rights against, and will waive and shall not make any claim against, any director (other than, if applicable, the Norwegian based directors of the Company), officer, employee, adviser or agent of: (i) the Company; or (ii) any member of the Purchaser Group, on whom the Seller may have relied before agreeing to any term of this Agreement or any other Transaction Document or before entering into this Agreement or any other Transaction Document. Notwithstanding the provisions of clause 32, the provisions of this clause 6.4 may be relied upon and enforced by each individual or entity for whose benefit it is expressed or intended to be given.
6.5    In the event of a breach of any of the Warranties, the Seller shall, subject to the provisions of this clause and Schedule 2 and without prejudice to any other rights or remedies the Purchaser may otherwise have, compensate the Purchaser for all damages incurred by the Purchaser, its Affiliates and the Company in connection with such breach of Warranty, including payment in cash to the Purchaser of a sum equal to the aggregate of:
		
	(a)
	the amount which would be necessary to put the Company into the financial position which would have existed had there been no breach of the Warranty; and

		
	(b)
	all other damages suffered or incurred by the Purchaser or any of its Affiliates (including the Company), directly or indirectly, as a result of or in connection with the breach of Warranty.

6.6    The Seller undertakes to notify the Purchaser in writing promptly if it or any other member of the Seller Group becomes aware of any circumstance arising after the date of this 

- 5 -

Agreement which would cause any Warranty (if the Warranties were repeated with reference to the facts and circumstances then existing) to become untrue or inaccurate or misleading in any material respect.
6.7    If the Seller has a liability arising under a Seller Obligation, any amounts due in satisfaction of that liability shall be paid in full without deduction or retention (except as required by law or as otherwise expressly permitted under this Agreement).  The Seller hereby waives and relinquishes any right of set-off or counterclaim which it may have in respect of the payment of any such amount.

7.    PURCHASER WARRANTIES
The Purchaser hereby represents and warrants to the Seller that on the date of this Agreement each and every one of the statements set forth in Schedule 3 is true and accurate.

8.    CONDUCT OF PURCHASER CLAIMS
8.1    If the Purchaser becomes aware of any claim or potential claim by a third party (a Third Party Claim) that might result in a Claim being made by the Purchaser, the Purchaser (subject to the Purchaser and each member of the Purchaser Group being indemnified and secured to the Purchaser’s reasonable satisfaction by the Seller against all reasonable out-of-pocket costs and expenses, including those of its legal advisers, incurred in respect of that Third Party Claim) shall:
		
	(a)
	as soon as reasonably practicable but in any event within 20 Business Days of becoming aware of such Third Party Claim, give notice of such Third Party Claim to the Seller and ensure that the Seller is given all reasonable information and facilities to investigate it;

		
	(b)
	not (and ensure that each member of the Purchaser Group shall not) admit liability or make any agreement or compromise in relation to the Third Party Claim without prior consultation with the Seller and shall ensure that any agreement or compromise shall at all times strike a fair balance between the interests of the Seller in keeping the damages as low as possible on one hand and the interests of the Purchaser in maintaining good business relationships with such third parties on the other hand; and

		
	(c)
	(subject to the Purchaser or the relevant member of the Purchaser Group being entitled to employ its own legal advisers) ensure that it and each member of the Purchaser Group shall take such action as the Seller may reasonably request to avoid, resist, dispute, appeal, compromise or defend the Third Party Claim, save to the extent that to do so would:

		
	(i)
	breach any duty of confidentiality owed by the Purchaser or a member of the Purchaser Group to a third party; or

		
	(ii)
	prejudice the ability of the Purchaser to bring a claim against the Seller.

8.2    The rights of the Seller under clause 8.1(b) and (c) shall only apply to a Third Party Claim if the Seller gives notice to the Purchaser in writing of its intention to exercise its rights within 10 Business Days of the Purchaser giving notice of the Third Party Claim and also 

- 6 -

acknowledges that the Seller is liable, subject to the remaining provisions of this Agreement, for damages to the Purchaser arising from that Third Party Claim.  If the Seller does not give notice during that period, the Purchaser shall be entitled in its absolute discretion to settle, compromise, or resist any action, proceedings or claim against any member of the Purchaser Group out of which that Third Party Claim may arise.
8.3    Neither the Purchaser nor any of its Affiliates shall be required to take any action or refrain from taking any action pursuant to clause 8.1 if the action or omission requested would, in the reasonable opinion of the Purchaser, be prejudicial to the business, including the commercial interests, reputation, goodwill or relationships, of the Purchaser or any of its Affiliates or to the Company, including its commercial interests, reputation, goodwill or relationships.
8.4    The Purchaser shall not be precluded from bringing any claim for breach of any of the terms of this Agreement by reason of any breach of the terms of this clause 8.1.

9.    ESCROW
9.1    The Seller, the Purchaser and the Escrow Agent shall enter into the Escrow Agreement on Closing.
9.2    The Escrow Amount shall be held in the Escrow Account in accordance with the terms and conditions of this Agreement and the Escrow Agreement.  
9.3    Subject to clause 9.4 below and the remaining provisions of this clause 9.3, the funds in the Escrow Account shall be retained for a period of 18 months from Closing (the Escrow Period). Subject to clause 9.4 below, the Purchaser and the Seller shall issue joint written instructions to the Escrow Agent to release to the Seller the funds in the Escrow Account in accordance with the terms of the Escrow Agreement and as follows:
		
	(a)
	on the first anniversary of the Closing Date (the First Release Date), the following amount shall be released to the Seller (solely if such amount is a positive number, it being agreed that no amount shall be released to the Seller if such amount is a negative number):

		
	(i)
	NOK 2,868,852,45; minus

		
	(ii)
	the total amount released from the Escrow Account to any person prior to the First Release Date; minus

		
	(iii)
	the aggregate amount of all outstanding Escrow Claims (if any) as of the First Release Date;

		
	(b)
	at the end of the Escrow Period (the Second Release Date), the following amount shall be released to the Seller (solely if such amount is a positive number, it being agreed that no amount shall be released to the Seller if such amount is a negative number):

		
	(i)
	the amount remaining in the Escrow Account as of the Second Release Date; minus

- 7 -

		
	(ii)
	the aggregate amount of all outstanding Escrow Claims (if any) as of the Second Release Date.

9.4    To the extent that the Purchaser shall have notified the Seller of any Escrow Claim prior to the expiry of the Escrow Period and the amount of any such Escrow Claim shall have been Agreed or Determined, the Seller and the Purchaser shall immediately upon such Agreement or Determination issue joint written instructions to the Escrow Agent to pay the amount of such Claim from the Escrow Account or, if the aggregate amount in the Escrow Account is less than the amount of the liability, the aggregate amount then standing to the credit of the Escrow Account, to the Purchaser.  
9.5    To the extent that the liability for or the quantum of any Escrow Claim or Escrow Claims notified shall not have been Agreed or Determined by the expiry of the Escrow Period (any such Claim, a Relevant Claim), then the amount of the Relevant Claim(s) shall be retained in the Escrow Account following expiry of the Escrow Period until such Relevant Claim(s) are Agreed or Determined.  Immediately upon such amount being Agreed or Determined the Seller and the Purchaser shall issue joint written instructions to the Escrow Agent to pay the amount of any Relevant Claim(s) from the Escrow Account or, if the aggregate amount in the Escrow Account is less than the amount of the liability (as so Agreed or Determined), the aggregate amount then standing to the credit of the Escrow Account, to the Purchaser. Immediately once all such Relevant Claims have been so Agreed or Determined and paid to the Purchaser, the balance (if any) remaining in the Escrow Account shall be paid to the Seller.
9.6    Both the Seller and the Purchaser undertake to issue instructions for payment from the Escrow Account of the amounts due under the above clauses without delay.

10.    NO RIGHTS OF RESCISSION OR TERMINATION
Other than in accordance with clause 3.7 or 5.3, neither party shall be entitled to rescind, dissolve or otherwise terminate this Agreement in any circumstances whatsoever (whether before or after Closing).  This shall not exclude any liability for (or remedy in respect of) fraudulent misrepresentation or wilful intent.

11.    TRADEMARK LICENSE
On Closing, the Seller, the Purchaser and Ciber Inc. shall enter into a trademark license agreement (Trademark License Agreement), in the Agreed Form attached hereto as Schedule 6.

12.    TRANSITIONAL SERVICES
On Closing, the Seller and the Purchaser shall enter into a transitional services agreement (Transitional Services Agreement), in the Agreed Form attached hereto as Schedule 6.

13.    TAX
13.1    The Seller hereby covenants with the Purchaser to indemnify the Purchaser on demand against any liability of the Company to make or suffer an actual payment of Tax:

- 8 -

		
	(a)
	which arises in respect of or in consequence of:

		
	(i)
	any income, profits or gains earned, accrued or received (or deemed to be earned, accrued or received) on or before Closing; or

		
	(ii)
	any Event which occurs or occurred (or is deemed to occur or to have occurred) on or before Closing; or

		
	(b)
	which is properly attributable to the Seller; or

		
	(c)
	which is attributable to the loss or non-availability to any extent of any Relief included in the Last Accounts.

13.2    For the purpose of clauses 13.1(a) and (b) there shall be treated as an actual payment of Tax an amount equal to the amount of Tax saved in consequence of any use or set-off of:
		
	(a)
	any Relief arising to the Company in respect of an Event occurring or period ending after the Closing: or

		
	(b)
	any Relief included in the Last Accounts: or

		
	(c)
	any Relief arising to the Purchaser or any member of the Purchaser Group, 

in circumstances where, but for such use or set off, the Company would have been liable to make an actual payment of Tax to which clause 13.1(a) or (b) would apply.
13.3    Clause 13.1(a) shall not apply if and to the extent that provision in respect of the liability to Tax is specifically provided or reserved for (and not released prior to Closing) in the Last Accounts.
13.4    The indemnity contained in this clause 13 shall extend to all costs and expenses reasonably incurred by the Purchaser or the Company in connection with a claim under this clause 13 or the subject matter of such a claim. 
13.5    Any reference in this clause 13 to an Event which occurs or occurred (or is deemed to occur or have occurred) on or before Closing shall include a series or combination of Events the first of which occurred on or before Closing.

14.    INSURANCE
14.1    From the date of this Agreement until 30 September 2016 (the Insured Period), the Seller shall (and shall ensure that each of its Affiliates shall), at the Company's cost from the Closing Date until the expiry of the Insured Period and at actual cost without any mark-up, continue in force and comply with all policies of insurance, including, for the avoidance of doubt, any workers compensation insurance, maintained by them in respect of the Company (including in respect of each of the Properties, except for those Properties where there is a lease and there is an obligation on the landlord to insure).
14.2    If any insured event occurs before the expiry of the Insured Period in relation to the Company or its business or assets, the Seller shall use all reasonable efforts to make recovery under the relevant policy prior to the expiry of the Insured Period.  To the extent that recovery 

- 9 -

is made, the Seller shall ensure that the proceeds are applied to restore or replace the relevant insured asset(s) or passed to the Purchaser on the last day of the Insured Period.
14.3    From the expiry of the Insured Period, the Seller shall ensure that all insurance policies which are in force at the expiry of the Insured Period continue in force on the same terms to the extent that (i) they provide cover in relation to the carrying on of the business of the Company before the expiry of the Insured Period and/or any matter or event occurring in relation to any assets of the Company before the expiry of the Insured Period and (ii) under their respective terms, claims can still be made or pursued after the expiry of the Insured Period. The claims that will be made or pursued by or on behalf of the Purchaser Group under the insurance policies (together the Permitted Claims) will include those that have already been notified to the relevant insurer(s) before the expiry of the Insured Period and are pending or outstanding at the expiry of the Insured Period and any additional claims that are notified to the relevant insurer(s) on or before the second anniversary of the Closing.
14.4    The Seller shall ensure that each member of the Seller Group shall take such steps as the Purchaser reasonably requires to make and/or pursue any Permitted Claim (including giving notice of the claim to the insurer at the request of the Purchaser) or to assist any member of the Purchaser Group in making the claim, and shall pay to the Purchaser any proceeds actually received within 5 Business Days of their receipt after deducting (in either case) all costs reasonably incurred by the Seller or relevant member of the Seller Group in recovering such proceeds.
14.5    Upon the expiry of the Insured Period, and subject to the provisions of clause 14.3 above, all insurance cover arranged in relation to the business or assets of the Company by the Seller Group (whether under policies maintained with third party insurers or other members of the Seller Group) shall cease (other than in relation to insured events taking place before the expiry of the Insured Period) and no member of the Purchaser Group shall make any claim under any such policies in relation to insured events arising after the expiry of the Insured Period.

15.    PAYMENT OF INTER-COMPANY DEBT
The provisions of Schedule 8 shall apply in respect of the payment of Inter-Company Debt.

16.    PROTECTIVE COVENANTS POST-CLOSING
16.1    Except as permitted pursuant to clause 17, the Seller shall ensure that neither it nor any of its Affiliates shall (whether alone or jointly with another and whether directly or indirectly) carry on or be engaged or concerned or interested economically or otherwise in any manner in any Competing Business in Norway for a period of 3 years after the Closing Date. For this purpose Competing Business means a business which competes with any business carried on during the 12 months preceding the Closing Date by the Company.
16.2    Neither the Seller nor any of its Affiliates shall (whether alone, jointly with another, directly or indirectly), for 2 years after Closing, offer to employ or seek to entice away from the Company, the Purchaser or any member of the Purchaser Group, or conclude any contract for services with, any person who was employed by the Company at any time during the 12 months ending on the date of this Agreement.

- 10 -

16.3    Each of the undertakings in clauses 16.1 and 16.2 is given to the Purchaser and to each of its Affiliates. The Seller acknowledges that each is an entirely independent restriction and is no greater than is reasonably necessary to protect the interests of the Purchaser and its Affiliates. If any such restriction shall be held void or unenforceable but would be valid if deleted in part or reduced in its application, then that restriction shall apply with such modifications as may be necessary to make it valid and effective.

17.    POST‐CLOSING UNDERTAKINGS
17.1    For 7 years following the Closing Date, and subject to the provisions of clause 20:
		
	(a)
	each member of the Purchaser Group shall provide the Seller (at the Seller’s cost) with reasonable access at reasonable times to (and the right to take copies of) the books, accounts, customer lists and all other records held by it after Closing to the extent that they relate to the Company and to the period up to Closing (the Purchaser Records), and such other information, assistance and access to records and personnel as it reasonably requires, but only for the purposes of the preparation of any reasonable accounting records, Tax return or regulatory filing by the Seller (or any member of the Seller Group) or as may be reasonably required for the performance by the Seller of its obligations under the Transaction Documents;

		
	(b)
	each member of the Seller Group shall provide the Purchaser (at the Purchaser’s cost) with reasonable access at reasonable times to (and the right to take copies of) the books, accounts, customer lists and all other records held by it after Closing to the extent that they relate to the Company (the Seller Records), and such other information, assistance and access to records and personnel as it reasonably requires, but only for the purposes of the preparation of any reasonable accounting records, Tax return or regulatory filing by the Purchaser (or any member of the Purchaser Group) or as may be reasonably required for the performance by the Purchaser of its obligations under the Transaction Documents.

		
	(c)
	no member of the Purchaser Group shall dispose of, or destroy any of, the Purchaser Records necessary for the preparation of any reasonable accounting records, any Tax return or regulatory filing by the Seller (or any member of the Seller Group) or as may be reasonably required for the performance by the Seller of its obligations under the Transaction Documents without first giving the Seller at least 2 months’ notice of its intention to do so and giving the Seller a reasonable opportunity to remove and retain any of them (at the Seller’s expense); and

		
	(d)
	no member of the Seller Group shall dispose of, or destroy any of, the Seller Records necessary for the preparation of any reasonable accounting records, any Tax return or regulatory filing by the Purchaser (or any member of the Purchaser Group) or as may be reasonably required for the performance by the Purchaser of its obligations under the Transaction Documents without first giving the Purchaser at least 2 months’ notice of its intention to do so and giving the Purchaser a reasonable opportunity to remove and retain any of such records (at the Purchaser’s expense).

17.2    Following the Closing Date:
		
	(a)
	notwithstanding the obligations of clause 8, each member of the Purchaser Group shall (at the Seller’s expense, to the extent the costs are reasonable) give such assistance to 

- 11 -

any member of the Seller Group (including access to records and personnel) as the Seller may reasonably request in relation to any third party proceedings by or against any member of the Seller Group so far as they relate to the Company, including proceedings relating to employees’ claims or Taxation; and
		
	(b)
	the Seller shall promptly give to the Purchaser all written notices, correspondence, information or enquiries received by it in relation to the Company; and

		
	(c)
	the Purchaser shall promptly give to the Seller all written notices, correspondence, information or enquiries received by it in relation to any business of the Seller Group not being the Company.

17.3    If, during a period of 18 months following the Closing Date:
		
	(a)
	any member of the Seller Group receives any correspondence or amount which is part of or relates to the Company (including, for the avoidance of doubt, any payments received into a bank account of the Seller or any member of the Seller Group for any receivables or Trade Debtors belonging to the Company), the Seller shall, as soon as practicable and in any event within 48 hours, ensure that such correspondence or amount (together with any benefit or sum, net of Tax and other out of pocket expenses, accruing to any member of the Seller Group as a result of holding that correspondence or amount since Closing) is transferred to such member of the Purchaser Group as the Purchaser shall specify, at no cost.  The Purchaser shall provide such assistance to the Seller as the Seller reasonably requires for this purpose;

		
	(b)
	any member of the Purchaser Group receives any correspondence or amount which is not part of and does not relate to the Company but rather belongs to any member of the Seller Group, the Purchaser shall, as soon as practicable and in any event within 48 hours, ensure that such correspondence or amount (together with any benefit or sum, net of Tax and other out of pocket expenses, accruing to any member of the Purchaser Group as a result of holding that correspondence or amount since Closing) is transferred to such member of the Seller Group as the Seller shall specify, at no cost. The Seller shall provide such assistance to the Purchaser as the Purchaser reasonably requires for this purpose.

17.4    The Purchaser agrees that it shall, in relation to any contracts to which the Company is a party as at the Closing and that provide for services to be rendered by any member of the Seller Group outside Norway (the Foreign Business Contracts), for the first 6 months after the Closing Date (the Foreign Business Contracts Period), continue to engage the relevant members of the Seller Group to render the relevant services outside of Norway, provided that:
		
	(a)
	the services shall be to a standard and level which is equivalent to the standard and level enjoyed in the 12 months prior to the Closing Date;

		
	(b)
	the relevant member of the Seller Group complies with its obligations under the applicable Foreign Business Contract;

		
	(c)
	the Seller and the relevant member of the Seller Group indemnifies the Purchaser against any claims or losses suffered by or against the Purchaser arising from or as a result of the conduct of the relevant member of the Seller Group under the relevant Foreign Business Contract; and

- 12 -

		
	(d)
	between the Closing Date and the end of the Foreign Business Contracts Period, the parties shall negotiate in good faith whether and, if so, on which terms the relevant members of the Seller Group will continue to render services under the Foreign Business Contracts after the end of the Foreign Business Contracts Period.

17.5    The parties furthermore agrees that where any customer contract, that is already in effect as at Closing and has been entered into between any member of the Seller Group (other than the Company), on the one hand, and a non-Norwegian client, on the other hand (each such contract a Foreign Seller Contract), provides for part of the services under such Foreign Seller Contract to be rendered in Norway (for example to such non-Norwegian client's Norwegian subsidiaries), the Seller or the relevant member of the Seller Group shall offer the Purchaser the opportunity to provide the relevant services in Norway on a sub-contracting basis via the Company, it being understood that:
		
	(a)
	the services shall be to a standard and level which is equivalent to the standard and level enjoyed in the 12 months prior to the Closing Date;

		
	(b)
	the Purchaser indemnifies the Seller against any claims or losses suffered by or against the Seller arising from or as a result of the conduct of the Purchaser under the relevant Foreign Seller Contract;

		
	(c)
	the Seller and the members of the Seller Group shall not implement or agree to the amendment or variation of any Norwegian element of a Foreign Seller Contract without the prior written consent of the Purchaser; and

		
	(d)
	the Seller and the members of the Seller Group shall not negotiate or enter into any new contract which provides for part of the services to be rendered in Norway or agree to the extension of any Foreign Seller Contract without the prior written consent of the Purchaser.

If the Purchaser informs the Seller that it does not want to or cannot provide the relevant services in Norway on a sub-contracting basis, or if the Purchaser does not respond to such offer within 15 Business Days, the Seller or the relevant member of the Seller's Group shall be entitled to provide such services in Norway and the non-compete obligations included in clause 16 shall not apply in respect of those services.
17.6    Following Closing, the details and accounting treatment in the Company’s books of account of the pension assets and liabilities of the Company and the treasury stock and restricted stock units of the Company, including any off-balance sheet pension assets and liabilities or stock (collectively the Balance Sheet Items), shall be confirmed in accordance with the provisions of Schedule 13 (the Accounting Review). To the extent that the Accounting Review results in a valuation or accounting treatment for any of the Balance Sheet Items which is different to that recorded in the Company’s books of account as at the date hereof, any such revaluations shall, to the extent relevant to the preparation of the Closing Statement and the financial items relevant thereto, be taken as the value or treatment of those items for purposes of the Closing Statement.

18.    PAYMENTS
18.1    Subject to any provision of this Agreement to the contrary, any payment to be made pursuant to this Agreement by the Purchaser (or any member of the Purchaser Group) to the 

- 13 -

Seller shall be made to the Seller’s Bank Account.  The Seller agrees to pay each member of the Seller Group that part of each payment to which it is entitled.
18.2    Any payment to be made pursuant to this Agreement by the Seller (or any member of the Seller Group) shall be made to the Purchaser’s Bank Account.  The Purchaser agrees to pay each member of the Purchaser Group that part of each payment to which it is entitled.
18.3    Payment under clauses 18.1 and 18.2 shall be in immediately available funds by electronic transfer on the due date for payment.  Receipt of the amount due shall be an effective discharge of the relevant payment obligation.
18.4    If any sum due for payment in accordance with this Agreement (a Due Sum) is not paid on the due date for payment (the Due Date), the person in default shall pay Default Interest on that sum from but excluding the Due Date to and including the date of actual payment calculated on a daily basis.
18.5    All sums payable under this Agreement shall be paid free and clear of all deductions or withholdings whatsoever, save only as provided in this Agreement or as required by law.
18.6    All payments required to be made by the Purchaser to the Seller in terms of this agreement and expressed in NOK shall be converted from NOK to United States Dollars at the US Exchange Rate and shall be paid by the Purchaser in United States Dollars. All payments required to be made by the Seller to the Purchaser or by the Purchaser to the Company (cf. payment of the Excluded Inter-Company Debt in accordance with Schedule 5),  shall be made in NOK.

19.    ANNOUNCEMENTS
Notwithstanding clause 20, neither the Seller nor the Purchaser (nor any of their respective Affiliates) shall make any announcement or issue any circular or press release in connection with the existence or subject matter of this Agreement (or any of the other Transaction Documents) without the prior written approval of the other (such approval not to be unreasonably withheld or delayed). To the extent permitted by laws or regulations, the foregoing also applies in case the announcement or circular is required by law, by any stock exchange or any regulatory or other supervisory body or authority of competent jurisdiction, whether or not the requirement has the force of law. To the extent not permitted by such laws or regulations, the party making the announcement or issuing the circular shall use its reasonable efforts to consult with the other party in advance as to its form, content, and timing, and the only contents of such announcement shall be as required by law.

20.    CONFIDENTIALITY
20.1    For the purposes of this clause 20:
		
	(a)
	Confidential Information means:

		
	(i)
	(in relation to the obligations of the Purchaser) any information received or held by the Purchaser (or any of its Representatives) relating to the Seller Group or, prior to Closing, to the Company; or

- 14 -

		
	(ii)
	(in relation to the obligations of the Seller) any information received or held by the Seller (or any of its Representatives) relating to the Purchaser Group or, following Closing, to the Company; and

		
	(iii)
	information relating to the provisions and subject matter of, and negotiations leading to, this Agreement and the other Transaction Documents;

and includes written information and information transferred or obtained orally, visually, electronically or by any other means and any information which the party has determined from such information;
		
	(b)
	Representatives means, in relation to a party, its respective Affiliates and the directors, officers, employees, agents, advisers, accountants and consultants of that party and/or of its respective Affiliates.

20.2    Each of the Seller and the Purchaser shall (and shall ensure that each of its Representatives shall) maintain Confidential Information in confidence and not disclose that Confidential Information to any person except (i) as this clause 20 permits or (ii) as the other party approves in writing.
20.3    Clause 20.2 shall not prevent disclosure by a party or its Representatives to the extent that it can demonstrate that:
		
	(a)
	disclosure is required by law or by any stock exchange or any regulatory, governmental or antitrust body (including any Tax Authority) having applicable jurisdiction (provided that, except in connection with disclosure to a Tax Authority, the disclosing party shall first inform the other party of its intention to disclose such information and take into account the reasonable comments of the other party);

		
	(b)
	disclosure is of Confidential Information which was lawfully in the possession of that party or any of its Representatives (in either case as evidenced by written records) without any obligation of secrecy prior to its being received or held;

		
	(c)
	disclosure is of Confidential Information which has previously become publicly available other than through that party’s fault (or that of its Representatives);

		
	(d)
	disclosure is required for the purpose of any arbitral or judicial proceedings arising out of this Agreement or any other Transaction Document.

20.4    Each of the Seller and the Purchaser undertakes that it (and its Affiliates) shall only disclose Confidential Information to Representatives if it is reasonably required for purposes connected with this Agreement and only if the Representatives are informed of the confidential nature of the Confidential Information.
20.5    If this Agreement terminates, the Purchaser shall as soon as practicable on request by the Seller:
		
	(a)
	return to the Seller all written documents and other materials relating to the Seller, the Company or this Agreement (including any Confidential Information) which the Seller (or its Representatives) have provided to the Purchaser (or its Representatives) without keeping copies of them;

- 15 -

		
	(b)
	destroy all information or other documents derived from such Confidential Information; and

		
	(c)
	so far as it is practicable to do so, expunge such Confidential Information from any computer, word processor or other device.

21.    ASSIGNMENT
21.1    Except as provided in this clause 21 or unless the Seller and the Purchaser specifically agree in writing, no person shall assign, transfer, charge or otherwise deal with all or any of its rights under this Agreement nor grant, declare, create or dispose of any right or interest in it.
21.2    The Purchaser may assign the benefit of this Agreement and/or of any other Transaction Document to which it is a party (in whole or in part) to, and it may be enforced by, any Permitted Assignee as if it were the Purchaser under this Agreement.  Any Permitted Assignee to whom an assignment is made in accordance with the provisions of this clause 21 may itself make an assignment as if it were the Purchaser under this clause 21.  Regardless of any such assignment, the Purchase shall remain fully liable towards the Seller. In the event that a Permitted Assignee to whom an assignment has been made in accordance with the provisions of this clause 21.2 ceases to be a Permitted Assignee (i.e. a member of the Purchaser Group), the Permitted Assignee must assign the benefits of this Agreement and/or any other relevant Transaction Document to which it is party (in whole or in part) to a Permitted Assignee no later than at the date it ceases to be a Permitted Assignee. For this purpose, a Permitted Assignee means any member or members of the Purchaser Group.
21.3    The Purchaser may assign its rights under this Agreement and/or under any other Transaction Document to which it is a party by way of security to any bank(s) and/or financial institution(s) lending money or making other banking facilities available to the Purchaser for the acquisition of the Shares.
21.4    Any purported assignment in contravention of this clause 21 shall be void.

22.    FURTHER ASSURANCES
22.1    Each of the Seller and the Purchaser shall perform (or procure the performance of) all further acts and things and execute and deliver (or procure the execution and delivery of) such further documents, as may be required by law or as may be necessary to implement and give effect to this Agreement.
22.2    Each of the Seller and the Purchaser shall procure that its Affiliates comply with all obligations under this Agreement which are expressed to apply to any such Affiliates.

23.    COSTS
Except as otherwise provided in this Agreement (or any other Transaction Document), the Seller and the Purchaser shall each be responsible for its own costs, charges and other expenses (including those of its Affiliates) incurred in connection with the Proposed Transaction.

- 16 -

24.    NOTICES
24.1    Any notice in connection with this Agreement shall be in writing in English and delivered by hand, registered post or courier using an internationally recognised courier company, or by email. A notice shall be effective upon receipt and shall be deemed to have been received: (i) at the time of delivery, if delivered by hand, registered post or courier; or (ii) if delivered by email, at the time of sending.
24.2    The addresses of the parties for the purpose of clause 24.1 are: 
	
			
	Seller
	Address:
	Email:

	For the attention of:
Christian Mezger
Chief Financial Officer
	6363 South Fiddler's Green Circle, Suite 1400, Greenwood Village, Colorado, USA
	CMezger@ciber.com

	With a copy to:
Sean Radcliffe
Senior Vice President, General Counsel and Corporate Secretary
	6363 South Fiddler's Green Circle, Suite 1400, Greenwood Village, Colorado, USA
	SRadcliffe@ciber.com

	Purchaser
	Address:
	Email:

	For the attention of:
Maalfrid Brath
	Tordenskiolds gate 2, 0160 Oslo
	Maalfrid.Brath@manpowergroup.no

	With a copy to:
Emily Gleeson
Director of Legal Affairs EMEA. 
ManpowerGroup
	The Helicon
One South Place, 
London 
EC2M 2RB
	Emily.Gleeson@manpowergroup.com

24.3    A party may notify the other party of a change to its name, relevant addressee, address or email address for the purpose of this clause 24, provided that such notice shall only be effective upon:
		
	(a)
	the date specified in such notice as the date on which the change is to take place; or

		
	(b)
	if, in such notice, no date is specified or the date to be specified is less than 5 Business Days after the date on which such notice is given, the date following 5 Business Days after such notice has been given.

25.    CONFLICT WITH OTHER AGREEMENTS
If there is any conflict between the terms of this Agreement and any other agreement, this Agreement shall prevail (as between the parties to this Agreement and as between the Seller and any members of the Purchaser Group) unless such other agreement expressly states that it overrides this Agreement in the relevant respect.

- 17 -

26.    WHOLE AGREEMENT
26.1    This Agreement and the other Transaction Documents together set out the whole agreement between the parties in respect of the sale and purchase of the Shares and supersede any prior agreement (whether oral or written) relating to the Proposed Transaction.

27.    WAIVERS, RIGHTS AND REMEDIES
27.1    Except as expressly provided in this Agreement, no failure or delay by any party in exercising any right or remedy relating to this Agreement or any of the Transaction Documents shall affect or operate as a waiver or variation of that right or remedy or preclude its exercise at any subsequent time.  No single or partial exercise of any such right or remedy shall preclude any further exercise of it or the exercise of any other remedy.

28.    EFFECT OF CLOSING
Notwithstanding Closing (i) each provision of this Agreement and any other Transaction Document not performed at or before Closing but which remains capable of performance (ii) the Warranties and (iii) all covenants, indemnities and other undertakings and assurances contained in or entered into pursuant to this Agreement or any other Transaction Document, will remain in full force and effect and (except as otherwise expressly provided) without limit in time.

29.    COUNTERPARTS
This Agreement may be executed in any number of counterparts, and by each party on separate counterparts. Each counterpart is an original, but all counterparts shall together constitute one and the same instrument. Delivery of a counterpart of this Agreement by e-mail attachment or telecopy shall be an effective mode of delivery.

30.    VARIATIONS
No amendment of this Agreement (or of any other Transaction Document) shall be valid unless it is in writing and duly executed by or on behalf of all of the parties to it.

31.    INVALIDITY
Each of the provisions of this Agreement and the other Transaction Documents is severable.  If any such provision is held to be or becomes invalid or unenforceable in any respect under the law of any jurisdiction, it shall have no effect in that respect and the parties shall use all reasonable efforts to replace it in that respect with a valid and enforceable substitute provision the effect of which is as close to its intended effect as possible.

32.    THIRD PARTY ENFORCEMENT RIGHTS

- 18 -

Except as expressly stipulated in this Agreement, this Agreement shall not grant any right to persons who are not a party to this Agreement. To the extent this Agreement expressly grants rights to third parties, the parties to this Agreement shall be permitted to change or exclude such rights at any time without the consent of the respective third party.

33.    MITIGATION
Nothing in this Agreement shall be deemed to relieve the Purchaser from any duty under applicable law to mitigate any loss or damage incurred by it as a result of a Claim.

34.    GOVERNING LAW AND JURISDICTION
34.1    This Agreement, including the arbitration provision contained in this clause 34, shall be governed by and construed in accordance with the laws of Norway.
34.2    All disputes between the parties hereto arising under or in connection with this Agreement or further agreements resulting from this Agreement, including all disputed claims for breach by any party of any representation, warranty, undertaking or covenant under this Agreement (a Dispute), shall be finally resolved by arbitration in accordance with the provisions of the Norwegian Arbitration Act dated 14 May 2004, no. 25 (the Arbitration Act) as supplemented and modified by the provisions of this Agreement, provided always that the parties have the right to submit any such dispute in summary proceedings to any court of competent jurisdiction of Oslo, Norway (i) for provisional relief pending the outcome of arbitration, including provisional injunctive relief or arrest or other pre-judgment attachment of assets, or (ii) to compel arbitration or enforce any arbitral award and the right to obtain seizure. The arbitrators, who shall be appointed in accordance with the Arbitration Act and this Agreement, shall decide according to the rules of the law. The arbitral tribunal shall consist of 3 arbitrators, each of whom shall be fluent in English. The arbitral proceedings shall be conducted in the English language. Each party shall nominate one arbitrator. The third arbitrator shall be jointly nominated by the arbitrators nominated by the parties, and shall act as chairman of the arbitration tribunal. The place of arbitration shall be the Municipality of Oslo.

Schedule 1 
 
SELLER WARRANTIES
Part A    : General/Commercial
1.    THE SELLER GROUP AND THE SHARES
1.1    Authorisations, valid obligations, filings and consents
		
	(a)
	The Seller, the Company and each other relevant member of the Seller Group, has obtained all corporate authorisations and (other than to the extent relevant to the Conditions) all other governmental, statutory, regulatory or other consents, licences, authorisations, waivers or exemptions required to empower it to enter into and perform its obligations under this Agreement and any other Transaction Document to which it 

- 19 -

is a party, subject to the provisions of clause 3 of this Agreement, and in particular the required consent from Wells Fargo Bank, N.A.
		
	(b)
	Entry into and performance by each member of the Seller Group and the Company of this Agreement and/or any Transaction Document to which it is a party will not: (i) breach any provision of its constitutional documents; or (ii) (subject to fulfilment of the Conditions) result in a breach of any laws or regulations in its jurisdiction of incorporation or of any order, decree or judgment of any court or any governmental or regulatory authority.

		
	(c)
	This Agreement and the Transaction Documents will, when executed, constitute valid and binding obligations of each relevant member of the Seller Group and the Company.

		
	(d)
	Except for filing to the U.S. Securities and Exchange Commission and as otherwise referred to in this Agreement, no member of the Seller Group (i) is required to make any announcement, consultation, notice, report or filing or (ii) requires any consent, approval, registration, authorisation or permit, in each case in connection with the execution and performance of this Agreement or any other Transaction Document.

1.2    Details of the Shares and the Company
		
	(a)
	The Seller and the Company are validly incorporated, in existence and duly registered under the laws of its jurisdiction of incorporation and the Company has full power to conduct its business as conducted at the date of this Agreement.

		
	(b)
	The Seller is the sole owner of the Shares free from all Third Party Rights.  The Seller is entitled to transfer or procure the transfer of the full ownership of the Shares to the Purchaser on the terms set out in this Agreement.

		
	(c)
	The Shares constitute the whole of the issued and allotted or, to the extent appropriate, registered, share capital of the Company.  All the Shares are fully paid or properly credited as fully paid and there is no liability to pay any additional contributions on the Shares.

		
	(d)
	No person has the right (exercisable now or in the future and whether contingent or not) to call for the allotment or issue of any share or loan capital in the Company.

		
	(e)
	The Company owns or is entitled to possess or use (when taken together with the services provided under the Transitional Services Agreement and for such period as such services are so provided) all the assets that are being used to carry on the business of the Company as it has been carried on in the 12 months prior to Closing.

		
	(f)
	The information in the Company's articles of association, company certificate and shareholders' book as set out in the Data Room is true, accurate and not misleading.

1.3    Other interests.  The Company does not own or have any interest of any nature in any shares, debentures or other securities issued by any undertaking.
2.    FINANCIAL MATTERS
2.1    The Last Accounts.  The Last Accounts give a true and fair view of the state of affairs of the Company, and its assets and liabilities as at the Last Accounts Date and of the results 

- 20 -

thereof for the financial year ended on the Last Accounts Date.  Furthermore, the Last Accounts were prepared in accordance with Norwegian GAAP.
2.2    Management Accounts.  The Management Accounts of the Company for all periods ended after the Last Accounts Date to which they relate were properly prepared in all material respects using accounting policies consistent with those adopted in the preparation of the Last Accounts. On the basis of the accounting bases, practices and policies used in their preparation and having regard to the purpose for which they were prepared, the Management Accounts:
		
	(a)
	are not misleading in any material respect;

		
	(b)
	do not materially overstate the value of the assets nor materially understate the liabilities of the Company as at the dates to which they were drawn up; and

		
	(c)
	do not materially overstate the profits or materially understate the losses of the Company in respect of the periods to which they relate.

In the context of this paragraph 2.2, material and materially shall be deemed to refer to facts, matters, circumstances, issues or events which have or the absence of which would have an aggregate cost, benefit or value to the Company of more than NOK 100,000.
2.3    Past transactions in accordance with applicable laws.  Whilst it has been a subsidiary of the Seller, the Company has in all material respects carried out all transactions in accordance with all applicable laws and regulations. To the Seller's knowledge, no such transaction constituted a transfer at an undervalue or an unlawful distribution or unlawful financial assistance by or to the Company.  At no time during the period have the net assets (being the aggregate value of all the assets less the aggregate value of all the liabilities of the relevant company at the relevant time) of the Company been less than the aggregate amount of its share capital and undistributable reserves.
2.4    Position since Last Accounts Date. Since the Last Accounts Date:
		
	(a)
	there has been no Material Adverse Change;

		
	(b)
	the Company has carried on in the ordinary and usual course;

		
	(c)
	the Seller and the Company has not acquired or disposed of, or agreed to acquire or dispose of, any one or more of the assets of the Company; and

		
	(d)
	the Company has not made any changes in terms of employment, including pension fund commitments, which would be inconsistent with the provisions of Schedule 4.

2.5    No undisclosed liabilities. There are no actual or contingent liabilities of the Company (whether or not those liabilities are required to be disclosed or provided for in accordance with generally accepted accounting principles) except for (i) liabilities disclosed or provided for in the Last Accounts (ii) liabilities incurred in the ordinary and usual course of business since the Last Accounts Date which, taken together, do not result in a Material Adverse Change or (iii) liabilities disclosed elsewhere in the Disclosed Information.
2.6    Accounting and other records.  The statutory books, books of account and other records of the Company required to be kept by applicable laws are up-to-date and have been maintained 

- 21 -

in accordance with those laws and relevant generally accepted accounting practices on a proper and consistent basis and comprise in all material respects complete and accurate records of all information required to be recorded.
3.    DEBT POSITION
3.1    Debts owed to the Company.  The Company has not lent any money which is due to be repaid and as at the date of this Agreement has not been repaid to it and the Company does not own the benefit of any debt (whether trading or otherwise) save as set out in the Disclosure Letter. For the avoidance of doubt, the Company shall not have any Inter-Company Debt after Closing, save for the Excluded Inter-Company Debt and Day-to-Day Inter-Company Debt Balances.
3.2    Book debts.  The book debts shown in the Last Accounts have realised their nominal amount less any specific provision for bad or doubtful debts included in the Last Accounts.  The book debts incurred by the Company since the Last Accounts Date and which are outstanding as at the date of this Agreement will realise within 3 months from that date not less than 95 per cent. of their nominal amount.
3.3    Debts owed by the Company.
		
	(a)
	The Company does not owe any Financial Debt other than moneys borrowed from third parties (which do not exceed NOK 100,000 in aggregate and details of which are set out in the Disclosure Letter).

		
	(b)
	The Company has not received any notice to repay any Financial Debt which is repayable on demand.

		
	(c)
	No Financial Debt of the Company has become due and payable, or capable of being declared due and payable, before its normal or originally stated maturity and neither the Company nor any member of the Seller Group has received a demand or other notice requiring any Financial Debt of the Company to be paid or repaid before its normal or originally stated maturity.

		
	(d)
	No event of default or any other event or circumstance which would entitle any person to call for early repayment of any Financial Debt of the Company or to enforce any security given by the Company (or, in either case, any event or circumstance which with the giving of notice would constitute such an event or circumstance) has occurred.

		
	(e)
	Save as set out in the Disclosure Letter, trade debts incurred by the Company in the ordinary course of its business since the Last Accounts Date and outstanding at the date of this Agreement do not exceed NOK 100,000 in aggregate for the Company (and none of them individually exceeds NOK 50,000).

3.4    Third Party Assurances. There are no Third Party Assurances given by or in favour of the Company or in respect of any of its assets or liabilities.
4.    REGULATORY MATTERS
4.1    Licences.  The Disclosed Information contains a complete and correct list of the licences, permissions, authorisations (public or private) or consents (together, Approvals) required for 

- 22 -

carrying on the business of the Company effectively in the places and in the manner in which it is carried on at the date of this Agreement in accordance with all applicable laws and regulations.  These Approvals are in full force and effect in accordance with their terms and have been complied with.  To the Seller's best knowledge, there are no circumstances which indicate that any Approval will or is reasonably likely to be revoked or not renewed, in whole or in part, in the ordinary course of events (whether as a result of the Proposed Transaction or any of the Transaction Documents or otherwise).
4.2    Compliance with laws. The Company has at all times conducted its business and corporate affairs in accordance with its articles of association or other equivalent constitutional documents and in accordance with all applicable laws and regulations in all material respects and there has been no material default order, decree or judgment of any court or any governmental or regulatory authority in any jurisdiction which applies to the Company.
5.    BUSINESS ASSETS
5.1    Business.  The Company owns or has legal valid right to use all assets used in the business of the Company, such assets are free from all Third Party Rights and consists of all assets that are necessary to carry on the business of the Company in the same manner as it was carried on prior to Closing.
5.2    Possession.  The assets used in the business of the Company are in the possession or under control of the Company. The Company has not disposed of, or agreed to dispose of, any such assets.
5.3    Insurances.  The Disclosed Information contains a complete and correct list of the insurance maintained in respect of the Company and its assets, together with details of all claims in excess of NOK 50,000 under any policy of insurance made by the Company in the 3 years before the date of this Agreement.
6.    CONTRACTUAL MATTERS
6.1    Largest customers and suppliers. The Disclosed Information contains a complete and correct list of the 20 largest customers and the 20 largest suppliers of the Company.
6.2    Material Agreements. All agreements with an annual value in excess of NOK 150,000 to which the Company is a party (the Material Agreements) have been disclosed in the Disclosed Information. Each agreement is listed in the appropriate category or categories, in each case specifying the relevant counterparty.
6.3    Key terms Material Agreements:
		
	(a)
	all Material Agreements were concluded on standard market terms and conditions and establish valid and enforceable rights of the Company; 

		
	(b)
	none of the Material Agreements has been terminated; 

		
	(c)
	the Company has not given or received any notice of ordinary or extraordinary termination to or from any counterparty with respect to any Material Agreement; or

- 23 -

		
	(d)
	except as disclosed in the Disclosed Information, none of the Material Agreements may be terminated as a consequence of the entry into and performance of the Transaction Documents; or

		
	(e)
	to the best of the Seller's knowledge, no circumstances are reasonably foreseeable due to which a Material Agreement could be terminated for good cause or otherwise be subject to extraordinary termination.

6.4    Defaults. In the last 24 months prior to the date of this Agreement, neither the Seller nor the Company or any counterparty to any Material Agreement has breached a material obligation under a Material Agreement. To the Seller's best knowledge none of the aforementioned parties is currently in performance default or will be in default as a result of the entry into and performance of the Transaction Document.
7.    LITIGATION AND INVESTIGATIONS
7.1    Except as disclosed in the Disclosed Information and other than any proceedings for collection of debts arising in the ordinary course, the Company is not involved as a party in any litigation, arbitration or contentious administrative proceedings and no such proceedings have been threatened in writing by or against the Company, and to the best of the Seller's knowledge, except as disclosed in the Disclosed Information, there are no circumstances existing which are likely to lead to any such proceedings in respect of the Company.
7.2    No governmental, administrative, regulatory or other official investigation or inquiry concerning the Company or its business or assets is in progress or pending and to the best of the Seller's knowledge there are no circumstances likely to lead to any such investigation or inquiry.
8.    INSOLVENCY ETC.
8.1    Winding up.  No order has been made, petition presented or meeting convened for the winding up of the Seller, the Company or any parent company of them, or for the appointment of any provisional liquidator or in relation to any other process whereby the business is terminated and the assets of the company concerned are distributed amongst the creditors and/or shareholders or other contributors, and there are no cases or proceedings under any applicable insolvency, reorganisation or similar laws in any relevant jurisdiction, and no events have occurred which, under applicable laws, would be reasonably likely to justify any such cases or proceedings.
8.2    Administration and receivership.  No person has taken any step, legal proceeding or other procedure with a view to the appointment of an administrator, whether out of court or otherwise, in relation to the Seller, the Company or any parent company of them, and no receiver (including any administrative receiver) has been appointed in respect of the whole or any part of any of the property, assets and/or undertaking of the Company nor has any such order been made (including, in any relevant jurisdiction, any other order by which, during the period it is in force, the affairs, business and assets of the company concerned are managed by a person appointed for the purpose by a court, governmental agency or similar body).
8.3    Voluntary arrangement etc.  None of the Seller, the Company or any parent company of them has taken any step with a view to a suspension of payments or a moratorium of any indebtedness or has made any voluntary arrangement with any of its creditors or is insolvent or unable to pay its debts as they fall due.

- 24 -

8.4    Registration of charges.  All material charges in favour of the Company required to be registered have been so registered to comply with all necessary formalities as to registration or otherwise in any applicable jurisdiction.
Part B    : IP/IT
1.    Owned IP. The Company does not own any Owned IP.
2.    Business IP.
		
	(a)
	The Company is the sole legal and beneficial owner of all of the rights and interests in, or has validly licensed to it, all of the Business IP.

		
	(b)
	The Business IP, the Intellectual Property Rights that are licensed to the Company by third parties and the Intellectual Property Rights that are acquired by or made available to the Company together comprise all of the Intellectual Property Rights that are required to carry on the business of the Company after Closing as it was carried on at the date of this Agreement and in the 6 months before the date of this Agreement.

3.    Licences. All list of all licences of Intellectual Property Rights granted to, and by, the Company are disclosed in the Disclosed Information. They are in force. So far as the Seller is aware, none of the parties to them is in default and there are no grounds on which they might be terminated. No disputes have arisen or, far as the Seller is aware, are foreseeable in connection with them.
4.    No infringement. None of the operations of or in connection with the Company infringe, or have in the 18 months before the date of this Agreement infringed, the Intellectual Property Rights of a third party. So far as the Seller is aware, no third party is infringing the Business IP.
5.    Confidential Information. All Proprietary Information has been kept confidential and has not been disclosed to third parties except in the ordinary course of business and subject to written confidentiality obligations from the third party.  These confidentiality obligations are in force and, so far as the Seller is aware, have not been breached. For the purposes of this paragraph, Proprietary Information means confidential information (in any form) relating to, held by or used by the Company, including:
		
	(a)
	information relating to Company’s financial or trading position, assets, customers, suppliers, employees, operations, processes, products, plans or market opportunities; 

		
	(b)
	know-how, trade secrets, technical information or software; and 

		
	(c)
	findings, data or analysis derived from anything in sub-paragraphs (a) or (b).

6.    Encumbrances. The Business IP is not subject to any Third Party Right.
7.    Information technology.
		
	(a)
	The Disclosed Information contains a complete and correct list of the IT Systems.

		
	(b)
	All of the IT Systems are owned by, or validly licensed, leased or supplied under IT Contracts to, the Company.  

- 25 -

		
	(c)
	All of the IT Systems are maintained and supported by the Company or by a third party under an IT Contract.

		
	(d)
	Listing of all material IT Contracts have been fairly disclosed in the Data Room.

		
	(e)
	So far as the Seller is aware, there are no circumstances in which the ownership, benefit or right to use the IT Systems might be lost, or rendered liable to termination, by virtue of the entry or the performance of the Transaction Documents.

		
	(f)
	In the 18 months before the date of this Agreement, the IT Systems have not failed to any material extent and so far as the Seller is aware the data that they process has not been corrupted or compromised. The Seller and the Company have implemented measures in accordance with best industry practice designed to prevent the IT Systems from being affected by viruses, bugs or other things that might distort their proper functioning, permit unauthorised access or disable them without the consent of the user.

		
	(g)
	The business of the Company has not adopted a business continuity and disaster recovery plan.

		
	(h)
	The IT Systems that are (i) owned by the Company; (ii) licensed, leased or supplied to the Company under IT Contracts; or (iii) acquired by or made available to the Company under this Agreement and the Transaction Documents together comprise all the IT Systems that are required to carry on the business of the Company after Closing as they were carried on at the date of this Agreement and in the last 6 months.

8.    Data protection. The Company complies, and has at all times within the 24 months before the date of this Agreement complied, with all applicable data protection laws, guidelines and industry standards.  The Company has not received any notice or allegation that the Company has not complied with any applicable data protection laws, guidelines and industry standards.
Part C    : Real Estate
1.    General. The Properties comprise all the land and buildings leased, controlled, occupied or used by the Company.  The information in respect of the Properties set out in the Disclosed Information is accurate in all respects, and the Company is in possession of the original title deeds in respect of the freehold Properties, copies of which are included in the Data Room as Folder 6 (Property).
2.    Possession and occupation.  The Company is in possession of the whole of each of the Properties and save as disclosed in the Disclosed Information no other person is in or actually or conditionally entitled to possession, occupation, use or control of any of the Properties.
3.    Adverse Interests.
		
	(a)
	no Property is subject to any matter which affects the Company’s ability to continue to carry on its existing business from that Property as at present; and

		
	(b)
	the Company is not in breach of any covenant, restriction, condition or obligation (whether statutory or otherwise) which affects the Properties.

- 26 -

4.    Outgoings.  The Properties are not subject to the payment of any outgoings other than the usual rates and taxes and, in the case of leaseholds, rent, insurance rent and service charge.
5.    Leasehold Properties. In relation to those Properties which are leasehold:
		
	(a)
	there are no subsisting notices alleging a material breach of any covenants, conditions and agreements contained in the relevant leases, on the part of the tenant;

		
	(b)
	no rent is currently under review;

		
	(c)
	the Company has not commuted any rent or other payment or paid any rent or other payment ahead of the due date for payment;

		
	(d)
	no surety has been released, expressly or by implication; and

		
	(e)
	no tenancy is being continued after the contractual expiry date whether pursuant to statute or otherwise.

Part D    : Employment
1.    The Disclosed Information contains a complete list of the Employees as per the date of the Agreement, including details of their current respective salaries, position, employee ID, start date and date of birth. In addition, the Data Room contains full and accurate details of:
		
	(a)
	the length of service and notice periods, restrictive covenants and duration, material benefits, 13th month, entitlement to participate in a retirement scheme, share incentive, profit sharing, bonus or other incentive scheme and whether they are on secondment;

		
	(b)
	the standard terms and conditions of employment applicable to the Employees;

		
	(c)
	the terms of all current contracts of employment or engagement of the Key Manager and all other benefits applicable to the Key Manager;

		
	(d)
	the terms of all collective (labour) agreements, employee handbooks, material policies and incentive, profit sharing, bonus or other incentive schemes applicable to any of the Employees (including any payments to be made to any Employee or any of its Affiliates) or which the Company is proposing to introduce, including for the avoidance of doubt details of any contractual severance, retention or change of control arrangement applicable to any of the Employees; 

		
	(e)
	the terms of all agreements with any trade union (whether independent or not), (central) works council, European works council or similar body representing the Employees; and

		
	(f)
	the conditions under which consultants and self-employed individuals are engaged by the Company.

2.    Employment terms. All Employees are employed substantially on the basis of the standard terms and conditions of employment disclosed in the Disclosed Information.

- 27 -

3.    Changes to remuneration. Save as set out in the Disclosure Letter, the Company is not obliged to and has not made any promise to increase or vary any Employee’s salary, bonus, pension benefits or other remuneration and benefits.
4.    No amounts owing. There are no sums or other liabilities owing by the Company to any Employee or former employee of the Company (or their dependants), other than amounts representing reimbursement of expenses in respect of the month preceding the date of this Agreement, wages for the current salary period and accrued holiday pay for the current holiday year. 
5.    No transaction related payments. Save as set out in the Disclosed Information, no contractual or gratuitous payments or other benefits have been made or may become due to be made to any Employee (or their dependants) in connection with the transactions contemplated by this Agreement or otherwise.
6.    Loans. There are no loans or notional loans to any current or former director or Employee or any of their nominees or associates made or arranged by the Company. 
7.    Key Manager. The Key Manager has not given or received notice terminating his employment or engagement, as the case may be, nor have termination proceedings been initiated or is it otherwise to be expected that the Key Manager’s employment or engagement will be terminated within a 12 month period following Closing. 
8.    Secondment of staff. The commercial contracts relating to the secondment of staff entered into by the Company contain adequate financial and factual protection against the risks caused by any specific dismissal rules or laws for the employer in case of termination of the assignment.
9.    Collective dismissals. Within the period of 2 years before the date of this Agreement, the Company has not initiated or completed the implementation of any collective dismissals or implemented or entered into a social plan. There is not and has not been any (collective) severance agreement, social plan or similar plan applicable to the Employees and/or former employees of the Company.
10.    Complaints. There are not currently, nor were there within the period of 2 years before the date of this Agreement any material complaints, disputes or claims, by or in respect of any Employee, former employee and/or employee representative bodies, and there are no matters which could give rise to any such claims. 
11.    Illness. Save as set out in the Disclosure Letter, none of the Employees are currently long-term ill or absent from work due to long-term illness.  
12.    Compliance. The Company has in relation to each of their Employees, former employees and/or employee representative bodies complied in all aspects with all of their obligations under any applicable law, statute regulations, codes of conduct, codes of practice, collective agreements, terms and conditions of employment, orders and/or agreements with third parties and have not incurred any liability to any Employee or former employee in respect of any accident or injury.
Part E    : Retirement Benefits

- 28 -

1.    Other than the Pension Schemes and any state pension arrangement, there is no arrangement for or in respect of any of the Employees or former employees that the Company is or may become liable (whether such liability be actual or contingent, present or future) to provide or contribute to, under or in connection with which benefits are payable on death or retirement (whether accidental or not). 
2.    Up-to-date, accurate and complete copies of the latest (plus subsequent amending documents) pension documents and rules (or other governing documents) and latest participant’s explanatory booklets relating to the Pension Schemes have been disclosed.
3.    All Pension Schemes are now and have at all times been made and duly administered in accordance with their governing documents and all applicable laws, regulations and requirements.
4.    All amounts due and payable on or before the date of Closing by the Company in relation to the Pension Schemes have been or will be duly paid in full on the due dates for such payments.
5.    The Company has not received notice in writing of any action, dispute or claim (other than routine claims for benefits) in relation to any of the Pension Schemes, or otherwise in respect of the provision of (or failure to provide) benefits payable on death or retirement, in respect of any Employee or former employee of the Company which has not been finally settled or terminated, nor are there any, nor have there been any, matters or circumstances that could give rise to any such actions, disputes or claims.
Part F    : Information
1.    All information contained or referred to in the Data Room and Disclosure Letter or which has otherwise been disclosed to the Purchaser or its advisors is true and accurate in all material respects. 
2.    The Seller has disclosed all information and facts relating to the Company, its assets and undertakings (including financial information) which could reasonably be expected to be relevant to a purchaser’s decision to enter into this Agreement and to the Seller's best knowledge there is no other fact, matter or circumstance which renders any such information misleading because of any omission, ambiguity or for any other reason.
Part G    Tax
1.    Last Accounts. All liabilities, whether actual, deferred, contingent or disputed, of the Company for Tax measured by reference to income, profits or gains earned, accrued or received on or before the Last Accounts Date or arising in respect of an Event occurring or deemed to occur on or before the Last Accounts Date are fully provided for or (as appropriate) disclosed in the Last Accounts, and the amount of any Tax asset shown in the Last Accounts does not exceed the amount actually available.  All other warranties relating to specific Tax matters set out in this Schedule are made without prejudice to the generality of this paragraph.
2.    Position since Last Accounts Date. Since the Last Accounts Date the Company has not been involved in any transaction which has given or may give rise to a liability to Tax on the Company (or would have given or might give rise to such a liability but for the availability of 

- 29 -

any Relief) other than Tax in respect of normal trading income or receipts of the Company arising from transactions entered into by it in the ordinary course of business.
3.    Payment of Taxes. All Tax due and payable by any the Company prior to the date hereof has been paid in full.
4.    Continuing commitments. All sums payable under any obligation incurred by the Company prior to Closing and which will continue to bind the Company after Closing have been and will continue to be deductible for the purposes of Corporate Tax.
5.    Returns etc. The Company has duly, and within any appropriate time limits,  made all returns, given all notices and supplied all other information required to be supplied to all relevant Tax Authorities and has maintained all records required to be maintained for Tax purposes; all such information was and remains complete and accurate in all material respects and all such returns and notices were and remain complete and accurate in all material respects and were made on the proper basis and do not, and so far as the Seller is aware are not likely to, reveal any transactions which may be the subject of any dispute with, or any enquiry raised by, any Tax Authority.
6.    Disputes, investigations. Save as set out in the Disclosure Letter, the Company is not involved in any current dispute with any Tax Authority or is or has in the last five years been the subject of any investigation, enquiry, audit or non-routine visit by any Tax Authority.  So far as the Seller is aware in relation to the Company there is no planned investigation, enquiry, audit or non-routine visit by any Tax Authority and there are no facts which might cause such an investigation, enquiry, audit or non-routine visit to be instituted.
7.    Penalties, interest, security. Within the past five years, the Company or any director or officer of the Company (in his capacity as such) has not paid or become liable to pay, and there are no circumstances by reason of which it or they may become liable to pay to any Tax Authority, any penalty, fine, surcharge or interest in respect of Tax (including in respect of any failure to make any return, give any notice or supply any information to any relevant Tax Authority, or any failure to keep or preserve any records or to pay Tax on the due date for payment), or had been criminally convicted of any offence related to Tax.  The Company has not within the past five  years been required to provide any security in respect of any amount of Tax and no asset of the Company is subject to any charge or power of sale in favour of any Tax Authority.
8.    Rulings etc. No transaction in respect of which any consent, ruling, confirmation or clearance (each a Ruling) was required or sought from any Tax Authority has been entered into or carried out by the Company without such Ruling having first been properly obtained.  All information supplied to any Tax Authority in connection with any such Ruling fully and accurately disclosed all facts and circumstances material to the giving of such Ruling.  Any transaction for which such Ruling was obtained has been carried out only in accordance with the terms of such Ruling and the application on which the Ruling was based and at a time when such Ruling was valid and effective.  No facts or circumstances have arisen since any such Ruling was obtained which would cause the Ruling to become invalid or ineffective.
9.    Special arrangements. No Tax Authority has operated or agreed to operate any special arrangement (being an arrangement which is not based on relevant legislation or any published practice) in relation to the Company's affairs.
10.    Withdrawal etc. of Reliefs after Closing.  No Relief has been claimed by and/or given to the Company, or taken into account either in determining or eliminating any provision for 

- 30 -

Tax or deferred tax in the Last Accounts or in determining any Tax asset in the Last Accounts, which could or might be effectively withdrawn, postponed, restricted or otherwise lost as a result of the sale and purchase hereunder or any other Event or circumstance occurring or arising at any time after the Last Accounts Date.
11.    Deemed disposals etc. of assets and liabilities.  The implementation of the transactions contemplated by this Agreement will not give rise to any deemed disposal or realisation by the Company of any asset or liability for any Tax purpose.
12.    Withholdings. The Company has made all deductions and retentions of or on account of Tax as it was or is obliged or entitled to make and all such payments of or on account of Tax as should have been made to any Tax Authority in respect of such deductions or retentions.

- 31 -

SCHEDULE 2     
 
LIMITATIONS ON LIABILITY
1.    If the Purchaser is notified or becomes aware of a fact, circumstance or event which may lead to or which has led to a Claim, the Purchaser shall inform the Seller thereof as soon as possible, however, not later than within 45 days of the Purchaser being so notified or having become so aware, stating, as far as the Purchaser is aware at that time, the nature of the fact, the circumstance or the event and the damages expected or sustained. Failure to notify the Seller of a Claim within the 45 day period referred to above shall not affect the rights of the Purchaser except to the extent the Seller is materially prejudiced by such failure.
2.    Time Limits.  The Seller shall not be liable for any Claim unless the Seller receives from the Purchaser written notice containing such details as are then available of the matter giving rise to the Claim:
		
	(a)
	in the case of a Claim arising from the breach of any Fundamental Warranty (a Fundamental Warranty Claim), before the date that falls 5 years after the Closing; 

		
	(b)
	in the case of a Tax Claim, before the date that falls six months after the expiry of the period set by the relevant statute of limitation in the case of such Tax Claim; and

		
	(c)
	in the case of any other Claim, before the date that falls 18 months after the Closing.

3.    Thresholds for Claims.  The Seller shall not be liable for any single Claim for breach of Warranty unless:
		
	(a)
	the amount of the liability pursuant to that single Claim (and, for these purposes, a number of Claims arising out of the same or similar subject matter, facts, events or circumstances may be aggregated and form a single Claim) exceeds 0.05% of the Debt Free/Cash Free Price (in which case the Purchaser shall be able to claim the full amount and not only the excess); and

		
	(b)
	the aggregate amount of the liability of the Seller for all Claims not excluded by sub paragraph (a) above exceeds 0.5% of the Debt Free/Cash Free Price (in which case the Purchaser shall be able to claim the full amount and not only the excess).

4.    Maximum limit for all Claims.  The maximum aggregate amount of the liability of the Seller for all Escrow Claims, Client Adjustment Amount claims and Claims, other than any Fundamental Warranty Claims, Tax Claims or any Claims under the Tax Covenant, shall not exceed a sum of 25% of the Debt Free/Cash Free Price.
5.    Source of remedy. The parties acknowledge that the Escrow Amount aims to provide coverage to the Purchaser in relation to the Claims. Subject to the limitations set out in this Agreement, the Seller and the Purchaser agree and acknowledge that the Escrow Amount shall be recoverable directly from the Escrow Account, such in accordance with the terms of the Escrow Agreement. 
The Purchaser shall have direct recourse against the Seller for any Claims which exceed the Escrow Amount, provided that such Claim(s) are within the Seller's maximum liability as set out in paragraph 4 of this Schedule (to the extent applicable).

- 32 -

6.    Matters disclosed. The Seller shall not be liable for any Claim if and to the extent that the fact, matter, event or circumstance giving rise to such Claim is fairly disclosed in the Disclosure Letter. For this purpose 'fairly disclosed' means any fact, matter, event or circumstance that was disclosed in a reasonably clear and understandable form so as to allow the Purchaser and its advisors to understand the nature and scope of the fact, matter, event or circumstance so disclosed and the significance of such fact, matter, event or circumstance for the Company, its business or assets.
7.    Matters specifically provided or reserved for in the Closing Statement. The Seller shall not be liable for any Claim if and to the extent that the fact, matter, event or circumstance giving rise to the Claim is specifically provided or reserved for (and not released prior to Closing) in the Closing Statement.
8.    Contingent liabilities.  If any Claim for breach of Warranty is based upon a liability which is contingent only, the Seller shall not be liable to make payment unless and until such contingent liability gives rise to an obligation to make a payment.  This is without prejudice to the right of Purchaser to give notice of the Claim in accordance with paragraph 2 and to issue and serve proceedings in respect of it before such time.  For the avoidance of doubt, the fact that the liability may not have become an actual liability by the relevant date provided in paragraph 2 shall not exonerate the Seller in respect of any Claim properly notified before that date.
9.    No liability for Claims arising from acts or omissions of Purchaser.  The Seller shall not be liable for any Claim to the extent that it would not have arisen but for any voluntary act, omission or transaction (other than any voluntary act, omission or transaction which is either: (i) contemplated by this Agreement; or (ii) carried out pursuant to a legally binding commitment created on or before Closing) carried out or permitted:
		
	(a)
	after Closing, by the Purchaser or any member of the Purchaser Group (or its respective directors, employees or agents or successors in title or any of its Affiliates) outside the ordinary and usual course of business of the business of the Company as at Closing and where such person had actual knowledge that such act, omission or transaction would or would be likely to give rise to a Claim and a reasonable alternate course of action was available which would not be expected to give rise to a Claim; or 

		
	(b)
	before Closing, by any member of the Seller Group: (i) at the written direction or request; or (ii) with the written consent, of the Purchaser or any member of the Purchaser Group.

10.    Insured Claims.  The Seller’s liability in respect of any Claim shall be reduced by an amount equal to any loss or damage to which the Claim related which has actually been recovered under a policy of insurance (after deducting any costs incurred in making such recovery including the amount of any excess or deductible and any Tax incurred as a result of the receipt of such recovery and taking into account any increased premium).
11.    Recovery from third party after payment from Seller. Where the Seller has made a payment to the Purchaser in relation to any Claim and the Purchaser or any member of the Purchaser Group recovers (whether by insurance, payment, discount, credit, relief or otherwise) from a third party a sum which is referable to the matter giving rise to the Claim or obtains any relief, saving or benefit which is so referable, the Purchaser or relevant member of the Purchaser Group shall pay to the Seller as soon as practicable after receipt:

- 33 -

		
	(a)
	an amount equal to the amount recovered from the third party (net of Taxation and less any reasonable costs of recovery) or the value of the relief, saving or benefit obtained, calculated by reference to the amount saved (less any reasonable costs of recovery); or

		
	(b)
	if the amount referred to in subparagraph (a) exceeds the amount paid by the Seller to the Purchaser or member of the Purchaser Group in respect of the relevant Claim, such lesser amount as shall have been so paid by the Seller.

12.    No liability for legislation or changes in rates of Tax or accounting principles. The Seller shall not be liable for any Claim if and to the extent it is attributable to, or the amount of such Claim is increased as a result of, any: (i) legislation not in force as at Closing; (ii) change of law (or any change in interpretation on the basis of case law), regulation, directive, requirement or administrative practice having the force of law; (iii) change in the rates of Taxation in force as at Closing, or (iv) a change after Closing in the accounting bases on which the Purchaser values the Company.
13.    No double recovery.  The Purchaser shall be entitled to make more than one Claim arising out of the same subject matter, fact, event or circumstance, but shall not be entitled to recover damages or obtain payment, reimbursement, restitution or indemnity more than once in respect of any one liability, loss, cost, shortfall, damage or deficiency regardless of whether more than one Claim arises in respect of it.

- 34 -

SCHEDULE 3     
 
PURCHASER WARRANTIES
1.    The Purchaser is validly incorporated, in existence and duly registered under the laws of its jurisdiction and has full power to conduct its business as conducted at the date of this Agreement.
2.    The Purchaser has obtained all corporate authorisations and (other than to the extent relevant to the Conditions) all other governmental, statutory, regulatory or other consents, licences, authorisations, waivers or exemptions required to empower it to enter into and perform its obligations under this Agreement where failure to obtain them would adversely affect to a material extent its ability to enter into and perform its obligations under this Agreement.
3.    Entry into and performance by each member of the Purchaser Group of this Agreement and/or any Transaction Document to which it is a party will not: (i) breach any provision of its constitutional documents; or (ii) (subject, where applicable, to fulfilment of the Conditions) result in a breach of any laws or regulations in its jurisdiction of incorporation or of any order, decree or judgment of any court or any governmental or regulatory authority, where any such breach would adversely affect to a material extent its ability to enter into or perform its obligations under this Agreement and/or any Transaction Document to which it is a party.
4.    The Purchaser has available commitments or available loan facilities which will at Closing provide in immediately available funds the necessary cash resources to pay the Initial Price and meet its other obligations under this Agreement (including in respect of the Final Price).

- 35 -

SCHEDULE 4     
 
CONDUCT OF THE COMPANY PRE‐CLOSING
1.    From the date of this Agreement until Closing, the Seller shall ensure that (except with the Purchaser’s written consent, such consent not to be unreasonably withheld or delayed):
		
	(a)
	the affairs of the Company are conducted only in the ordinary and usual course and the Company will not make or agree to make any payment other than routine payments in the ordinary and usual course of business;

		
	(b)
	all reasonable steps are taken to preserve and protect the assets of the Company and to preserve and retain its goodwill (including the existing relationships with customers and suppliers);

		
	(c)
	subject to clause 20 (Confidentiality), the Purchaser’s representatives shall be allowed such access as is reasonably requested, upon reasonable notice and during Working Hours, to (i) the books and records of the Company (including all statutory books, minute books, leases, contracts, supplier lists and customer lists), with the right to take copies and (ii) the premises used by, and management of, the Company;

		
	(d)
	neither the Company nor any other member of the Seller Group does, allows or procures any act or omission which would constitute or give rise to a breach of any Warranty if the Warranties were repeated at any time before Closing by reference to the facts and circumstances then existing as if references in the Warranties to the date of this Agreement were references to the relevant date;

		
	(e)
	all relevant information which comes to its notice or that of any other member of the Seller Group in relation to any fact or matter (whether existing on or before the date of this Agreement or arising afterwards) which may constitute a breach of any Warranty if the Warranties were to be repeated on or at any time before Closing by reference to the facts and circumstances then existing as if references in the Warranties to the date of this Agreement were references to the relevant date, is promptly disclosed to the Purchaser;

		
	(f)
	the Company does not declare, authorise, make or pay any dividend or other distribution (whether in cash, stock or in kind) or reduces, purchases or redeems an part of its paid-up share capital;

		
	(g)
	the Company does not (i) create, allot or issue or agree to create, allot, or issue any share or loan capital or other security or (ii) grant any option over or right to subscribe for any share or loan capital or other security;

		
	(h)
	neither the Company nor any member of the Seller Group sells or purchases or disposes of any interest in any share or loan capital or other security of the Company;

		
	(i)
	that no agreements are entered into between the Company and any member of the Seller Group or any other business unit of the Seller, and in any event that all transactions between the Company and members of the Seller Group or any other business unit of the Seller must take place on arm’s length terms;

- 36 -

		
	(j)
	no changes are made in terms of employment (including pension fund commitments) other than those required by law;

		
	(k)
	except to replace employees on substantially the same terms, no member of the Seller Group shall employ or agree to employ any new persons fully or part time in the business of the Company or dismiss any existing employees (except for incompetence or gross misconduct or other reasonable cause justifiable in law);

		
	(l)
	no member of the Seller Group permits any of its insurances in respect of or relating to the Company, its business or assets to lapse or do or permit anything that would make any such insurance policy void or unenforceable;

		
	(m)
	no Key Manager is given notice of termination of employment or is dismissed; and

		
	(n)
	no action is taken by any member of the Seller Group or the Company, which is inconsistent with the provisions of this Agreement or implementation of the Proposed Transaction.

2.    Pending Closing, the Seller shall ensure that no member of the Seller Group or the Company agrees to or permits (except with the Purchaser’s written consent, such consent not to be unreasonably withheld or delayed):
		
	(a)
	the reorganisation of the Company, or the discontinuance of any part of its business;

		
	(b)
	any failure to settle in accordance with the payment procedures and timescales normally observed by the Company any debts incurred by the Company in the normal course of trading;

		
	(c)
	any entry into or termination of any contract or arrangement, including any funding agreement or the making of any bid, tender, proposal or offer likely to lead to any such contract or arrangement, with respect to any bid, tender, proposal or offer for any contract or arrangement with a value exceeding an amount of NOK 250,000 per annum;

		
	(d)
	the entry into of any funding agreement, the giving of any guarantee, indemnity or other agreement to secure an obligation of a third party;

		
	(e)
	entry into or modification of any Third Party Assurance;

		
	(f)
	the institution or settlement of any litigation in respect of the Company, its business or assets;

		
	(g)
	the entry into or material modification of any agreement with any trade union or other body representing its Employees or relating to any works council;

		
	(h)
	the creation of any Third Party Right over the Shares or the shares or assets of the Company, or any of them;

		
	(i)
	the granting, modification or termination of any rights, or entry into any agreement, relating to the IT Systems or Business IP or allowing any of the Seller Group’s rights relating to the IT Systems or Business IP to lapse;

		
	(j)
	the acquisition or disposal of any material asset or material stocks;

- 37 -

		
	(k)
	in connection with the Properties (i) the termination or serving of any notice to terminate, surrender or accept any surrender of or waiving the terms of any lease, tenancy or licence and (ii) entering into or varying any agreement, lease, tenancy, licence or other commitment in each case which is material in the context of the Company.

- 38 -

SCHEDULE 5     
 
CLOSING ARRANGEMENTS
Part A    : Seller Obligations
1.    At or before Closing, the Seller shall deliver or ensure that there is delivered to the Purchaser (or made available to the Purchaser’s satisfaction):
		
	(a)
	all necessary documents, duly executed or endorsed where so required, to enable title in all the Shares to pass fully and effectively into the name of the Purchaser or its nominee, including any documents, such as necessary waivers of pre-emption rights or other consents, as may be required to enable the Purchaser and/or its nominee to be registered as the holder of the Shares;

		
	(b)
	a written notification in accordance with section 4-10 of the Norwegian Private Limited Liability Companies Act, duly executed on behalf of the Company, confirming that the Purchaser is entered into the Company’s Shareholders Register as owner of the Shares, accompanied by a certified true copy of the Shareholders Register showing that the Shares are registered in the name of the Purchaser free of Third Party Rights;

		
	(c)
	minutes from the meeting of the board of directors of the Company evidencing that the board of directors has passed an unconditional resolution to approve the transfer of the Shares from the Seller to the Purchaser;

		
	(d)
	minutes from the meeting of the board of directors of the Company evidencing that that board of directors has resolved to convene an extraordinary general meeting in order to accept any resignations from the directors as required in terms of this Schedule 5 and (i) elect new members to the board of directors of the Company as nominated by the Purchaser and (ii) appoint new auditors of the Company as selected by the Purchaser,;

		
	(e)
	in respect of the Company, the certificate of registration, shareholder register and the articles of association;

		
	(f)
	a letter of resignation in the Agreed Form duly executed by such directors of the Company as the Purchaser may notify to the Seller prior to Closing in respect of their directorships of the Company;

		
	(g)
	a copy of a resolution of the board and/or supervisory board (as necessary to provide valid authorisation) of directors of the Seller (or, if required by the law of its jurisdiction or its articles of association, by-laws or equivalent constitutional documents, of its shareholders) authorising the execution of and the performance by the relevant company of its obligations under this Agreement and each of the Transaction Documents to be executed by it;

		
	(h)
	a DVD or memory stick, as the case may be, containing copies of the documents and other information relating to the Company made available by the Seller to the Purchaser in the Data Room; and

		
	(i)
	a certificate, signed by a duly authorised representative of the Seller, confirming that the Warranties are true and accurate immediately before Closing.

- 39 -

Part B    : Purchaser Obligations
1.    At Closing, the Purchaser shall:
		
	(a)
	deliver or ensure that there is delivered to the Seller (or made available to the Seller’s satisfaction) a copy of a resolution (certified by a duly appointed officer as true and correct) of the board and/or supervisory board (as necessary to provide valid authorisation) of directors of the Purchaser (or, if required by the law of its jurisdiction or its articles of association, by-laws or equivalent constitutional documents, of its shareholders) authorising the execution of and the performance by the relevant company of its obligations under this Agreement and each of the Transaction Documents to be executed by it; 

		
	(b)
	deliver documentary evidence of the notification to the Company of the purchase of the Shares in accordance with section 4-12 of the Private Limited Liability Companies Act;

		
	(c)
	(immediately after Closing) procure that an extraordinary general meeting of the Company accepts any resignations from the Company as required in terms of this Schedule 5 and (i) elects new members to the board of directors of the Company as nominated by the Purchaser, and (ii) appoints new auditors of the Company as selected by the Purchaser;

		
	(d)
	pay to the Seller the Initial Price in accordance with clause 2.2;

		
	(e)
	pay the Excluded Inter-Company Debt to the Company on behalf of and for the full release of the Seller Group's liability in respect of this amount towards the Company on Closing; and

		
	(f)
	pay the Escrow Amount to the Escrow Agent in accordance with clause 2.2.

Part C    : Inter‐Company Debt
At or before Closing the Seller and the Purchaser shall carry out those of their respective obligations under Schedule 8 (Inter-Company Debt) required to be performed at or before Closing.
Part D    : General
1.    The Seller and the Purchaser shall negotiate in good faith with a view to agreeing before the Closing Date the final form of any Transaction Document which is not in Agreed Form at the date of this Agreement.  If not so agreed by the Closing Date, the Transaction Document shall be in the form specified by the Purchaser, provided it is consistent with the terms of this Agreement.
2.    At or before Closing, the Seller and the Purchaser shall execute and deliver to each other (or procure that their relevant Affiliates shall execute and deliver) the following other documents in the Agreed Form required by this Agreement to be executed on or before Closing, namely:
		
	(a)
	the Trademark License Agreement;

- 40 -

		
	(b)
	the Escrow Agreement; and

		
	(c)
	the Transitional Services Agreement.

3.    If any document listed in this Schedule 5 is required to be notarised, the parties shall execute such document at a location notified by the Purchaser to the Seller at least 2 Business Days before Closing where a notary with the required qualification will be present.
4.    All documents and items delivered at Closing shall be held by the recipient to the order of the person delivering them until such time as Closing shall be deemed to have taken place. Simultaneously with:
		
	(a)
	delivery of all documents and all items required to be delivered at Closing (or waiver of its delivery by the person entitled to receive the relevant document or item);

		
	(b)
	confirmation from the Purchaser’s bank that the cash transfer request in respect of the electronic funds transfer to the Escrow Account of the Escrow Amount has been confirmed, including a SWIFT or IBAN, as the case may be, message evidencing the cash transfer;

		
	(c)
	confirmation from the Purchaser’s bank that the cash transfer request in respect of the electronic funds transfer to the designated account of the Company of the Excluded Inter-Company Debt has been confirmed, including a SWIFT or IBAN, as the case may be, message evidencing the cash transfer; and

		
	(d)
	confirmation from the Purchaser’s bank that the cash transfer request in respect of the electronic funds transfer to the Seller’s Bank Account of the Initial Price has been confirmed, including a SWIFT or IBAN, as the case may be, message evidencing the cash transfer,

the documents and items delivered in accordance with this Schedule shall cease to be held to the order of the person delivering them and Closing shall be deemed to have taken place.

- 41 -

SCHEDULE 6     
 
TRADEMARK LICENSE AGREEMENT
Please see attached

- 42 -

SCHEDULE 7     
 
TRANSITIONAL SERVICES AGREEMENT
Please see attached

- 43 -

SCHEDULE 8     
 
INTER-COMPANY DEBT
Inter‐Company Debt
1.    In relation to Inter‐Company Debt:
		
	(a)
	the Seller shall procure that any Inter-Company Debt which is owed at and/or before Closing by the Company is paid to the relevant member of the Seller Group on or before the Closing Date; and

		
	(b)
	the Seller shall procure that any Inter-Company Debt which is owed at and/or before Closing by any member of the Seller Group is paid to the Company on or before the Closing Date,

so that, for the avoidance of doubt, there shall be no Inter-Company Debt outstanding at Closing, save for the Day-to-Day Inter-Company Debt Balances. . For the avoidance of doubt, the Purchaser shall pay the Excluded Inter-Company Debt to the Company on behalf of and for the full release of the Seller Group's liability in respect of this amount towards the Company on Closing in accordance with the provisions of Schedule 5.
As part of the Closing Statement the Purchaser shall present an overview of the Day-to-Day Inter-Company Debt Balances, including the net amount of the Day-to-Day Inter-Company Debt Balances, to be settled by the Seller Group or the Company (as the case may be), in accordance with the procedure set out in Part C of Schedule 9. 

- 44 -

SCHEDULE 9     
 
POST‐CLOSING FINANCIAL ADJUSTMENTS
Part A    : Preliminary
1.    In preparing the Closing Statement:
		
	(a)
	the items and amounts to be included in the calculation of External Debt, Cash and Working Capital for the purposes of the Closing Statement shall be identified by applying the relevant definition in Schedule 14 (subject, where applicable, to the provisions of Part A of this Schedule) and any adjustments made pursuant to Schedule 13;

		
	(b)
	the Closing Statement shall be prepared by using the same format and principles as for the calculation of the Initial Price as per Part A of Exhibit 1, save for the calculation of the Day-to-Day Inter Company Debt, which shall be prepared in accordance with Schedule 8.

2.    For the purposes of calculating Day-to-Day Inter-Company Debt, External Debt, Cash and Working Capital for the Company, any amounts which are to be included in any such calculation which are expressed in a currency other than NOK shall be converted into NOK at the Exchange Rate as at the Closing Date.
3.    If any insured event occurs after the date of this Agreement but before Closing in relation to any asset of the Company which needs to be replaced or restored in order for the relevant business to continue to be conducted in the ordinary course, then, to the extent that a member of the Seller Group recovers any proceeds or is entitled to a receivable under a policy but the relevant asset is not replaced or restored before Closing, any such proceeds shall be deducted from Cash and any such receivable shall not be included in Working Capital and, accordingly, shall not, in each case, be included in the Closing Statement.
Part B    : Specific Accounting Treatments
1.    Information available for Closing Statement.  Information available up until Closing and the date of agreement or determination of the Closing Statement shall be taken into account insofar as it provides evidence of the state of affairs of the Company at Closing.  The Closing Statement will reflect the position of the Company as at Closing and will not take into account the effects of any post‐Closing reorganisations or, in any way, the post‐Closing intentions or obligations of the Purchaser.
2.    No re-appraisal of asset values.  The Closing Statement shall not re‐appraise the value of any of the assets of the Company as a result of the change in their ownership (or any changes in the business of the Company since Closing following such change in ownership) except only as specifically set out in this Schedule.
Part C    : Closing Statement

- 45 -

1.    The Purchaser shall, or shall procure that the Purchaser’s accountants shall, after Closing prepare a draft statement (the Closing Statement) showing (i) the External Debt, Cash and Working Capital of the Company and the (ii) Day-to-Day Inter-Company Debt.  The portion of the Closing Statement with regard to item (i) shall be in the form set out in Exhibit 1 and incorporate separate statements in the form set out in that Exhibit showing the calculation of the Working Capital of the Company.  The portion of the Closing Statement with regard to item (ii) shall be in accordance with Schedule 8. The Purchaser shall deliver the draft Closing Statement to the Seller within 30 days after Closing.
2.    The Seller shall notify the Purchaser in writing (an Objection Notice) within 15 days after receipt whether or not it accepts the draft Closing Statement for the purposes of this Agreement.  An Objection Notice shall set out in detail the Seller’s reasons for such non‐acceptance and specify the adjustments which, in the Seller’s opinion, should be made to the draft Closing Statement in order for it to comply with the requirements of this Agreement.  Except for the matters specifically set out in the Objection Notice, the Seller shall be deemed to have agreed the draft Closing Statement in full.
3.    If the Seller serves an Objection Notice in accordance with paragraph 2, the Purchaser and the Seller shall use all reasonable efforts to meet and discuss the objections of the Seller and to agree the adjustments (if any) required to be made to the draft Closing Statement, in each case within 15 days after receipt by the Purchaser of the Objection Notice.
4.    If the Seller is satisfied with the draft Closing Statement (either as originally submitted or after adjustments agreed between the Seller and the Purchaser pursuant to paragraph 3) or if the Seller fails to give a valid Objection Notice within the 15 day period referred to in paragraph 2, then the draft Closing Statement (incorporating any agreed adjustments) shall constitute the Closing Statement for the purposes of this Agreement.
5.    If the Seller and the Purchaser do not reach agreement within 15 days of receipt by the Purchaser of the Objection Notice, then the matters in dispute may be referred (on the application of either the Seller or the Purchaser) for determination by an independent firm of chartered accountants of international standing as the Seller and the Purchaser shall agree or, failing agreement, by the President for the time being of the Association of Accountants in Norway (the Firm).  The Firm shall be requested to make its decision within 45 days (or such later date as the Seller, the Purchaser and the Firm agree in writing) of confirmation and acknowledgement by the Firm of its appointment.  The following provisions shall apply once the Firm has been appointed:
		
	(a)
	the Seller and Purchaser shall each prepare a written statement within 15 days of the Firm’s appointment on the matters in dispute which (together with the relevant supporting documents) shall be submitted to the Firm for determination and copied at the same time to the other;

		
	(b)
	following delivery of their respective submissions, the Purchaser and the Seller shall each have the opportunity to comment once only on the other’s submission by written comment delivered to the Firm not later than 10 days after receipt of the other’s submission and, thereafter, neither the Seller nor the Purchaser shall be entitled to make further statements or submissions except insofar as the Firm so requests (in which case it shall, on each occasion, give the other party (unless otherwise directed) 10 days to respond to any statements or submission so made);

- 46 -

		
	(c)
	in giving its determination, the Firm shall state what adjustments (if any) are necessary, solely for the purposes of this Agreement, to the draft Closing Statement in respect of the matters in dispute in order to comply with the requirements of this Agreement and to determine finally the Closing Statement;

		
	(d)
	the Firm shall act as an expert (and not as an arbitrator) in making its determination which shall, in the absence of manifest error, be final and binding on the parties and, without prejudice to any other rights which they may respectively have under this Agreement, the parties expressly waive, to the extent permitted by law, any rights of recourse they may otherwise have to challenge it.

6.    The Seller and the Purchaser shall each be responsible for their own costs in connection with the preparation, review and agreement or determination of the Closing Statement.  The fees and expenses of the Firm shall be borne equally between the Seller and the Purchaser or in such other proportions as the Firm shall determine.
7.    To enable the Purchaser to meet its obligations under this Schedule 9, where relevant, each party shall provide to the other party and the other party’s accountants reasonably required access to the books and records, employees and premises of the Company and, where relevant, if at all, of that party for the period from the Closing Date to the date that the draft Closing Statement is agreed or determined.  The parties shall co-operate fully with one another and shall permit the other party and/or the other party’s accountants to take copies (including electronic copies) of the relevant books and records and shall provide all assistance reasonably requested by the other party to facilitate the preparation of the Closing Statement.
8.    When the Closing Statement has been agreed or determined in accordance with the preceding paragraphs, then the amounts shown in the Closing Statement as the Working Capital, External Debt and Cash for the Company shall be final and binding for the purposes of this Agreement.
Part D    : Financial Adjustments
1.    When the Closing Statement has been finally agreed or determined in accordance with this Schedule 9, the following adjustments shall be made to the Initial Price.
Working Capital
2.    In relation to Working Capital:
		
	(a)
	if the aggregate Working Capital of the Company is greater than the Estimated Working Capital, then the Purchaser shall pay an amount equal to the difference to the Seller; or

		
	(b)
	if the aggregate Working Capital of the Company is less than the Estimated Working Capital, then the Seller shall pay an amount equal to the difference to the Purchaser.

External Debt
3.    In relation to External Debt:
		
	(a)
	if the aggregate External Debt of the Company is less than the Estimated External Debt, then the Purchaser shall pay an amount equal to the difference to the Seller; or

- 47 -

		
	(b)
	if the aggregate External Debt of the Company is greater than the Estimated External Debt, then the Seller shall pay an amount equal to the difference to the Purchaser.

Cash
4.    In relation to Cash:
		
	(a)
	if the aggregate Cash of the Company is greater than the Estimated Cash, then the Purchaser shall pay an amount equal to the difference to the Seller; or

		
	(b)
	if the aggregate Cash of the Company is less than the Estimated Cash, then the Seller shall pay an amount equal to the difference to the Purchaser.

Day-to-Day Inter-Company Debt
5.    In relation to Day-to-Day Inter Company Debt:
		
	(a)
	if the net Day-to-Day Inter Company Debt is an Inter-Company Payable, then the Purchaser shall pay to the Seller an amount equal to that amount owed by the Company; or

		
	(b)
	if the net Day-to-Day Inter Company Debt is an Inter-Company Receivable, then the Seller shall pay to the Purchaser an amount equal to that amount owed by the Seller Group

and the relevant net Day-to-Day Inter Company Debt shall be treated as discharged to the extent of that payment. 
General
6.    Any payment required to be made pursuant to any of paragraphs 2 to 5 inclusive of this Part D shall be paid by the Seller or the Purchaser (as the case may be) together with an amount equal to interest on such payment at LIBOR for the period from (but excluding) the Closing Date to (and including) the due date for payment thereof, calculated on a daily basis.
7.    The Seller and Purchaser agree that, once the Closing Statement has been agreed or determined in accordance with the provisions of Part C of this Schedule 9, the sums which each is respectively obliged to pay pursuant to this Part D shall be aggregated and set off against each other.  Whichever of the Seller or Purchaser is then left with any payment obligation under this Part D shall make the applicable payment(s) within 5 Business Days of the date on which the Closing Statement is agreed or so determined.  Any such payment shall be made in accordance with the provisions of clause 18.1 or 18.2 of this Agreement, as the case may be.

- 48 -

SCHEDULE 10     
 
CLIENT ADJUSTMENT AMOUNT
1.    For the purposes of this Schedule, the following terms shall have the following meaning:
		
	(a)
	Client has the meaning given in clause 2 below;

		
	(b)
	Client Contract means, with respect to each Client as at the date hereof, the terms and conditions on the basis of which the Company delivers services to the relevant Client.

		
	(c)
	Determination Date means the date that falls 12 months after the Closing Date.

		
	(d)
	Leaving Client means a Client that:

		
	(i)
	actually terminates the applicable Client Contract(s) due to a change of control provision in their agreement with the Company;

		
	(ii)
	delivers to the Seller, the Purchaser or the Company a written notice of termination of any applicable Client Contract(s) due to a change of control provision in their agreement with the Company; or

		
	(iii)
	in the case of Statens vegvesen and/or Komplett Service AS, actually terminates or otherwise withdraws the applicable Client Contract(s) or delivers to the Seller, the Purchaser or the Company a written notice of termination or withdrawal of the applicable Client Contract(s),

provided that a Client shall not be a Leaving Client if the applicable Client Contract expires or is terminated, or notice of termination of the applicable Client Contract is received, as a result of a failure by the Purchaser or, after the Closing, the Company, to properly perform its obligations under the relevant Client Contract. To the extent that a Client terminates, gives notice of termination or otherwise withdraws, as described above, only a portion of its Client Contracts or services with the Company (and not all or the entirety of its Client Contracts with the Company), that Client shall be deemed to be a Leaving Client on a pro rata basis, measured by reference to those terminated or withdrawn Client Contract(s) or services and its remaining Client Contract(s) and services with the Company, and the remaining provisions of this Schedule 10 shall apply mutatis mutandis.
2.    Exhibit 12 to the Disclosure Letter contains (i) a true, correct and complete list of the top 20 clients of the Company as at the date hereof (the Clients) and (ii) an amount, in NOK, corresponding to the agreed value of each Client (the Client Value). The applicable Client Value for the relevant Client shall be reduced by the Gross Profit that the Company has actually billed to the relevant Client as from the date of Closing up to the date of termination or withdrawal, as the case may be, of that Client.
3.    The parties hereby agree that by no later than the 15th Business Day after the Determination Date, the Purchaser shall deliver to the Seller a notice (Client Adjustment Notice) which:
		
	(a)
	shall indicate details as to whether – between the Closing Date and the Determination Date – one or more Clients have become a Leaving Client;

- 49 -

		
	(b)
	shall attach, where available, copies of the relevant notices or other writing from a relevant Client showing that such Client qualifies as a Leaving Client; and

		
	(c)
	shall indicate the calculation of the Client Adjustment Amount, which shall be equal to the sum of the Client Values of each of the Leaving Clients.

4.    Upon receipt of the Client Adjustment Notice, the following applies: 
		
	(a)
	The Seller shall notify the Purchaser in writing (an Objection Notice) within 15 days after receipt whether or not it accepts the Client Adjustment Amount as set out in the Client Adjustment Notice, specifying the Seller’s objections.

		
	(b)
	The Seller and the Purchaser shall use all reasonable efforts to meet and discuss the objections of the Seller and to agree on the Client Adjustment Amount within 15 days after receipt by the Seller of the Objection Notice.

		
	(c)
	If the Seller is satisfied with the Client Adjustment Amount as set out in the Client Adjustment Notice it will inform the Purchaser thereof in writing within 15 days after receipt of the Client Adjustment Notice, in which case the Client Adjustment Amount shall be deemed agreed. If the Seller has not provided an Objection Notice within the 15 day period referred to in paragraph 4(a) above the Seller shall be deemed to be in agreement with the content of the Client Adjustment Notice, in which case the Client Adjustment Amount shall also be deemed to be agreed.

		
	(d)
	If the Seller and the Purchaser do not reach agreement within 15 days of receipt by the Purchaser of the Objection Notice, then the matters in dispute may be referred (on the application of either the Seller or the Purchaser) for determination by an independent legal firm of international standing as the Seller and the Purchaser shall agree or, failing agreement, appointed by the president of the Norwegian Bar Association (the Firm).  The Firm shall be requested to make its decision within 45 days (or such other date as the Seller, the Purchaser and the Firm agree in writing) of confirmation and acknowledgement by the Firm of its appointment.  The following provisions shall apply once the Firm has been appointed:

		
	(i)
	the Seller and Purchaser shall each prepare a written statement within 15 days of the Firm’s appointment on the matters in dispute which (together with the relevant supporting documents) shall be submitted to the Firm for determination and copied at the same time to the other;

		
	(ii)
	following delivery of their respective submissions, the Purchaser and the Seller shall each have the opportunity to comment once only on the other’s submission by written comment delivered to the Firm not later than 10 days after receipt of the other’s submission and, thereafter, neither the Seller nor the Purchaser shall be entitled to make further statements or submissions except insofar as the Firm so requests (in which case it shall, on each occasion, give the other party (unless otherwise directed by the other party) 10 days to respond to any statements or submission so made);

		
	(iii)
	in giving its determination, the Firm shall state what adjustments (if any) are to be made to the Client Adjustment Amount in respect of the matters in dispute;

- 50 -

		
	(iv)
	the Firm shall act as an expert (and not as an arbitrator) in making its determination which shall, in the absence of fraud or manifest error, be final and binding on the parties and, without prejudice to any other rights which they may respectively have under this Agreement, the parties expressly waive, to the extent permitted by law, any rights of recourse to the courts they may otherwise have to challenge it.

		
	(e)
	The Seller and the Purchaser shall each be responsible for their own costs in connection with the preparation, review and agreement or determination of Client Adjustment Amount.  The fees and expenses of the Firm shall be borne equally between the Seller and the Purchaser or in such other proportions as the Firm shall determine.

		
	(f)
	To enable the parties to meet their obligations under this paragraph 4, each party shall provide to the other party reasonably required access to the books and records and shall co‐operate fully with one another and shall permit the other to take copies (including electronic copies) of the relevant books and records.

		
	(g)
	When the Client Adjustment Amount has been agreed or determined in accordance with the preceding paragraphs, then the Client Adjustment Amount shall be final and binding for the purposes of this Agreement.

5.    The Client Adjustment Amount (as agreed in accordance with paragraphs 3 and 4) shall be payable by the Seller to the Purchaser. The Seller and the Purchaser agree that the Client Adjustment Amount shall also be considered as constituting an Escrow Claim and therefore also payable out of the Escrow Account in accordance the provisions of the Escrow Agreement. Both the Seller and the Purchaser undertake to issue instructions for payment from the Escrow Account of the amounts due under this clause without delay.

- 51 -

SCHEDULE 11     
 
DATA ROOM INDEX
Please see attached

- 52 -

SCHEDULE 12     
 
DISCLOSURE LETTER
Please see attached

- 53 -

SCHEDULE 13     
 
ACCOUNTING REVIEW
Part A    : Preliminary
1.    In conducting the Accounting Review:
		
	(a)
	it shall be determined whether the Balance Sheet Items have been properly accounted for;

		
	(b)
	in determining which items and amounts are to be included in the Accounting Review of the Balance Sheet Items, if and to the extent that the treatment or characterisation of the relevant item or amount or type or category of item or amount:

		
	(i)
	is dealt with in the accounting principles, policies, treatments, practices and categorisations (including in relation to the exercise of accounting discretion and judgement) that were used in the preparation of the Last Accounts (the Accounting Principles), the applicable Accounting Principle(s) shall apply; and

		
	(ii)
	is not dealt with in the Accounting Principles, United States GAAP shall apply.

Part B    : Accounting Review
1.    The Purchaser shall, or shall procure that the Purchaser’s accountants shall, after Closing prepare a draft statement (the Accounting Statement) showing the Balance Sheet Items of the Company.  The Purchaser shall deliver the draft Accounting Statement to the Seller at the same time as the Closing Statement.
2.    The Seller shall notify the Purchaser in writing (an Objection Notice) within 15 days after receipt whether or not it accepts the draft Accounting Statement for the purposes of this Agreement.  An Objection Notice shall set out in detail the Seller’s reasons for such non‐acceptance and specify the adjustments which, in the Seller’s opinion, should be made to the draft Accounting Statement in order for it to comply with the requirements of this Agreement.  Except for the matters specifically set out in the Objection Notice, the Seller shall be deemed to have agreed the draft Accounting Statement in full.
3.    If the Seller serves an Objection Notice in accordance with paragraph 2, the Purchaser and the Seller shall use all reasonable efforts to meet and discuss the objections of the Seller and to agree the adjustments (if any) required to be made to the draft Accounting Statement, in each case within 15 days after receipt by the Purchaser of the Objection Notice.
4.    If the Seller is satisfied with the draft Accounting Statement (either as originally submitted or after adjustments agreed between the Seller and the Purchaser pursuant to paragraph3) or if the Seller fails to give a valid Objection Notice within the 15 day period referred to in paragraph 2, then the draft Accounting Statement (incorporating any agreed adjustments) shall constitute the Accounting Statement for the purposes of this Agreement.

- 54 -

5.    If the Seller and the Purchaser do not reach agreement within 15 days of receipt by the Purchaser of the Objection Notice, then the matters in dispute may be referred (on the application of either the Seller or the Purchaser) for determination by an independent firm of chartered accountants of international standing as the Seller and the Purchaser shall agree or, failing agreement, by the President for the time being of the Association of Accountants in Norway (the Firm).  The Firm shall be requested to make its decision within 45 days (or such later date as the Seller, the Purchaser and the Firm agree in writing) of confirmation and acknowledgement by the Firm of its appointment.  The following provisions shall apply once the Firm has been appointed:
		
	(a)
	the Seller and Purchaser shall each prepare a written statement within 15 days of the Firm’s appointment on the matters in dispute which (together with the relevant supporting documents) shall be submitted to the Firm for determination and copied at the same time to the other;

		
	(b)
	following delivery of their respective submissions, the Purchaser and the Seller shall each have the opportunity to comment once only on the other’s submission by written comment delivered to the Firm not later than 10 days after receipt of the other’s submission and, thereafter, neither the Seller nor the Purchaser shall be entitled to make further statements or submissions except insofar as the Firm so requests (in which case it shall, on each occasion, give the other party (unless otherwise directed) 10 days to respond to any statements or submission so made);

		
	(c)
	in giving its determination, the Firm shall state what adjustments (if any) are necessary, solely for the purposes of this Agreement, to the draft Accounting Statement in respect of the matters in dispute in order to comply with the requirements of this Agreement and to determine finally the Accounting Statement;

		
	(d)
	the Firm shall act as an expert (and not as an arbitrator) in making its determination which shall, in the absence of manifest error, be final and binding on the parties and, without prejudice to any other rights which they may respectively have under this Agreement, the parties expressly waive, to the extent permitted by law, any rights of recourse they may otherwise have to challenge it.

6.    The Seller and the Purchaser shall each be responsible for their own costs in connection with the preparation, review and agreement or determination of the Accounting Statement.  The fees and expenses of the Firm shall be borne equally between the Seller and the Purchaser or in such other proportions as the Firm shall determine.
7.    To enable the Purchaser to meet its obligations under this Schedule 13, where relevant, each party shall provide to the other party and the other party’s accountants reasonably required access to the books and records, employees and premises of the Company and, where relevant, if at all, of that party for the period from the Closing Date to the date that the draft Accounting Statement is agreed or determined.  The parties shall co-operate fully with one another and shall permit the other party and/or the other party’s accountants to take copies (including electronic copies) of the relevant books and records and shall provide all assistance reasonably requested by the other party to facilitate the preparation of the Accounting Statement.
8.    When the Accounting Statement has been agreed or determined in accordance with the preceding paragraphs, then the amounts shown in the Accounting Statement as the Balance Sheet Items for the Company shall be final and binding for the purposes of this Agreement.

- 55 -

SCHEDULE 14     
 
DEFINITIONS AND INTERPRETATION
1.    Definitions.  In this Agreement, the following words and expressions shall have the following meanings:
Accounting Principles has the meaning given in Part A of Schedule 9;
Accounts means, in relation to any financial year of the Company, the audited balance sheet of the Company (and, where relevant, the audited consolidated balance sheet of the Company and its subsidiary undertakings) and the audited profit and loss account of the Company (and, where relevant, the audited consolidated profit and loss account of the Company and its subsidiary undertakings), in each case as at the relevant Accounts Date in respect of that financial year, as set out in the Data Room, together with any notes, reports, statements or documents included in or annexed or attached to them;
Accounts Date means the last date of each financial year for which Accounts are being warranted;
Affiliate means in relation to any party, any subsidiary or parent company of that party and any subsidiary of any such parent company, in each case from time to time;
Agreed or Determined means either agreed in writing signed by both the Seller and the Purchaser or a final and binding judgment rendered (without a right of appeal or in respect of which any right of appeal has lapsed) in legal proceedings between the Seller and the Purchaser pursuant to and in accordance with clause 34, and Agreement or Determination shall be construed accordingly;
Agreed Form means, in relation to a document, the form of that document which has been initialled for the purpose of identification by or on behalf of the Seller and the Purchaser (in each case with such amendments as may be agreed by them or on their behalf);
Business Day means a day other than a Saturday or Sunday or public holiday in Norway on which banks are open in Oslo for general commercial business;
Business IP means the Owned IP and all other Intellectual Property Rights used by the Company, excluding any Intellectual Property Rights relating to Utilities in a Box, which is owned by Ciber Inc.;
Cash means, in relation to the Company, the aggregate of its cash (whether in hand or credited to any account with any banking, financial, acceptance credit, lending or other similar institution or organisation) and its cash equivalents, including all interest accrued thereon, as at Closing, as shown by the books of the Company but, for the avoidance of doubt, excluding any Inter-Company Receivables (and any interest thereon) and all items to be treated as debtors in Working Capital;
Claim means any claim for breach of the Warranties or under the Tax Covenant;
Client Adjustment Amount shall be the amount as calculated in accordance with Schedule 10;
Closing means completion of the sale and purchase of the Shares in accordance with the provisions of this Agreement;

- 56 -

Closing Date has the meaning given in clause 5.1;
Closing Statement has the meaning given in Schedule 9;
Company means Ciber Norge AS, a private company with limited liability (Norwegian: Aksjeselskap), with corporate seat in Oslo, Norway and its office address at Stortorvet 10, 0155 Oslo, registered at the Norwegian Register of Business Enterprises under number 931 390 643;
Conditions means the conditions to Closing set out in clause 3.1 and Condition means any of them;
Confidential Information has the meaning given in clause 20;
Corporate Tax means any Tax on income, profits or gains;
Costs means losses, damages, costs (including reasonable legal costs) and expenses (including Taxation) in each case of any nature whatsoever;
Data Room means the virtual data room comprising the copies of documents and other information relating to the Company made available by the Seller as listed on the data room index in the Agreed Form attached as Schedule 11;
Debt Free/Cash Free Price has the meaning given in clause 2.1;
Default Interest means interest at LIBOR plus 5 per cent;
Disclosed Information means any facts, matters or other information included or provided in (i) this Agreement or any other Transaction Document or (ii) the Disclosure Letter (including any documents attached to such Disclosure Letter);
Disclosure Letter means the disclosure letter from the Seller to the Purchaser executed and delivered immediately before the signing of this Agreement and attached as Schedule 12, which may be updated during the period between Signing and Closing but only if such updates are agreed to by the Purchaser and also included in an updated Disclosure Letter that is duly executed by both parties;
Due Date has the meaning given in clause 18.4;
Due Sum has the meaning given in clause 18.4;
Employees means the employees of the Company immediately prior to Closing;
Escrow Account means the account in the name of the Escrow Agent in which the Escrow Agent holds the Escrow Amount under the terms and conditions of the Escrow Agreement;
Escrow Agent means ABN AMRO BANK N.V. (trading as ABN AMRO Escrow and Settlement);
Escrow Agreement means the escrow agreement which serves as security for the obligations of the Seller under the Warranties and other obligations under this Agreement, which shall be substantially in the Agreed Form;
Escrow Amount has the meaning given to it in clause 2.2;

- 57 -

Escrow Claims means any claim under the provisions of this Agreement submitted to the Escrow Agent and the Seller in accordance with the provisions of this Agreement and the Escrow Agreement in respect of a Claim, any indemnity provided in terms of this Agreement, any breach of the undertakings of the Seller set out in clause 4 and Schedule 4 and for the payment of any Client Adjustment Amount;
Escrow Period has the meaning given to it in clause 9.3;
Estimated Cash means the estimate of what the Cash attributable to the Company will be at Closing, as shown in Exhibit 1;
Estimated External Debt means the estimate of what the External Debt attributable to the Company will be as at Closing, as shown in Exhibit 1;
Estimated Working Capital means the estimate of what the Working Capital attributable to the Company will be at Closing, as shown in Exhibit 1;
Event includes any act, occurrence, transaction or omission whatsoever, and any reference to an event occurring on or before a particular date shall include events which for Tax purposes are deemed to have, or are treated as having, occurred on or before that date;
Exchange Rate means, with respect to a particular currency for a particular day, the spot rate of exchange (the closing mid-point) for that currency into NOK on such date as published by Bloomberg or, where no such rate is published in respect of that currency for such date, at the rate quoted by Reuters as at the close of business in Norway on such date;
Excluded Inter-Company Debt means Inter-Company Receivables in an amount of NOK 30 million;
Exhibits means exhibit 1 to this Agreement, and Exhibit shall be construed accordingly;
External Debt means, in relation to the Company, the aggregate of the Financial Debt owed by the Company (as shown by the books of the Company) as at Closing (together with any accrued interest) to any banking, financial, acceptance credit, lending or other similar institution or organisation, any institutional investor or other third party which, in each case, is not a member of the Seller Group; and for the avoidance of doubt, neither Inter-Company Payables (and any interest thereon) nor any items to be treated as creditors in Working Capital constitute External Debt, but any and all amounts which are due to be paid to Espen Vogt-Østli as a transaction bonus in respect of the implementation of the transaction contemplated in this Agreement and the Transaction Documents shall be regarded as External Debt. In addition, if the Accounting Review results in any additional liability for the Company in respect of any of the Balance Sheet Items, such additional liability shall be regarded as External Debt for purposes of this Agreement;
Final Price has the meaning given in clause 2.1;
Financial Adjustments means any adjustment(s) required in accordance with Part D of Schedule 9;
Financial Debt means all borrowings and other indebtedness by way of overdraft, acceptance credit or similar facilities, loan stocks, bonds, debentures, notes, debt or inventory financing, finance leases or sale and lease back arrangements or any other arrangements the purpose of which is to borrow money, together with forex, interest rate or other swaps, hedging obligations, 

- 58 -

bills of exchange, recourse obligations on factored debts and obligations under other derivative instruments;
Fundamental Warranties means any Warranty contemplated in paragraphs 1 and 2 of Part A of Schedule 1;
Fundamental Warranty Claim has the meaning given in paragraph 2 of Schedule 2;
Governmental Entity means any supra‐national, national, state, municipal or local government (including any subdivision, court, administrative agency or commission or other authority thereof) or any quasi‐governmental or private body exercising any regulatory, importing or other governmental or quasi‐governmental authority, including the European Union and any Tax Authority;
Gross Profit means the amount of billed client revenues less the cost of sales attributed to the relevant Client as calculated through the SAP BW system, consistent with the same methodology used to determine the Client Value;
Initial Price means the cash price payable on Closing under clause 2.2;
Intellectual Property Rights or IPR means:
		
	(a)
	patents, utility models and rights in inventions; 

		
	(b)
	rights in each of know-how, confidential information and trade secrets; 

		
	(c)
	trade marks, service marks, rights in logos, trade names, rights in each of get-up and trade dress, rights to sue for passing off (including trade mark-related goodwill), rights to sue for unfair competition, and domain names;

		
	(d)
	copyright, moral rights, database rights, rights in designs, and semiconductor topography rights; 

		
	(e)
	any other intellectual property rights; and 

		
	(f)
	all rights or forms of protection, subsisting now or in the future, having equivalent or similar effect to the rights referred to in paragraphs (a) to (e) above, 

in each case: (i) anywhere in the world; (ii) whether unregistered or registered (including all applications, rights to apply and rights to claim priority); and (iii) including all divisionals, continuations, continuations-in-part, reissues, extensions, re-examinations and renewals;
IT Contract means any third party contract under which an IT System is licensed, leased, supplied, maintained or supported; 
IT Systems means the information and communications technologies used by the Company, including hardware, software, networks and associated documentation;
Day-to-Day Inter-Company Debt Balances means day-to-day Inter-Company Debt balances created in the ordinary course of business for the Company up to and including the Closing Date;
Inter-Company Debt means Inter-Company Payables and Inter-Company Receivables;

- 59 -

Inter-Company Payables means, in relation to the Company, any amounts owed as at Closing by the Company to any member of the Seller Group together with accrued interest, if any, up to the date of Closing on the terms of the applicable debt;
Inter-Company Receivables means, in relation to the Company, any amounts owed as at Closing to the Company by any member of the Seller Group together with accrued interest, if any, up to the date of Closing on the terms of the applicable debt;
Key Managers means Espen Vogt-Østli, Terje Rabben (CFO), Lise Craig (HR), Thomas Brackel (Business Consulting and SAP) and Roy Tore Gurskevik (ADM);
Last Accounts means, in relation to the Company, the Accounts of that entity in respect of its financial year ended on the Last Accounts Date, as set out in the Data Room;
Last Accounts Date means 31 December 2015;
LIBOR means the display rate per annum of the offered quotation for deposits in NOK for a period of one month which appears on the appropriate page of the Reuters Screen (or such other page as the parties may agree) at or about 11.00a.m. Oslo time on the date on which payment of the sum under this Agreement was due but not paid;
Management Accounts means the unaudited monthly management accounts during the period commencing on the Last Accounts Date and ending on the Management Accounts Date, each in the form contained in the Data Room;
Management Accounts Date means the unaudited monthly management accounts of the Company for the period commencing on 31 December 2015 and ending on 23 August 2016, each in the form contained in the Data Room;
Material Adverse Change means any event, circumstance, effect, occurrence or state of affairs or any combination thereof which is or is reasonably likely to be materially adverse to the business, operations, assets, liabilities (including contingent liabilities), Properties, business or financial condition, results or prospects of the Company taken as a whole, its assets or business, excluding any such event, circumstance, effect, occurrence or state of affairs or any combination thereof which (i) arises from changes in economic conditions generally that do not have an effect on the Company taken as a whole that is disproportionate to the effect on other companies or businesses operating in the same industry and markets; (ii) arises from movements or developments in the financial securities markets or currency exchange rates; (iii) arises from changes in applicable law; (iv) arises from changes in the political climate in general (including but not limited to war or the announcement thereof) that do not have an effect on the Company taken as a whole that is disproportionate to the effect on other companies or businesses operating in the same industry and markets; (v) relates to developments or trends in the market or industry in which the Seller operates that do not have an effect on the Company taken as a whole that is disproportionate to the effect on other companies or businesses operating in the same industry and markets; (vi) arises from changes in accounting policies required by law; or (vii) the Purchaser is actually aware of at the date hereof as a result of such matter being disclosed in the Disclosure Letter; or (viii) has been remedied before the Unconditional Date by Seller or any member of Seller Group to the satisfaction of the Purchaser;
Owned IP means the Intellectual Property Rights owned by the Company;

- 60 -

parent company means any company which holds a majority of the voting rights in another company, or which is a member of another company and has the right to appoint or remove a majority of its board of directors, or which is a member of another company and controls a majority of the voting rights in it under an agreement with the other members, in each case whether directly or indirectly through one or more companies;
Pension Schemes means the pension schemes contained in the Data Room at “Final Diligence\HR\E09. Pension Schemes\”;
Permitted Assignee has the meaning given in clause 21;
Properties means the freehold and leasehold interests of the Company, brief particulars of which are as follows (see Exhibit 9 to the Disclosure Letter for further details): 
		
	(a)
	leasehold agreement with GlasMagasinet ANS relating to lease of approximately 531 square metre gross area in Glasmagasinet (building 1, 6th Floor), Stortorvet 10, 0155 Oslo, Norway, title no. 208/667 in Oslo municipality (office premises);

		
	(b)
	leasehold agreement with GlasMagasinet ANS relating to lease of approximately 1524 square metre gross area in Glasmagasinet (building 2 and 3, 6th Floor), Stortorvet 10, 0155 Oslo, Norway, title no. 208/667 in Oslo municipality (office premises);

		
	(c)
	leasehold agreement with GlasMagasinet ANS/attn. KLP Eiendom relating to lease of 3 parking lots in Glasmagasinet, Stortorvet 10, 0155 Oslo, Norway, title no. 208/667 in Oslo municipality;

		
	(d)
	leasehold agreement with GlasMagasinet ASN relating to lease of 24 square metre gross area (incl. common area and technical room) in the basement floor of Glasmagasinet, Stortorvet 10, 0155 Oslo, title no. 208/667 in Oslo municipality (storage premises);

		
	(e)
	fixed-term lease agreement (Nw. åremålsleieavtale) with Hyttestyret Bjarne Fredriksen/Georg Lützow-Holm relating to the Company's alpin cabin no 1 A, Trysilfjellet, 2420 Trysil, Norway; and

		
	(f)
	the Company owns a ski chalet in Norefjell, Norway (title no. 209/2, section no. 13 in Krødsherad municipality) for purposes of company retreats/social events;

Proposed Transaction means the transaction contemplated by the Transaction Documents;
Purchaser Group means the Purchaser and its Affiliates from time to time;
Purchaser Obligation means any representation, covenant, warranty or undertaking to indemnify given by the Purchaser to the Seller under this Agreement;
Purchaser’s Bank Account means the Purchaser’s bank account at Nordea Bank Norge ASA; in the name of the Purchaser; account number 6005.05.22566; IBAN number NO98 6005 0522 566; SWIFT: NDEANOKK (or such other account(s) as the Purchaser may notify the Seller of in writing);
Relief includes, unless the context otherwise requires, any allowance, credit deduction, exemption or set-off in respect of Tax or relevant to the computation of any income, profit or gains for the purposes of any Tax or any repayment or saving of Tax (including any repayment supplement or interest in respect of Tax);

- 61 -

Representatives has the meaning given in clause 20.1;
Seller Group means the Seller and its Affiliates from time to time but excluding the Company;
Seller Obligation means any representation, covenant, warranty or undertaking to indemnify given by the Seller to the Purchaser under this Agreement (including the Tax Covenant);
Seller’s Bank Account means the Seller’s bank account at Wells Fargo Bank; beneficiary name: Ciber International BV; account number: 279959; SWIFT: WFBIUS6S (or such other account(s) as the Seller and Purchaser may agree in writing);
Shares means the shares comprising issued share capital of the Company;
Specific Accounting Treatments has the meaning given in Part A of Schedule 9;
subsidiary and subsidiaries means any company in relation to which another company is its parent company;
Surviving Provisions means clauses 13 (Tax), 19 (Announcements), 20 (Confidentiality), 21 (Assignment), 23 (Costs), 24 (Notices), 25 (Conflict with other Agreements), 26 (Whole Agreement), 27 (Waivers, Rights and Remedies), 30 (Variations), 31 (Invalidity), 32 (Third Party Enforcement Rights), 34 (Governing Law and Jurisdiction) and Schedule 14 (Definitions and Interpretation);
Target Working Capital means the target of what the reasonable Working Capital attributable to the Company should be, as shown in Exhibit 1;
Tax and Taxation includes, without limitation (a) taxes on gross or net income, profits and gains, and (b) all other taxes, levies, duties, imposts, charges and withholdings of any fiscal nature, including any excise, property, wealth, capital, value added, sales, use, occupation, transfer, franchise and payroll taxes and any social security or social fund contributions, and any liability for repayment of unlawful state aid in relation to Tax, and any payment whatsoever which the relevant person may be or become bound to make to any person as a result of the discharge by that person of any tax which the relevant person has failed to discharge, together with all penalties, charges and interest relating to any of the foregoing or to any late or incorrect return in respect of any of them and regardless of whether such taxes, levies, charges, withholdings, penalties and interest are chargeable directly or primarily against or attributable directly or primarily to the relevant person or any other person and of whether any amount of them is recoverable from any other person;
Tax Authority means any taxing or other authority competent to impose any liability to Tax, or assess or collect any Tax;
Tax Claim means a claim for a breach of any of the Tax Warranties or a claim under the Tax Covenant;
Tax Covenant mean the covenants relating to Tax set out in clause 13
Tax Warranties means the warranties set out in Schedule 1Part G;
Third Party Assurances means all guarantees, indemnities, counter‐indemnities and letters of comfort of any nature given (i) to a third party by the Company in respect of any obligation of 

- 62 -

a member of the Seller Group; and/or (as the context may require) (ii) to a third party by a member of the Seller Group in respect of any obligation of the Company;
Third Party Right means any interest or equity of any person (including any right to acquire, option or right of pre-emption or conversion) or any mortgage, charge, pledge, lien, assignment, hypothecation, security interest, title retention or any other security agreement or arrangement, or any agreement to create any of the foregoing;
Trade Creditors means amounts payable at Closing in respect of trade creditors by the Company (including, in each case, any customers’ prepayments and trade bills payable);
Trade Debtors means amounts receivable at Closing in respect of trade debtors by the Company (including, in each case, any amounts recoverable, payments in advance, trade bills recoverable, prepayments and accrued income);
Transaction Documents means this Agreement, the Disclosure Letter, the Escrow Agreement, the Transitional Services Agreement, the Trademark License Agreement any other documents in the Agreed Form;
Transitional Services Agreement has the meaning given in clause 12;
Unconditional Date has the meaning given in clause 3.6;
US Exchange Rate means the spot rate of exchange (the closing mid-point) for NOK into United States Dollars on the day before the relevant payment date as published by Bloomberg or, where no such rate is published in respect of that currency for such date, at the rate quoted by Reuters as at the close of business in Norway on the day before the relevant payment date;
VAT means value added tax and any similar sales or turnover tax of any relevant jurisdiction;
Warranties means the warranties given pursuant to clause 6 and set out in Schedule 1;
Working Capital means, in relation to the Company, the working capital of the Company as at Closing, comprising each of the line items set out in Exhibit 1 and no others; for the avoidance of doubt Working Capital includes all Trade Creditors, all Trade Debtors and all interest payable or receivable accrued as at Closing, except on External Debt or in respect of any Inter-Company Debt (including, for the avoidance of doubt, the Excluded Inter-Company Debt); and
Working Hours means 9.30am to 5.30pm in the relevant location on a Business Day.
2.    Interpretation.  In this Agreement, unless the context otherwise requires:
		
	(a)
	references to a person include any individual, firm, body corporate (wherever incorporated), government, state or agency of a state or any joint venture, association, partnership, works council or employee representative body (whether or not having separate legal personality);

		
	(b)
	a reference to any statute or statutory provision shall be construed as a reference to the same as it may have been, or may from time to time be, amended, modified or re-enacted except to the extent that any amendment or modification made after the date of this Agreement would increase or alter the liability of the Purchaser under this Agreement;

- 63 -

		
	(c)
	headings do not affect the interpretation of this Agreement; the singular shall include the plural and vice versa; and references to one gender include all genders;

		
	(d)
	references to any Norwegian legal term or concept shall, in respect of any jurisdiction other than Norway, be construed as references to the term or concept which most nearly corresponds to it in that jurisdiction;

		
	(e)
	references to NOK are references to the lawful currency from time to time of Norway;

		
	(f)
	references to times of the day are to Oslo time;

		
	(g)
	references to writing shall include any modes of reproducing words in a legible and non-transitory form;

		
	(h)
	for the purpose of applying a reference to a monetary sum expressed in NOK, an amount in a different currency shall be deemed to be an amount in NOK translated at the Exchange Rate at the relevant date (which in relation to a Claim, shall be the date of receipt of notice of that Claim under Schedule 2);

		
	(i)
	any statement in this Agreement qualified by the expression to the best of the Seller’s knowledge or so far as the Seller is aware or any similar expression shall be deemed to include an additional statement that it has been made after due and careful enquiry and shall be deemed also to include the knowledge of the Company and each member of the Seller Group; and

		
	(j)
	any phrase introduced by the terms including, include or any similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms.

3.    Enactments.  Except as otherwise expressly provided in this Agreement, any express reference to an enactment (which includes any legislation in any jurisdiction) includes references to (i) that enactment as amended, consolidated or re-enacted by or under any other enactment before or after the date of this Agreement; (ii) any enactment which that enactment re‐enacts (with or without modification); and (iii) any subordinate legislation (including regulations) made (before or after the date of this Agreement) under that enactment, as amended, consolidated or re‐enacted as described in (i) or (ii) above, except to the extent that any of the matters referred to in (i) to (iii) occurs after the date of this Agreement and increases or alters the liability of the Seller or the Purchaser under this Agreement.
4.    Schedules and Exhibits.  The Schedules and Exhibits comprise schedules and exhibits to this Agreement and form part of this Agreement.
5.    Inconsistencies.  Where there is any inconsistency between the definitions set out in this Schedule and the definitions set out in any clause or any other Schedule, then, for the purposes of construing such clause or Schedule, the definitions set out in such clause or Schedule shall prevail.

- 64 -

SIGNATURE
This Agreement is signed by duly authorised representatives of the parties:
	
					
	SIGNED
	)
	SIGNATURE:
	/s/ Christian Mezger
	 

	for and on behalf of
	)
	 
	 
	 

	CIBER INTERNATIONAL B.V.
	)
	NAME:
	Christian Mezger
	 

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	SIGNED
	)
	SIGNATURE:
	/s/ Maalfrid Brath
	/s/ Anett Kristensen

	for and on behalf of
	)
	 
	 
	 

	EXPERIS AS
	)
	NAME:
	Maalfrid Brath
	Anett Kristensen

	 
	 
	 
	 
	 

- 65 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]